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ABSTRACT
ASPECTS OF HIGH-LEVEL TRIMETHOPRIM RESISTANCE IN 
GRAM-NEGATIVE BACTERIA ISOLATED IN SOUTH AFRICA
WYLIE, Barbara Ann, Ph.D. University of the Witwatersrand, 
Johannesburg, 1991.
Trimethoprim is a broad-spectrum antimicrobial agent 
frequently used either in combination with sulphamethoxazole 
(cotrimoxazole) or alone in the treatment of urinary and 
respiratory tract infections. Since the introduction of this 
drug in 1969 resistance to it has been monitored in several 
centres in Europe continuously but only intermittently in the 
United States of America and developing countries in Africa, 
Asia, Central and South America. In Europe the incidence of 
trimethoprim resistance has increased significantly in the 
last 20 years. In developing countries no trends have been 
established but the incidence of resistance appears to be 
greater in these countries than in Europe or the USA.
The mechanisms mediating resistance to trimethoprim have been 
investigated. Generally alterations of the chromosomal DNA of 
the organism result in intermediate resistance (trimethoprim 
minimum inhibitory concentration (MIC) 16 to 1 024 mg/1) 
while high-level resistance (MIC >1 024 mg/1) most frequently
Ill
due to plasmid-mediated dihydrcfolate reductases (DHFRs) 
which are resistant to trimethoprim. High-level resistance is 
important not only because the organisms are resistant to 
greater concentrations of trimethoprim than are achievable in 
body fluids but because the genes mediating resistance are 
transferable from one organism to another. They have been 
found on both plasmids and transposons and, more recently, 
integrated into the bacterial chromosome.
In 1982 a survey was undertaken to determine resistance to 
cotrimoxazole in isolates from the Johannesburg General 
Hospital and Baragwanath Hospital. The results showed a 
higher incidence of resistance than in equivalent hospitals 
in Europe and the USA at that time. While this gave some 
indication of the incidence of resistance to trimethoprim the 
results measured resistance to cotrimoxazole and could not, 
therefore, be considered accurate for trimethoprim. The 
present study was undertaken in order to establish the 
incidence of resistance to trimethoprim alone in 
gram-negative bacteria and to investigate the genes mediating 
high-level resistance in these organisms.
A three-month survey of trimethoprim resistance in 
gram-negative isolates from the Johannesburg, Hillbrow and 
Baragwanath hospitals was performed. A total of 56.2% of the 
isolates was resistant to trimethoprim (MIC >8 mg/1) while 
42.8% of the resistant isolates was resistant to >1 024 mg/1
IV
of trimethoprim. This was higher than the incidence observed 
in Europe and the USA but similar to that found in other 
developing countries. Preliminary hybridization studies using 
type I and type II DHFR probes indicated that the occurrence 
of these two genes in South African isolates was less 
frequent than expected. An investigation of the DHFRs of
highly resistant organisms which did not hybridize with
either of the probes resulted in the isolation and
characterization of a novel enzyme . This was called DHFR
type VI. The type VI DHFR gene, which was located on a
self-transmissable plasmid, was cloned into the plasmid and 
bacteriophage vectors pUC18, Ml3mpl8 and mpl9. The gene was 
sequenced and analyzed. Although the type VI DHFR gene was 
identical in size to both the type I and type V DHFR genes 
there was an overall amino acid homology between the types I 
and VI of only 63% and between the types V and VI of 61% . 
The subunit structure of the type VI DHFR and the incidence 
of this gene in the bacterial population are currently being 
investigated.
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1CHAPTER 1 OVERVIEW OF THE STRUCTURE AND ANTIMICROBIAL 
ACTION OF TRIMETHOPRIM AND THE MECHANISMS AND 
EPIDEMIOLOGY OF RESISTANCE TO THIS AGENT.
21•1 Structure, mechanism of action and properties of 
trimethoprim
1.1.1 Structure of trimethoprim
Trimethoprim (Tp) is a synthetic antimicrobial 
agent belonging to the diaminopyrimidines. Its 
structure is shown in Figure 1.1.
Figure 1.1 Structure of trimethoprim - 
2,4-diamino-(3 ' , 4 ' , 5 1-trimethoxybenzyl) pyrimidine 
(from Bushby & Hitchings, 1968) .
1.1.2 Mechanism of action of trimethoprim
The mechanism of action of trimethoprim is based 
on a general property of all diaminopyrimidines 
viz. inhibition of folate reductases. In bacteria
NH2 o c h3
o c h3
3dihydrofolate reductase (DHFR) catalyzes the 
reduction of dihydrofolic acid (DHF) to 
tetrahydrofolic acid (THF), derivatives of which 
are required as catalysts in the manufacture of at 
least two amino acids (methionine and glycine), 
for purine synthesis and initiation of protein 
synthesis. In addition 5,10-methylene 
tetrahydrofolate is required as a substrate in the 
conversion of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) by thymidylate 
synthetase (Hitchings, 1973) . These 
interconversions are detailed in Figure 1.2.
By inhibiting the production of tetrahydrofolate 
trimethoprim was shown to have a bactericidal 
effect when an organism (Escherichia coli) was 
grown in complex medium lacking thymine 
derivatives (Amyes & Smith, 1974a). A 
bacteristatic effect was observed, however, when 
the organism was grown in minimal medium (Then & 
Angehrn, 1973; Amyes & Smith, 1974b) but the 
addition of methionine to the minimal medium 
resulted in a bactericidal effect. The reversal of 
bacteriostasis was found to be dependent upon 
continued protein synthesis which deprived the 
cell of 5,10-methylene THF. Since no dTMP could
4methionine DHF serine
Figure 1.2. Interconversions of THF intermediates 
and their relationship with purine and protein 
synthesis. Points of repression are indicated by
------ and points of inhibition by ----—
*, this reaction is virtually irreversible with 
the equilibrium biased towards methionine and THF 
under normal conditions (from Amyes & Smith, 
1974b).
5then be synthesized DNA replication ceased. 
Bacterial growth could be restored to prototrophs 
grown under these conditions by the addition of 
thymine and lysine (Amyes & Smith, 1974b).
1.1.3 Properties of trimethoprim
Trimethoprim has been used as an antimicrobial 
agent for approximately 21 years and has a number 
of properties which make it suitable for such use:
i) most folate inhibitors e.g. methotrexate and 
aminopterin bind both bacterial and mammalian 
DHFRs but trimethoprim selectively binds 
bacterial DHFRs. Consequently patients 
experience fewer side effects (Burchall, 
1973; Burchall, 1979)
ii) trimethoprim was shown to be active against a 
broad spectrum of organisms especially 
selected gram-negative bacilli and 
streptococci. It was ineffective against 
Pseudomonas aeruginosa and Clostridium 
perfrinaens (Bushby & Hitchings, 1968).
iii) trimethoprim was shown to be readily absorbed 
after oral administration with concentrations 
of the drug in organs and tissues being
6several times greater than in serum. It had a 
half clearance time of approximately 14 
hours, concentrating in the urine, and only 
weak pharmacodynamic effects.
These properties made trimethoprim eminently 
suitable for therapeutic use. However, it was not 
introduced as a single antimicrobial agent until 
1972 in Finland and 1979 in other European 
countries.
1.2 Cotrimoxazole
The sulphonamides were the first group of modern 
antimicrobial agents to be developed and used in 
clinical and veterinary practice. By the time 
trimethoprim was developed sulphonamides had been in 
use for approximately 34 years and consequently 
resistance to these agents was common (Hamilton-Miller, 
1979) . Sulphonamides act within the folic acid 
biosynthetic pathway by competitively inhibiting 
dihydropteroate synthetase, the enzyme which catalyzes 
the condensation of p-aminobenzoic acid with 
dihydropteridine to form dihydropteroate (Brown, 1962). 
Dihydropteroic acid is a precursor in the synthesis of 
dihydrofolic acid. Because both sulphonamides and
7trimethoprim act within the same biosynthetic pathway it 
was felt that the use of both drugs in combination would 
extend the effectiveness of the sulphonamides. When 
trimethoprim first came onto the market in 1969, 
therefore, it was available only in combination with the 
sulphonamide, sulfamethoxazole (Smx). This combination 
was known as cotrimoxazole and its use was justified by 
the following observations:
i) cotrimoxazole was shown to have a synergistic
effect in vitro (Bushby and Hitchings, 1968; 
O'Brien et al., 1982; Acar, Goldstein & Chabbert, 
1973)
ii) in vitro the two drugs in combination were 
bactericidal as opposed to bacteristatic when used 
singly (Then & Angehrn, 1973)
iii) trimethoprim was found to be a sulphonamide
potentiator, extending the spectrum of these
antibiotics to include such species as Proteus,
Bordetella, Haemophilus and Neisseria (Bushby & 
Hitchings, 1968; Brumfitt, Hamilton-Miller &
Kosmidis, 1973) .
Although no data was available it was thought that the
administration of the combination would delay the
emergence of resistance to trimethoprim (Bushby &
Hitchings, 1968). The spectrum of activity of
8cotrimoxazole could not be denied but because of the 
differing pharmacokinetic properties of the two drugs 
many workers questioned the assumption that the in 
vitro findings would pertain in vivo (Greenwood, 
1979; Griineberg, 1979; Lacey, 1979; Amyes, 1982; Lacey, 
1982; Salter, 1982) . Many also felt that use of the 
combination would have no effect on delaying the 
emergence of resistance to trimethoprim. However, 
despite the arguments for and against the use of 
cotrimoxazole it has been an effective therapeutic agent 
and its use has continued despite the subsequent 
introduction of trimethoprim as a single agent.
1.3 Mechanisms of resistance to trimethoprim
Resistance to antimicrobial agents has always been a 
problem in clinical practice since the extent of 
resistance limits the usefulness of the drug in 
question. A knowledge of the mechanisms involved in 
resistance is important, therefore, if it is to be both 
understood and prevented.
An antimicrobial agent can be rendered ineffective by 
alteration of the drug by the micro-organism. While drug 
inactivation is an important mechanism of resistance 
against the @-lactams and aminoglycosides, it does not
9appear to be important where trimethoprim is concerned 
(Hamilton-Miller, 1979). This may be due to the fact 
that trimethoprim is a synthetic drug and is not as 
prone to metabolic degradation as are other naturally 
occurring drugs.
Changes in the environment have been shown to affect 
susceptibility of micro-organisms to trimethoprim. The 
presence of thymidine in the medium, for example, has 
been shown to render trimethoprim ineffective (Then, 
1982) .
A drug can also be rendered ineffective by a change in 
the micro-organism. These changes are the most important 
mechanisms involved in trimethoprim resistance and can 
be divided into two broad categories viz. intrinsic and 
acquired resistance (Hamilton-Miller, 1979; Burchall, 
Elwell & Fling, 1982; Then, 1982) .
1.3.1 Intrinsic resistance
Intrinsic resistance to trimethoprim has not been 
extensively studied but at least two mechanisms 
have been shown to operate in bacteria which are 
naturally resistant to trimethoprim. These 
characteristically give rise to intermediate 
resistance (minimum inhibitory concentration (MIC)
10
of trimethoprim 16 to 1 024 mg/1).
i) impermeability of the bacterial cell wall to 
the drug. This is seen most commonly in 
Pseudomonas aeruginosa and other Pseudomonas 
species (Then, 1982) .
ii) production of chromosomal dihydrofolate
reductases (DHFRs) which have a low affinity 
for trimethoprim. This occurs in Neisseria 
spp. . Branhamella catarrhalis. Nocardia s o p. 
and anaerobic bacteria such as
Bacteroides s p p. and Clostridium spp.. (Then 
& Angehrn, 1979; Then, 1982).
1.3.2 Acquired resistance
Acquired resistance may be due either to 
alterations in the chromosome of the organism or 
due to the acquisition of plasmids and/or 
transposons bearing resistance determinants. 
Chromosomal mutations usually confer intermediate 
resistance on the organism (MIC 16 to 1 024 mg/1) 
while plasmid- and/or transposon-mediated 
resistance is characterized by high-level 
resistance (MIC >1 024 mg/1).
11
1.3.2.1 Resistance arising from alterations to the 
chromosome
Chromosomal mutations may result in any of 
the following:
i) thymidine auxotrophy. Thy" mutants 
lack a functional thymidylate 
synthetase enzyme which is required 
to convert dUMP to dTMP. As a result 
these organisms require exogenous 
sources of either thymine or 
thymidine to grow. This allows the 
organism to function in the presence 
of trimethoprim as it is not 
dependent on THF derivatives for the 
synthesis of thymidylate (Amyes & 
Smith, 1974b).
ii) cell wall impermeability. Mutations
resulting in decreased penetration of 
the cell wall by the antibiotic have 
been described in Klebsiella
pneumoniae by Smith (1976). Changes 
in the outer membrane proteins have 
also been associated with resistance 
to multiple antimicrobial agents
12
including trimethoprim in species of 
Enterobacter. Serratia and Klebsiella 
(Gutmann et al., 1985).
iii) over-production of normal chromosomal
dihydrofolate reductase. This type of 
resistance occurs as a result of one 
or more mutations in the regulatory 
region of the dhfr gene and has been 
described by several workers 
(Flensburg & Skold, 1984;
Tennhammar-Ekman, Sundstrom & Skold, 
1986; Flensburg & Skold, 1987; De 
Groot et al., 1988).
iv) production of chromosomal DHFRs less
sensitive to trimethoprim. Organisms 
producing such enzymes have been 
described by Then & Herman (1981) and 
Smith & Calvo (1982) . A combination 
of this mechanism with
hyperproduction of the enzyme has 
also been reported by Flensburg & 
Skold (1984, 1987) in a clinical
isolate of E.coli.
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1.3.2.2 Plasmid- and transposon-mediated 
trimethoprim resistance
Plasmid-mediated resistance to
trimethoprim is the most common form of 
acquired resistance and the most 
important. Plasmids and transposons bear 
genes for dihydrofolate reductases (DHFRs) 
which have little affinity for 
trimethoprim and are, therefore, resistant 
to the drug. They usually confer an MIC of 
trimethoprim >1 024 mg/1. However, two of 
the enzyme groups confer intermediate 
resistance (MIC 16 to 1 024 mg/1) . The 
first of the plasmid-mediated enzymes was 
reported by Fleming, Datta & Gruneberg 
(1972) three years after the introduction 
of trimethoprim into clinical use. At this
time eight groups of resistant DHFRs havethe genes coding for
been identified and whileAall of them have 
been located in plasmids, some of them 
have also been found in transposons. By 
this means they have become integrated 
into the bacterial chromosome (Towner, 
Venning & Pinn, 1982) . The enzymes have
14
been identified mainly in 
Enterobacteriaceae but have spread to 
other gram-negative organisms e.g. 
Pseudomonas spp. and Vibrio cholerae 
(Goldstein, Papadopoulou & Acar, 1986; 
Young & Amyes, 1986b). They have also been 
found in staphylococci (Archer, Coughter & 
Johnston, 1986; Coughter, Johnston & 
Archer, 1987; Tennant et al., 1988).
1.4 Plasmids and transoosable elements
In view of the role that plasmids and transposons play 
in mediating trimethoprim resistance a brief outline of 
the essential features of both elements follows. Both 
plasmids and transposons have been the subject of 
intensive studies of which the following references are 
representative (Broda, 1979; Lorian, Ed., 1986; 
Kleckner, 1981; Shapiro, Ed., 1983).
1.4.1 Plasmids
1.4.1.1 Definition and characteristics of plasmids
Plasmids are extrachromosomal elements of
15
double stranded (ds) DNA which are found 
in both eukaryotic and prokaryotic cells. 
In bacteria, these elements are common and 
range in size from <1 to >400 Kb. More 
than one species of plasmid may co-exist 
and it is not uncommon to find several 
different plasmids in a single cell. 
However, the total amount of plasmid DNA 
which can be stably maintained in a cell 
is limited and in exponentially growing 
bacteria the number of each species of 
plasmid ranges typically from 0.7 to 40 
copies per chromosome. Plasmids have 
characteristic copy numbers and generally 
this is inversely proportional to the size 
of the plasmid. They are also able to 
spontaneously acquire foreign DNA/delete 
portions, of their own DNA.
1.4.1.2 Classification of plasmids
Plasmids are classified broadly by 
incompatibility grouping. This system of 
classification is based on the fact that 
closely related plasmids respond to the
16
copy number regulating mechanisms of one 
another and cannot, therefore, co-exist 
stably. In a cell where there is an 
established plasmid introduction of a 
second, related plasmid will result in the 
elimination of the resident plasmid. Such 
plasmids belong to the same 
incompatibility group. This system of 
classification has been verified by 
electronmicroscopy of plasmid heteroduplex 
formations. Heteroduplexes formed between 
plasmids belonging to the same 
incompatibility group have been shown to 
exhibit greater homology than those formed 
by plasmids from different incompatibility 
groups.
1.4.1.3 Vertical transfer of plasmids
At the time of cell division, each 
daughter cell receives at least one copy 
of each resident plasmid. This is termed 
vertical transfer and it ensures the 
maintenance of each plasmid within a 
single bacterial species. In order for
17
vertical transfer to occur a basic minimum 
of plasmid-encoded functions is required. 
These include determinants for initiation 
of plasmid replication and control of copy 
number i.e. regulation of replication 
initiation. In addition regulation of 
distribution of plasmid copies at the time 
of cell division and monomerization of 
plasmid multimers is required. Although 
regulation of plasmid replication is 
autonomous the process is, nevertheless, 
dependent on host-specified proteins. This 
dependence (or relative independence) 
reflects the host range of the plasmid. 
Where a plasmid has a degree of 
self-sufficiency in specifying the 
essential replication functions the host 
range is broader.
1.4.1.4 Horizontal transfer of plasmids
Apart from the ability of plasmids to 
transfer vertically they have a propensity 
for transfer from one species to another 
and sometimes from one genus to another.
18
This type of transfer is called horizontal 
transfer and is effected by conjugation 
and to a lesser extent by transformation, 
transduction and protoplast fusion. Apart 
from the essential genes required for 
plasmid maintenance many plasmids carry 
determinants for conjugal transfer to new 
host cells. The most extensively studied 
transfer system is that of the F- or 
fertility factor. Since conjugation is a 
complex process requiring many genes only 
large plasmids are capable of this type of 
transfer. However, smaller, co-resident 
plasmids may take advantage of another 
plasmid's conjugation system provided they 
have their own origins of transfer and 
can mobilize the conjugation functions.
1.4.1.5 Role of plasmids in chromosomal gene 
transfer
During conjugation plasmids may also 
effect the transfer of chromosomal genes 
from one bacterium to another. Although 
the bacterial chromosome and plasmid DNA
19
are physically and functionally discrete 
physical interaction between these two 
entities can and does occur. Integration 
of the F-factor into the chromosome, for 
example, yields a high frequency 
recombinant strain which, when 
transferring F-factor genes to a recipient 
strain, transfers the chromosomal genes 
adjacent to the F-factor at the same time. 
A second means by which plasmids may 
acquire and transfer chromosomal genes 
occurs as a result of imprecise excision 
of an integrated plasmid from the 
chromosome. Chromosomal genes adjacent to 
the plasmid may be incorporated into the 
plasmid in this manner.
1.4.1.6 Plasmid-encoded functions
The bacterial properties specified by 
plasmids vary considerably and range from 
resistance to noxious agents to factors 
which enhance pathogenicity. These 
properties can be divided into four broad 
categories:
20
i) Resistance to noxious agents.
Bacteria are continually exposed to 
noxious substances in their 
environment e.g. mutagenic chemicals, 
antibiotics, toxic heavy metal ions, 
ultraviolet irradiation and lytic 
viruses. Resistance to some of these 
challenges, most notably to heavy
metal ions and antibiotics, have been 
found to be plasmid-mediated.
ii) Enhanced bacterial competitiveness.
Some bacteria are known to produce 
proteins and oligopeptides which 
enhance their own competitiveness by 
inhibiting the growth of other
competing organisms. Examples of such 
substances are bacteriocins and
microcins and these are generally 
plasmid-mediated.
Ferric iron is essential for 
bacterial growth and is present in 
the environment in very small 
quantities. Some bacteria produce 
siderophores which have a high 
affinity for iron and thereby deplete
21
the environment thus enhancing their 
own competitiveness. The genes for 
production of the siderophore and the 
siderophore-iron complex uptake 
system are plasmid-mediated.
The capacity of some bacteria to 
adhere to cell surfaces enhances 
their ability to colonize particular 
tissues (e.g. intestinal mucosa). 
Such adhesins are plasmid-mediated,
iii) Adaptation to specialized ecosystems. 
In clinical situations there are many 
examples of such adaptations. The 
hospital environment is particularly 
hostile to bacteria but many 
plasmid-mediated functions assist 
bacteria to survive. These include 
resistance to many antibiotics, 
mutagenic compounds such as 
acriflavin and noxious chemicals e.g. 
mercury and hexachlorophenes which 
are common components of
disinfectants.
In the human body invading bacteria 
are subjected to a battery of host
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defences. Some bacteria have 
developed their own defences to help 
them colonize and multiply in this 
hostile environment. These mechanisms 
include the production of 
siderophores, adhesins, complement 
resistance factors and antiphagocytic 
factors. The acquisition of multiple 
antibiotic resistance factors also 
enhances their ability to survive,
iv) Increased pathogenicity. In some 
cases the ability of an organism to 
cause severe disease is related to 
the presence of one or more plasmids. 
A well known example is that of 
enterotoxigenic E.coli. E.coli is 
part of the normal flora of the large 
intestine and does not cause disease 
under normal circumstances. However, 
if this organism acquires plasmids 
encoding an enterotoxin and an 
adhesin and colonizes the small 
intestine, symptoms similar to 
cholera are produced. Other examples 
of enhanced pathogenicity due to the
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presence of plasmid-mediated genes 
can be seen in shigellae and 
enteroinvasive E.coli. In both 
organisms their ability to penetrate 
and multiply within the intestinal 
mucosa is due to the expression of 
genes located on a large plasmid. 
Because of the mobility of plasmids and their 
facility for acquisition, deletion and exchange of 
genetic material plasmids are important factors in 
the successful adaptation of bacteria to changing 
environmental conditions.
1.4.2 Transposable elements
Transposable elements are discrete units of 
double-stranded (ds) DNA capable of translocating 
to new sites in the bacterial chromosome and 
plasmids without requiring extensive DNA homology.
1.4.2.1 Classification of transposable elements
i) Insertion sequences. The smallest, 
simplest transposable elements are 
insertion sequences. These consist of
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short inverted repeat sequences (10— 
to 40-bp in length) on either end of 
a central sequence which contains the 
genes necessary for transposition. In 
addition short, direct repeat 
sequences (4- to 11-bp) of target DNA 
can be found on both sides of the 
inserted element (Figure 1.3.).
< ..
----------►
Figure 1.3. Structure of an insertion 
sequence. Black triangles indicate 
inverted repeat sequences and arrows 
indicate direction of transcripts 
(from Schmitt, 1986).
Insertion sequences are commonly 
found in bacterial DNA and range in 
size from 700- to 1 800-bp. The 
terminal repeats serve as recognition 
sequences for the transposases that 
catalyze the fusion of these ends
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with the target DNA. The intervening 
DNA sequence usually contains a 
single, large open reading frame 
(ORF) encoding a polypeptide of 300 
to 400 amino acids. Frequently there 
is a smaller ORF within the larger 
one but in the anti-sense 
orientation.
ii) Transposons. These are more complex 
in structure than insertion sequences 
and are divided into three classes:
a) Class I transposons (compound 
transposons) contain antibiotic 
resistance genes flanked on either 
side by two copies of an insertion 
sequence in direct or inverted 
orientation (Figure 1.4.).
Examples of this type are Tn5 and
TnlO.
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resistance genes >
Figure 1.4. Structure of Class I 
transposons (from Schmitt, 1986).
b) Class II or complex transposons 
are flanked on either end by an 
inverted repeat sequence. The 
central sequence encodes genes for 
transposition and frequently 
antibiotic resistance. The
inverted repeat sequences serve as
recognition sites for the
transposases (Figure 1.5.) . An
example of this class of
transposon is Tn3.
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transposition genes resistance genes
Figure 1.5. Structure of Class II 
transposons (from Schmitt, 1986) .
c) Class III transposable elements 
consist of transposing
bacteriophages such as Mu and 
D108. The structure of these 
elements is different from Class I 
and Class II transposons in that 
their ends do not have inverted 
repeat sequences. Homologies do 
occur, however, but they are not 
symmetrical. Sequences at the 
beginning of the bacteriophage 
have been shown to be homologous 
with sequences occurring
approximately 80-bp in from the 
other end. In addition a seven to 
nine base pair sequence at one end 
has been found to be repeated
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several times at the other end of 
the element and is homologous with 
the insertion sequence IS5.
1.4.2.2 Transposition
The most important property of 
transposable elements is their ability to 
integrate into DNA. This process involves 
non-homologous recombination catalyzed by 
transposon-encoded transposases. It is 
entirely independent of homologous 
recombination mediated by the recA system 
of the bacterium. The mechanisms involved 
in transposition are not well defined 
owing to a lack of suitable in vitro 
systems. However, there is evidence 
supporting at least two different 
mechanisms of transposition viz. 
conservative and replicative. In 
conservative transposition (exhibited by 
Class I elements) the donor replicon is 
lost whereas in replicative transposition 
(exhibited by Class I and Class II 
elements) both the donor and target
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replicons retain copies of the transposon. 
Although transposons insert into various 
loci of the target DNA most elements show 
a preference for specific sites. It is 
thought that this is determined by the 
preference of the transposase enzymes for 
certain sequences.
1.4.2.3 Transposons and trimethoprim resistance
Although numerous transposons mediating 
antibiotic resistance have been identified 
only five have been associated with 
trimethoprim resistance. The most common 
of these is the element Tn7. This encodes 
resistance to mercury, streptomycin and 
spectinomycin as well as trimethoprim 
(Barth et al., 1976). Tn402 contains the 
gene dhfrlie and codes for trimethoprim 
resistance only (Shapiro & Sporn, 1977). 
The gene encoding DHFR type lb resides in 
Tn4132 (Young & Amyes, 1985) and recently 
a Tn21-like transposon was found to 
harbour three different trimethoprim 
resistance genes, dhfrla, dhfrII and
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dhfrV. in addition to a sulphonamide
resistance gene, sull (Sundstrom & Skold, 
1990). The fifth transposon, Tn4003, bears 
the gene for DHFR SI which was found in 
staphylococci (Young, Skurray & Amyes, 
1987) .
The ability of transposons to insert into any DNA 
replicon has greatly increased the spread of 
antibiotic resistance genes which, in turn, has 
resulted in marked changes in the epidemiology of 
antibiotic resistance.
1.5 Plasmid-mediated trimethoprim-resistant dihydrofolate 
reductase enzymes
The plasmid- and/or transposon-mediated resistant DHFRs 
have been classified according to their biochemical and 
physical properties. These are summarized in Table 1.1.
1.5.1 Resistant DHFRs in gram-negative bacteria
i) There are two type I DHFRs: the prototype
type la (Skold & Widh, 1974; Pattishall 
et al., 1977; Fling & Elwell, 1980) and the 
type lb (Young & Amyes, 1985). The type la is
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the most ubiquitous of all DHFRs, having been 
found on all continents (Amyes, 1989; Amyes & 
Towner, 1990). It is larger than the 
chromosomal DHFR - 35 Kda vs 17.7 Kda (Smith 
& Calvo, 1980) - and has been shown to
consist of two subunits each approximately 
18 Kda (Fling & Elwell, 1980) . The type lb 
has similar biochemical properties but is 
smaller than the type la - 24.5 Kda. It is 
not known whether this enzyme functions as a 
monomer or a dimer. It is not as commonly 
found as the type la and to date has only 
been reported in the United Kingdom (Young & 
Amyes, 1985). Both enzymes confer
trimethoprim minimum inhibitory
concentrations (MIC) >1 000 mg/1 on their 
host organisms. The type la gene is located 
most commonly in transposon Tn7 which also 
mediates resistance to streptomycin and 
spectinomycin. However, it has recently been 
found in a Tn21-like transposon which also 
mediates sulphonamide resistance (Sundstrom & 
Skold, 1990) .
ii) The type II group of DHFRs has three subtype 
enzymes: the prototype type Ila (R67), the
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type lib (R388) and the type lie (R571:Tn402) 
(Shapiro and Sporn, 1977; Pattishall et al.,
1977; Amyes & Smith, 1974c; Amyes and Smith
1976; Amyes & Smith, 1978; Fling & Elwell,
1980; Broad & Smith, 1982) . These enzymes
differ in their affinity for trimethoprim but 
for practical purposes they are all 
insensitive to the drug. They confer MICs 
>1 000 mg/1 on their hosts. The type Ila and 
lib enzymes are both 35 Kda in size while the 
type lie is slightly smaller - 34 Kda. The 
type Ila has been shown to function as a 
tetramer (Smith et al., 1979), each subunit 
being 8.5 Kda in size. The types Ila and lib 
have been identified in Europe, America and 
Asia but the type lie has only been found in 
the United Kingdom and possibly Finland 
(Amyes & Towner, 1990; Huovinen, Pulkkinen & 
Toivanen, 1983).
iii) The type III group of DHFRs also contains 
three subtypes, the prototype having been 
isolated from a strain of Salmonella 
tvohimurium in New Zealand (Anderson, 1980; 
Fling, Elwell & Walton, 1982; Joyner et al.,
1984) . This enzyme has subsequently also been
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found in the United Kingdom (Thomson, Barg & 
Amyes, 1990) . It is distinct from the types I 
and II DHFRs in all its biochemical and 
physical properties but most notably in the 
trimethoprim MIC it confers on its host 
bacterium (MIC = 64 mg/1) . This was the
first example of plasmid-mediated, 
intermediate trimethoprim resistance. More 
recently type Illb and IIIc enzymes have been 
identified in the United States (Barg et al., 
1990) . They differ from the prototype and one 
another in their pi values. Comparison of the 
first 47 amino acid residues of the type Ilia 
and Illb enzymes shows that they differ 
significantly in this respect as well 
(Thomson, Barg & Amyes, 1990) .
iv) The type IV DHFR has only been found in 
bacteria isolated in South India (Young & 
Amyes, 1986a). This enzyme also confers 
intermediate resistance on its host
organism (MIC 10 to 160 mg/1) but has the 
unique property of inducibility. This enzyme 
is the largest of the DHFRs having a 
molecular weight of 46.7 Kda. Recently
Thomson, Young & Amyes (1990) have shown that
Table 1.1. Properties of plasmid-encoded dihydrofolate reductases.
DHFR DHFR Plasmid MIC for Tp ID50 Tp ID50 Mtx Km DHF Ki Tp TD50 Mr
type sub-type (mg/1) (pM) (pM) (pM) (pM) (min) (Kda)
I a R483(Tn7) >1 000 57 4.4 5.6 7.4 0.5 35
b pUKl63(Tn4132) >1 000 32 2.8 11 41 1.2 24.5
II a R67bis >1 000 70 000 1 100 4.6 6 100 >12 35
b R388 >1 000 80 000 7.5 8.3 150 >12 35
c R751(Tn402) >1 000 20 000 1 000 4.2 400 >12 34
III a pAZl 64 2.1 ND 0.4 0.019 ND 16.9
b pBH600 128 2.0 0.02 9.52 0.4 >12 17.0
c pBH700 256 3.0 0.007 3.12 0.52 > 8 22.0
IV pUK1123 10 0.2 0.02 37 0.063 >12 46.7
V pLM028(Tn21-like ) >1 000 23 3.5 15.5 3.2 3.0 35
VI pUK672 >1 000 200 7.25 31.25 75 0.4 10.0
VII pUN835 >1 000 30 3.0 20.0 7.0 1.5 11.5
SI pSKlOO(Tn4003) >1 000 50 0.002 10.8 11.6 >12 19.7
Tp = trimethoprim; Mtx *= methotrexate; DHF = dihydrofolate; DHFR «= dihydrofolate reducatase
ID50 = concentration of drug required to inhibit enzyme activity by 50*
o
TD50 = time taken for the enzyme to lose half its activity at 45 C
MIC = minimum inhibitory concentration; ND = not done; *, as determined by column chromatography 
References: Skold & Widh, 1974; Pattishall et a l ., 1977; Young & Amyes, 1985; Smith et al., 1979; 
Broad & Smith, 1982; Amyes, 1986; Amyes & Smith, 1974c; Amyes & Smith, 1976; Joyner et al., 1984; 
Amyes & Towner, 1990; Barg et al., 1990; Young & Amyes, 1986a; Sundstrom et al., 1987;
Wylie et al., 1988; Amyes et al., 1989; Young, et al., 1987).
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this enzyme comprises two dissimilar 
subunits: the native DHFR protein - 33 Kda, 
and the DNA-binding protein NS1 - £. 10 Kda. 
The function of the latter subunit has not 
been clarified but it has been suggested that 
it performs some role in the induction of the 
enzyme.
v) The type V DHFR has been found in isolates 
from Sri Lanka (Sundstrom, Vinayagamoorthy & 
Skold, 1987) and more recently in the United 
Kingdom (Towner et al.f 1990), Finland 
(Heikkila et al., 1990) and Sicily (Agodi et 
al., 1990). This enzyme is very similar to 
the type I DHFRs but was classified in a 
separate category on account of its small 
molecular weight - £. 5 Kda - and the lack of 
hybridization with a type I gene probe 
(Thomson & Amyes, 1988). Sequence analysis 
(Sundstrom et al., 1988) together with 
analysis of the molecular weight by native 
polyacrylamide gel electrophoresis (PAGE) 
(Thomson, 1990) has shown that it has a 
molecular weight of 35 Kda and functions as a 
dimer. Although there is 75% sequence 
homology between the type I and type V DHFR
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genes the lack of hybridization between the 
two genes indicates that the type V should 
remain in a separate class. Like the type la 
DHFR the type V DHFR gene has also been 
located in a Tn21-like transposon mediating 
sulphonamide resistance (Sundstrdm et al., 
1988; Sundstrom & Skold, 1990) .
vi) The type VI DHFR has only been described in 
isolates from South Africa (Wylie et al., 
1988) . It has unique biochemical properties 
and confers an MIC >1 000 mg/1 on its host 
organism. This enzyme will be discussed more 
fully in a later chapter.
vii) After the isolation of the type VI DHFR Amyes 
et al. (1989) isolated another type I-like 
enzyme mediating high-level resistance (MIC 
>1 000 mg/1). Because it had a different 
molecular weight - 11.5 Kda - and did not 
hybridize with probes of other DHFRs it was 
classified as DHFR type VII.
The dihydrofolate reductases described above have 
all been isolated in various species of 
enterobacteria, the type la having been found in 
other gram-negative bacteria as well (Young & 
Amyes, 1986b).
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1.5.2 Resistance DHFRs in gram-positive bacteria
The type SI DHFR, located on transposon Tn4003, is 
unique to staphylococci and is the only such 
enzyme reported in gram-positive bacteria at this 
time (Young, Skurray & Amyes, 1987; Tennant et
al.f 1988). The SI DHFR is biochemically distinct 
from all other plasmid-mediated DHFRs found in 
gram-negative bacilli and confers high-level 
resistance on its host organism (MIC >1 000 mg/1). 
It was first described in an Australian isolate 
but has been identified in the USA, United Kingdom 
and more recently in Switzerland (Archer, Coughter 
& Johnston, 1986; Coughter, Johnston & Archer, 
1987; Amyes & Towner, 1990; Burdeska et al.,
1990) .
1.6 Epidemiology of trimethoprim resistance
Comparison of the prevalence rates of resistance to
trimethoprim is difficult as many factors may influence 
the percentage of resistant strains reported. These
factors include:
i) Choice of organism and specimen. Urinary isolates
are subjected to much higher concentrations of
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trimethoprim than those from sputum (Brumfitt, 
Hamilton-Miller & Kosmidis, 1973) hence a greater 
selective pressure on urinary organisms for 
acquired resistance. A greater percentage of 
Klebsiella are intrinsically resistant to 
trimethoprim than E.coli and this could also 
affect the reported resistance rate.
ii) Methodology. Some media have been reported to be 
antagonistic to trimethoprim activity (Amyes & 
Smith, 1974a) due to the presence of thymine 
and/or thymine derivatives. The inoculum size is 
important as apparent resistance occurs where the 
number of colony forming units per millilitre is 
too great (Bach et al., 1973).
iii) Type of patient and hospital. It has been shown 
that trimethoprim-resistant organisms are isolated 
more frequently from elderly patients (Huovinen, 
1984; Amyes Doherty & Young, 1986; Huovinen & 
Toivanen, 1986) and from patients in so called 
"long stay" hospitals (Amyes et al., 1980; Young & 
Amyes, 1983; Huovinen & Toivanen, 1986). There is 
also a difference in the number of resistant 
organisms isolated from in-patients compared to 
those visiting general practitioners (Towner, 
Smith & Cowlishaw, 1983), resistant strains being
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isolated more frequently from in-patients. This 
has been presumed to be due to the greater 
exposure of patients and organisms to antibiotics 
in a hospital environment.
iv) Occurrence of local epidemics. An epidemic of one 
or more resistant organisms has obvious problems 
in epidemiology but such a situation is more 
easily recognisable than an epidemic of a 
trimethoprim-resistant plasmid. Many such 
epidemics have been reported (Goldstein, 
Papadopoulou & Acar, 1986) and are only recognised 
when extensive plasmid analyses are performed.
v) Use of cotrimoxazole discs. The use of combination
discs does not allow an accurate assessment of
trimethoprim resistance. Cotrimoxazole is active
r s
against organisms which are trimethoprim Smx 
(Acar, Goldstein & Chabbert, 1973; Amyes, 1981). 
For these reasons assessment of changes in trimethoprim 
resistance is really only significant when long-term, 
follow-up studies are performed by the same laboratory. 
Since the introduction of trimethoprim as a 
chemotherapeutic agent resistance to the drug has been 
monitored on a continuous basis in several centres. These 
include Edinburgh, Nottingham and London (United 
Kingdom), Paris (France) and Turku (Finland). Single
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surveys have been performed in many other areas in 
Europe, South, Central and North America, Asia, the 
Middle East and Africa but there has been no follow-up 
data published from these areas so far.
Most studies have included all members of 
Enterobacteriaceae although a number of studies have been 
performed in which resistance to trimethoprim in a single 
member (E.coli) or group (shigellae) has been monitored. 
The following discussion of trimethoprim resistance will, 
unless specified, be confined to the family of 
Enterobacteriaceae.
1.6.1 Trimethoprim resistance in London
The changing pattern of trimethoprim resistance has 
been monitored in various London hospitals since 
the introduction of trimethoprim into clinical 
practice. In the Whittingdon Hospital a survey 
performed in 1970 by Anderson, Datta & Shaw (1972) 
showed that resistance to trimethoprim occurred in 
5.6% of all Enterobacteriaceae causing infections. 
Surveys were repeated five and seven years later in 
1975 and 1977 by Amyes, Emmerson & Smith (1978) and 
nine, eleven and thirteen years later in 1979, 1981 
and 1983 by Chirnside, Emmerson & Smith (1985).
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Over this period of time the incidence of 
trimethoprim resistance in urinary tract isolates 
rose from 9.8% in 1975 to 13.1% in 1979 and then 
decreased to 11.9% in 1983. Comparison of 
trimethoprim resistance in isolates from 
in-patients with those from out-patients showed a 
slightly different pattern. While resistance in 
organisms isolated from in-patients followed the 
general trend described, resistance in organisms 
isolated from out-patients increased steadily from 
0.5% in 1975 to 6.5% in 1983. Transferable 
R-plasmids were seen in 10.3% of all resistant 
isolates in 1975 and this increased by 27.8% to 
38.1% in 1983. During this period the number of 
isolates with transferable R-plasmids from 
out-patients was greater than those from 
in-patients.
In 1981 the first trimethoprim R-plasmids 
transferring resistance to trimethoprim alone were 
isolated and these were more numerous in 
out-patient than in-patient isolates. Prior to this 
trimethoprim resistance genes most frequently 
co-transferred with streptomycin/spectinomycin and 
sulphonamide resistance.
At the Hammersmith Hospital, London, the number of
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plasmid incompatibility groups associated with 
trimethoprim resistance was found to have increased 
by 1977. Initially trimethoprim resistance 
determinants were only found on IncW plasmids 
(Jobanputra & Datta, 1974) but by 1977 trimethoprim 
R-plasmids belonging to seven different 
incompatibility groups were found (Datta et al., 
1980) .
The first survey of trimethoprim resistance at the 
Royal Free Hospital, London, took place between 
1973 and 1975. In this study isolates from infected 
urines were studied (Grey, Hamilton-Miller & 
Brumfitt, 1979). The total trimethoprim resistance 
was only 3.2% when a breakpoint of 2 mg/1 was used. 
Of these resistant organisms 11.3% were highly 
resistant (MIC >1 000 mg/1) and trimethoprim 
R-factors were demonstrated in only 9%. These 
plasmids were all of the IncW incompatibility 
group. A second survey in the same hospital 
followed immediately from 1975 to 1977 (Brumfitt, 
Hamilton-Miller & Gooding, 1980). This showed that 
the incidence of trimethoprim resistance in 
hospital isolates had increased by 9.2% to 12.4% 
and that high-level resistance had increased by 
7.1% to 18.4%. Resistance in out-patient isolates
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was determined to be 7.5% of which 20% was 
high-level resistance. A third survey from October 
1978 to December 1979 (Hamilton-Miller, Gooding & 
Brumfitt, 1981) showed that the incidence of 
trimethoprim resistance had remained constant at 
11.5%. Of the resistant gram-negative bacilli 60% 
had MICs >1 000 mg/1, which was a substantial 
increase (41.6%) over the previous survey. Of the 
resistant isolates 14.5% transferred their 
determinants. A fourth survey of urinary pathogens 
collected at this hospital two years later in 1981 
(Brumfitt, Hamilton-Miller, & Wood, 1983) showed 
that trimethoprim resistance had remained stable at 
13% and high-level resistance was now present in 
75% to 90% of the resistant strains, an increase of 
15% to 30%. Resistance in isolates from general 
practice was only 5.8% at this time. The statistics 
of these surveys suggested that the rate at which 
resistance was being acquired was slowing down and 
that the introduction of trimethoprim as a single 
agent in 1979 had had no discernible effect on 
trimethoprim resistance as a whole. Four years 
later in 1985, however, trimethoprim resistance in 
urinary isolates from this hospital increased by 
12.6% to 25.6% (Hamilton-Miller & Purves, 1986)
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while the incidence in isolates from general 
practice increased dramatically from 5.8% to 21%. 
The proportion of gram-negative resistant strains 
with MICs >1 000 mg/1 was 81%, a figure comparable 
to the 1981 survey.
At the University Hospital, London, Gruneberg 
(1976) surveyed resistance in all urinary pathogens 
from 1971 to 1974 from both the hospital and 
general practice. In the community isolates 
trimethoprim resistance rose gradually from 6% in 
1971 to 10.5% in 1974 while in hospital strains 
resistance increased from 20.1% to 28.5%. There was 
little change in the percentage of E. coli which 
acquired resistance over the four years indicating 
that, up until that time, R-plasmids had not spread 
to any great extent in this environment.
1.6.2 Trimethoprim resistance in Nottingham and 
other areas in England
In Nottingham trimethoprim resistance has been 
monitored consistently from 1978 to 1985 (Towner & 
Slack, 1986). From 1978 to 1983 resistance in 
urinary isolates from in-patients gradually rose 
from 9.7% to 13.6%. In 1984, however, there was a
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sharp increase of 5.9% to 19.3% and thereafter a 
levelling off to 18.9%.
The trend in isolates from general practice 
paralleled this but at a lower level. Initially 
resistance was only 0.5% in 1978 but increased to 
11.6% in 1983. In 1984 and 1985 the percentage 
increased to 16.9% and 15.8% respectively. Although 
the incidence of resistance fell slightly in 1979 
the number of isolates owing their resistance to 
transferable R-plasmids trebled. There was also a 
large increase in the proportion of high-level 
resistance which was not transferable (Towner et 
al., 1980). Further study of these strains resulted 
in the first report of chromosomally-located 
transposon Tn7 (Towner, 1981). This type of 
resistance was found to be more common than first 
anticipated as 12 out of 50 isolates were shown to 
possess transposons integrated into the chromosome 
(Towner, Venning & Pinn, 1982).
Trimethoprim resistance plasmids in this area were 
first reported to belong to the IncP and IncI 
incompatibility groups (Towner et al., 1979) but 
later a greater variety of groups was implicated 
(Towner & Wise, 1983) . The first R-plasmids 
mediating resistance to trimethoprim alone were
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reported in 1980 and an increasing number of 
trimethoprim-resistant strains was found to be 
susceptible to sulphonamides. This was attributed 
to the changed selection pressure when trimethoprim 
was introduced on its own in 1979.
A survey of trimethoprim-resistant Shigella 
dysenteriae, S. boydii and S. flexneri isolated in 
England and Wales between 1979 and 1983 (Gross, 
Threlfall & Ward, 1984) showed an increase in 
trimethoprim resistance from 1.3% to 16.8%. 
Contrary to expectation the proportion of patients 
with recent foreign contact was smaller amongst 
those with resistant strains than among those with 
susceptible strains. This indicated that resistance 
factors were being acquired locally by these 
bacteria.
1.6.3 Trimethoprim resistance in Scotland
The incidence of trimethoprim resistance in 
Edinburgh, Scotland, has been monitored in various 
types of hospitals and in general practice since 
1978. From 1978 to 1982 the percentage of 
trimethoprim-resistant isolates (MIC >10 mg/1) in 
general hospitals ranged from 12.5% to 20.4%. Five
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percent of the isolates had MICs >1 000 mg/1 
and trimethoprim R-plasmids were found in 5% of the 
resistant isolates (Amyes et al., 1980; Amyes, 
1983; Amyes, 1986).
During the period October 1978 to April 1979 the 
incidence of resistance in a convalescent hospital 
was much greater (46%) with 13.4% of the isolates 
possessing R-plasmids (Amyes et al., 1980). Later, 
in 1981, the incidence of trimethoprim resistance 
in urinary isolates from patients in the 
orthopaedic unit of the Edenhall Hospital (a "long 
stay" situation) was reported to be an 
unprecedented 64%. A total of 25.5% of these 
isolates was resistant to >1 000 mg/1 trimethoprim 
(Amyes et al., 1982). Of 100 representative 
isolates 11 were shown to possess trimethoprim 
R-plasmids while 12 were unable to transfer
resistance and did not appear to possess any
plasmids. Resistance in the latter isolates was
shown to be due to the insertion into the
chromosome of two different transposons bearing 
resistant DHFR genes (Young & Amyes, 1983) .
The incidence of resistance in general hospitals 
between 1982 and 1984 was seen to decline from
18.3% to 12.3%. There was also a decrease in
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high-level resistance from 13.6% to 8.0%. In 1982 
the proportion of highly resistant isolates was 74% 
but this decreased in 1984 to approximately 65%. 
The number of strains possessing R-plasmids also 
decreased from 6.9% in 1982 to 2.7% in 1984 and not 
all of these were transmissible (Amyes, Doherty & 
Young, 1986). In 1982 half of the highly resistant 
strains were unable to transfer resistance but by 
1984 this had increased to two thirds. It was 
suggested that this trend was due to the 
integration of transposons bearing resistant DHFR 
genes into the chromosome.
A study of urinary isolates obtained from patients 
attending general practitioners was performed from 
October 1981 to October 1982 (Amyes, 1987). A total 
of 11.4% of the isolates was resistant to 
trimethoprim (MIC >10 mg/1) and of these 69.8% were 
resistant to >1 000 mg/1 trimethoprim. This 
represents 8% of all isolates which is a little 
over half that seen in hospital isolates at the 
same time. Transferable resistance was seen in 45% 
of the highly resistant isolates and most of these 
carried streptomycin/spectinomycin resistance 
determinants linked to trimethoprim. This suggested 
the presence of the transposon Tn7. In the
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remaining 55% of the high-level resistant isolates 
resistance was not transferable. Only 5 of these 
lacked visible plasmids.
In Glasgow, Scotland, resistance has been monitored 
but less frequently than in the centres reported 
above. From July 1979 to February 1980 192 
resistant urinary isolates were collected and of 
these 56% were highly resistant (Kraft, Platt & 
Timbury, 1983) . One hundred and twenty-three 
isolates were E.coli of which 71% had MICs 
>1 000 mg/1. Resistance was transferable in 50% of 
the E.coli. the balance of the resistance being 
presumed to be due to the presence of transposons 
or tra plasmids. In a follow-up survey two years 
later in 1982 (Kraft, Platt & Timbury, 1984) an 
increase of 10% in the number of highly resistant 
E.coli was seen - 71% to 81%. However, only 35% of 
these highly resistant isolates transferred their 
trimethoprim resistance markers. Plasmids which 
transferred trimethoprim resistance independently 
of Su resistance were more common in the second 
series although the majority of the strains were 
still resistant to sulphonamides. This suggested 
that although cotrimoxazole was still prescribed 
almost exclusively the genetic location and linkage
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of resistance markers was changing.
A similar study of trimethoprim-resistant coliform 
urinary isolates from out-patients was performed 
between 1981 and 1983 (Kraft, Platt & Timbury, 
1985). Only 10.2% of all isolates were resistant to 
trimethoprim (MIC >10 mg/1) . Of the 44 
trimethoprim-resistant E.coli studied 73% were 
highly resistant, which was similar to the 
percentage in hospital isolates. Resistance was 
transferable in 34% and the percentage of 
co-transferred trimethoprim and Su and of Su 
resistance without trimethoprim was similar to that 
in the 1982 hospital study.
1.6.4 Trimethoprim resistance in Europe and Scandinavia
In Europe trimethoprim resistance has been studied 
primarily in two centres (Paris, France and Turku, 
Finland) while single reports have emanated from 
other countries.
Trimethoprim resistance in Paris has been monitored 
since 1972 (Acar & Goldstein, 1982; Goldstein, 
Papadopoulou & Acar, 1986). All Enterobacteriaceae 
isolated from clinical specimens at the St Joseph 
Hospital, Paris, from 1972 to 1984 were collected
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and tested for trimethoprim resistance. The
majority of thesei isolates were from urine
specimens (£. 70%) and q . 25% were from
out-patients.
Over a ten-year period there was an increase in 
trimethoprim resistance from 17.9% in 1972 to a 
peak of 35.4% in 1982/3. In 1984 the incidence of 
resistance fell by 11.1% to 24.3%. The percentage 
of resistant strains which were highly resistant 
rose by 50.5% from 44.9% in 1974/5 to 95.4% in 
1984. The pattern of transferability, however, was 
different. In 1972/3 31.2% of high-level resistance 
was transferable. Ten years later this reached a 
peak of 62.6% and then decreased by 12.6% to 50% in 
1984. This pattern is consistent with that 
described in the United Kingdom at the same time. 
The most common incompatibility group of plasmids 
transferring trimethoprim resistance was IncC, 
although a variety of other groups was represented. 
These plasmids frequently transferred trimethoprim 
and Su as well as other antibiotic markers 
(Papadopoulou et al., 1986).
Other countries in Europe have reported on 
trimethoprim resistance at various times. In Italy 
Romero & Perducca (1977) reported an increase in
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resistance of 16.8% from 13.5% in 1973 to 30.3% in 
1975. There was also an increase in the proportion 
of highly resistant organisms from 12% to 23.3%. By 
1975 20% of the resistance was R-factor mediated 
and a number of different plasmid incompatibility 
groups was involved.
Trimethoprim resistance in Spain is apparently 
common in enterobacteria although no surveys have 
been published (Delgado & Otero, 1988). Resistance 
in Shigella. a common pathogen in Madrid, has been 
shown to occur in 89% to 97% of isolates 
(Lopez-Brea et al., 1983; Palenque, Otero & 
Noriega, 1983) . The majority of these highly 
resistant organisms contained the type I DHFR gene 
(Delgado & Otero, 1988).
In Bulgaria the first trimethoprim-resistant 
Shigella sonnei were isolated in 1980 (Bratoeva & 
John, 1989). In the period 1983 to 1987 20% of all 
shigellae isolated were trimethoprim resistant. The 
type I DHFR was present and all of the strains 
tested transferred their resistance.
In Finland cotrimoxazole was introduced in 1969 as 
in other European countries, but trimethoprim on 
its own came into clinical use in 1972, seven years 
earlier than in most other countries (Kasanen &
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Sundquist, 1982; Huovinen, 1987) . Since 1981 the 
amount of trimethoprim prescribed to out-patients 
has exceeded the amount of cotrimoxazole prescribed 
(Huovinen et al., 1985). However, the levels of 
resistance are comparable with those reported in 
Europe and some areas of the United Kingdom. This 
suggests that the use of trimethoprim alone does 
not adversely affect the development of resistance 
(Kasanen & Sundquist, 1982).
In 1978 enterobacteria isolated from in- and 
out-patients at the Turku Unversity Hospital 
(Huovinen & Toivanen, 1980) were tested for 
resistance to trimethoprim. Out-patient isolates 
were less resistant to trimethoprim than in-patient 
isolates (20.3% vs 39.8% respectively). Three years 
later in 1981 this survey was repeated using 
in-patient isolates (Huovinen, Pulkkinen & 
Toivanen, 1983) and only 9% were found to be 
resistant to trimethoprim, 38.6% of these being 
highly resistant. Resistance was transferable in 
19% of these isolates.
A survey in 1979 of trimethoprim resistance in 
enterobacteria isolated from urine specimens at the 
Turku City Hospital - a "long stay" hospital - 
(Huovinen, Pulkkinen & Toivanen, 1983) showed that
54
41% of the isolates were resistant (MIC >8 mg/1). 
The proportion of resistant isolates with MICs 
>1 000 mg/1 was 60.4%. Transferable resistance 
occurred in 13% of these isolates. The survey was 
repeated approximately one year later in 1980/1 and 
showed a similar situation. Resistance was now 
found in 35.4% of the isolates, compared to the 
previous 41%, and 68.7% of these, an increase of 
8.3%, were highly resistant. The incidence of 
transferable plasmids had also increased by 7% to 
20%.
Analysis of isolates collected in the Turku City 
Hospital in 1981/2 from patients more than 65 years 
of age in the geriatric wards showed an overall 
resistance rate of 22%. However, 38% of isolates 
from those patients who were catheterized were 
resistant to trimethoprim while only 13.4% of the 
strains from the non-catheterized patients were 
resistant (Huovinen, 1984) .
In 1983/4 trimethoprim resistance at Turku City 
Hospital remained between 32% and 35% (Huovinen et 
al., 1986). A high proportion of these isolates 
(47.2%) were shown to possess Tn7-like sequences 
suggesting the presence of DHFR type I in these
isolates.
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Two large surveys of trimethoprim resistance in 
out-patient isolates were undertaken in the Turku, 
Helsinki and Rovaniemi districts from 1978 to 1984 
and 1986 to 1988 (Huovinen, et al., 1985; Heikkila 
et al., 1990a). In the Turku area resistance 
virtually trebled from 5.4% in 1978 through 9.2% in 
1984 to 16% in 1988. Of the resistant isolates 
studied in the 1978 survey 83% were highly 
resistant and 39% carried Tn7-like sequences. Nine 
years later in 1987 93% of the resistant isolates 
from this area had MICs >1 000 mg/1, a 10% 
increase.
In the Helsinki district resistance was reported to 
be 1.0% from 1972 to 1977 (Kasanen & Sundquist, 
1982) and then increased in 1980 to between 2.9% 
and 4.2%. By 1984 resistance had increased to 11.1% 
of which 84% were highly resistant. Tn7-like 
sequences were demonstrated in 66% of the strains 
with MICs >1 000 mg/1 (Huovinen et al., 1985). Four 
years later in 1988 the incidence of resistance had
increased by 7.9% to 19%, high-level resistance
being present in 94% to 99% of the resistant
strains.
In the Rovaniemi district resistance remained 
constant initially, being reported as 3.1% in 1980
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and 5.7% in 1984. Only 76% of the resistant 
isolates in 1984 had MICs >1 000 mg/1 and 49% were 
shown to contain Tn7-like sequences. This situation 
changed between 1986 and 1988 when 14% of all 
isolates were found to be resistant to >8 mg/1. In 
1986 and 1987 all of the resistant isolates had 
MICs >1 000 mg/1 but in 1988 this decreased to 89%. 
The percentage of E.coli containing the type I DHFR 
increased steadily in all three regions from 1986 
to 1988, the largest increase occurring in the 
Helsinki district (7.3% to 13.9%).
Heikkila et al. (1990b) performed a study of 
trimethoprim resistance in Shigella species 
isolated in Finland between 1975 and 1988. Their 
results showed that resistance in these organisms 
was low (3.0%) between 1975 and 1982 but increased 
dramatically in the ensuing years to 42% in 1988. 
High-level resistance in these organisms 
predominated (98%) and the type I DHFR gene was 
found in 85% of the isolates studied. The type V 
DHFR was present in those strains isolated from 
travellers to Sri Lanka.
In Stockholm, Sweden, the level of resistance in 
urinary isolates from in-patients varied between 
1.6% and 3.6% in 1977/8 (Dornbusch & Toivanen,
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1981) . Transfer of resistance was achieved in 25% 
of resistant donors but a Tn7-like sequence was 
demonstrated in only one of the donor organisms 
(Dornbusch & Hagelberg, 1983) .
In a remote area of Sweden (Jamtland) only 153 
resistant isolates were recovered from about 2 000 
specimens. Of these isolates 28% were highly 
resistant, 34.9% of which contained Tn7-like 
sequences. These were transferable in some strains 
but not in others (Steen & Skold, 1985). There was 
good correlation between the use of trimethoprim 
and the occurrence of resistant bacteria in the 
community. However, 33% of the patients who had not 
been exposed to trimethoprim before harboured 
resistant flora (Skold, Boethius & Steen, 1986). 
This was thought to be due to selective pressure 
exerted by other antibiotics on bacteria harbouring 
multiple resistance plasmids or the spread of Tn7 
in enterobacteria.
1.6.5 Trimethoprim resistance: overview of Europe
Trimethoprim resistance in the United Kingdom, 
Europe and Scandinavia developed in much the same 
way although percentages varied from centre to
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centre. Initially trimethoprim resistance was low 
in most areas and was due largely to intrinsic 
mechanisms of resistance. There was a gradual but 
steady increase in resistance in the seventies but 
a marked rise in the proportion mediated by 
transferable R-plasmids. The R-plasmids also 
belonged to an increasing number of incompatibilty 
groups. In the early eighties a surge of resistance 
occurred with the majority of resistant isolates 
being highly resistant. A decrease in the number of 
transferable R-plasmids was observed and the first 
chromosomally integrated transposons bearing 
resistant DHFR genes were reported. The proportion 
of non-transferable, high-level resistance 
increased steadily while there was an apparent 
levelling off of the number of
trimethoprim-resistant organisms isolated. Some 
centres such as Edinburgh and Portsmouth even 
showed a decrease in the incidence of trimethoprim 
resistance (Maskell, 1985; Amyes, Doherty & Young, 
1986) .
1.6.6 Trimethoprim resistance in the USA
Trimethoprim resistance trends in the United States
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have not been as closely monitored as in Europe and 
the UK. Additionally, where surveys have been 
undertaken, resistance was tested using Tp/Smx 
combination discs and, therefore, the percentage 
reported cannot be considered an accurate 
indication of the incidence of trimethoprim 
resistance. Individual reports emanating from the 
USA suggest, however, that there has not been the 
same surge in resistance as was seen in Europe and 
the UK. In a worldwide survey of Tp/Smx resistance 
O'Brien et al. (1982) reported that resistance to 
cotrimoxazole in isolates collected between 1977 
and 1980 in 4 hospitals in the USA ranged from 3% 
to 9.5%. In a later report Mayer et al. (1985) 
further elaborated that in the Brigham and Woman's 
Hospital, Boston, resistance in Enterobacteriaceae 
from 1977 to 1982 had remained stable except in 
E.coli and Klebsiella. In E.coli resistance had 
increased from 2% to 5% and in Klebsiella from 7% 
to 14%. In 1983 resistance to cotr imoxazole was 
reported to range from 4% to 6% in E.coli isolated 
at three hospitals (Murray et al., 1985).
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1.6.7 Trimethoprim resistance in developing countries
Although trimethoprim resistance has not been 
surveyed in Mexico, reports on its emergence in 
faecal organisms isolated from students receiving 
prophylactic cotrimoxazole therapy while staying in 
Mexico indicated that high-level resistance 
determinants were not only present in that area but 
were probably fairly common (Murray et al., 1982). 
From a sample of 100 trimethoprim-resistant faecal 
E.coli 40 were found to transfer their 
trimethoprim resistance determinants. The type I 
DHFR gene was shown to be present in 12 of 20 tra+ 
isolates (Rudy & Murray, 1984) and frequently 
co-transferred with ampicillin and streptomycin 
resistance markers (Murray & Rensimer, 1983) .
In Santiago, Chile, Murray et al. (1985) reported 
that the incidence of resistance to Tp/Smx in 
E.coli isolated during February and July 1983 was 
44%. High-level trimethoprim resistance occurred in 
all of the 15 isolates tested and seven of these 
isolates transferred this marker. There was no 
difference in the incidence of trimethoprim 
resistance in the out-patient strains compared to 
the in-patient strains. In a more comprehensive
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study performed in the same area (Urbina et al., 
1989) 34% of all enterobacteria collected between
1983 and 1984 were resistant to trimethoprim. In 
this survey resistance to trimethoprim and Smx was 
determined separately and, therefore, these
statistics reflect trimethoprim resistance more
accurately than those of Murray et al. (1985). Of 
the resistant bacteria 52% were able to transfer 
their resistance by conjugation. In the majority of 
cases (87%) trimethoprim resistance was linked to 
Smx resistance. The linkage of trimethoprim with 
streptomycin resistance markers suggested the 
presence of the transposon Tn7 in this area and 
hence the type I DHFR.
Murray et al. (1985) performed a study of Tp/Smx
resistance in enteric pathogens (E.coli. Shigella 
spp. and Salmonella s o p . ) in Brazil and showed that 
44.4% were resistant to the combination. In 
Honduras the same authors reported Tp/Smx
resistance in E.coli isolated in 1983 to be 38% 
while a survey of a smaller number in Costa Rica 
showed that between 25% and 48% of the E.coli were 
resistant.
A study similar to that performed in Chile by 
Murray et al. (1985) was undertaken in Bangkok,
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Thailand, and this showed that 40% of all E,coli
isolated were resistant to Tp/Smx . The incidence of
resistance was the same when out-patient and
in-patient isolates were compared •
In Israel Alon et al. (1987) reported that
resistance to Tp/Smx in urinary pathogens had
increased steadily from 1980 to 1985. It is
probable, . therefore, that resistance to
trimethoprim alone increased in a similar fashion. 
In two hospitals (B & C) resistance in 1980 was 46% 
and 28% respectively. This increased to 63% in 
hospital B and 54% in hospital C in 1984. In an 
out-patient study resistance to Tp/Smx increased 
from 27% in 1981 to 51% in the first half of 1985. 
The slower development of resistance in community 
isolates correlates with that experienced in the 
UK.
In Kuwait Chugh (1985) collected enteric pathogens 
(E.colit Shigella s p p. and Salmonella s o p.) from 
1980 to 1983 and found that a total of 22.9% were 
resistant to trimethoprim. Of the highly resistant 
strains 98% transferred their determinants.
A study of trimethoprim resistance in urinary 
pathogens isolated at a hospital in Vellore, South 
India (Young et al., 1986) showed that 64% of the
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isolates were resistant to 10 mg/1 of trimethoprim. 
High-level resistance dominated, occurring in 57.3% 
of all isolates studied. More than half of the 
resistant isolates (58.2%) transferred their 
resistance genes. A high proportion of trimethoprim 
R-plasmids also carried Smx resistance 
determinants. A more recent report on trimethoprim 
resistance in Vibrio cholerae 01 isolated in this 
hospital (Jesudason & John, 1990) indicated that 
prior to 1987 these bacteria were susceptible to 
cotrimoxazole. However, from July 1987 to October 
1987 resistance increased at an alarming rate from 
4.5% to 81.5%. All of the isolates with 
trimethoprim MICs >1 000 mg/1 which were selected 
for further analysis were shown to be tra+ .
Plasmids with five different antibiograms were 
identified although one, which conferred resistance 
to Smx and chloramphenicol in addition to
trimethoprim, predominated. It was not determined 
which high-level resistance gene or genes were 
responsible for this resistance. However, the type 
I DHFR has been reported in Shiaella dvsenteriae 1 
in other centres in India (Haider et al., 1990).
In Africa Amyes & Young (1987) reported that 
resistance in enterobacteria isolated in Dar es
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Salaam, Tanzania, was 36%, high-level resistance 
occurring in 22% of the isolates. The type la DHFR 
was identified in a strain of Vibrio cholerae. this 
being the the first report of the presence of this 
gene outside of the Enterobacteriaceae.
In Nigeria Lamikrana & Ndep (1989) reported that 
63.3% of the gram-negative bacilli causing urinary 
tract infections were resistant to trimethoprim. 
The majority of resistant isolates (86%) were 
highly resistant and 50.8% were capable of 
transferring their resistance. Trimethoprim and Smx 
resistance co-transferred in 93.4% of the isolates 
and trimethoprim and streptomycin resistance only 
occurred in 7.5% of isolates. This suggested that 
Tn7 is not as widely spread in Nigeria as in other 
areas.
A survey of trimethoprim resistance in South Africa 
was undertaken from November 1986 to January 1987. 
The results of this will be discussed fully in the 
following chapter.
1.6.8 Trimethoprim resistance: developed vs developing
countries
Comparison of the available data on trimethoprim
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resistance from first-world and developing 
countries shows that the incidence of resistance is 
much greater in developing countries. It has been 
postulated that this could be due to the fact that 
trimethoprim is freely available in some of these 
countries without prescription and its use, 
therefore, is not as well controlled as in western 
countries (Farrar, 1985). In addition, 
trimethoprim is commonly used for the treatment and 
prevention of diarrhoeal disease in third-world 
countries and because these agents are relatively 
inexpensive and have broad spectrum activity, they 
have been over-utilised by practitioners more 
extensively in third-world countries. Inefficient 
control of hospital cross-infection may also play a 
role in the high frequencies of antimicrobial 
resistance in organisms isolated from hospital 
patients. Poor sanitary conditions, which are 
widespread in the third-world, also allow constant 
exposure of the population to enteric pathogens. 
This in turn probably assists in the spread of many 
antibiotic resistance determinants. Although a 
large proportion of trimethoprim resistance in 
developing countries is high-level (MIC 
>1 000 mg/1) most of the determinants have
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been shown to be transferable. This suggests that, 
unlike trends in Europe and the UK, resistance has 
remained plasmid-associated in third-world 
countries. Changes in this regard may yet become 
evident as more data are gathered from these 
countries.
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CHAPTER 2 EPIDEMIOLOGY OF TRIMETHOPRIM RESISTANCE IN
SOUTH AFRICA.
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2.1 INTRODUCTION
The incidence of trimethoprim resistance in South Africa 
had not been investigated prior to 1987. However, data on 
the incidence of resistance to cotrimoxazole in isolates 
from the Johannesburg General Hospital (now the Hillbrow 
Hospital) and Baragwanath Hospital were published as part 
of the worldwide survey of O'Brien et al. in 1982. 
Resistance to cotrimoxazole was greater in the South 
African hospitals than in most other participating 
hospitals which indicated that resistance to trimethoprim 
would also be high.
A three-month survey (November 1986 to January 1987) was 
performed in which resistance to trimethoprim alone was 
determined in gram-negative bacteria. Isolates were 
collected from the Johannesburg, Hillbrow and Baragwnanth 
Hospitals. In a preliminary study a number of isolates 
(36) were also tested for the presence of the type I 
and/or type II DHFR genes by DNA hybridization.
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2.2 MATERIALS AND METHODS
2.2.1 Bacteria
Gram-negative bacteria isolated in the routine 
diagnostic laboratories of the Baragwanath, 
Hillbrow and Johannesburg Hospitals were collected 
and identified to genus level by standard 
biochemical tests. Twenty-seven highly resistant 
isolates from this survey together with nine other 
gram-negative organisms (MIC >1 024 mg/1) which
were isolated in 1983 were selected for 
hybridization studies.
2.2.2 Minimum inhibitory concentration (MIC) 
determination
The MIC of trimethoprim for each organism was
determined by the method advocated by the National
Committee for Clinical Laboratory Standards
(1985) . A small volume (1 ml) of Davis-Mingioli
(DM) minimal medium (Davis & Mingioli, 1950)
containing 2.8% glucose was inoculated with the
o
isolate and incubated at 37 C until the medium was
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turbid (c. 2 to 2.5 h). The log phase culture was
4
diluted to q . 5.10 cfu/ml and inoculated onto DM
minimal agar plates containing 2.8 g/1 glucose and
appropriate concentrations of trimethoprim lactate
(Wellcome). A multipoint inoculator (Mast) was used
o
for this purpose. The plates were incubated at 37 C 
and read at 42 h. Isolates that did not grow on 
this medium were then tested on DM minimal medium 
plus thymidine (25 mg/1). Organisms that failed to 
grow on the supplemented minimal medium were 
retested on Iso-Sensitest agar (Oxoid). High-level 
resistance was defined as MIC >1 024 mg/1 and 
low-level (intermediate) resistance as MIC 16 to 
1 024 mg/1.
2.2.3 Gene probes
. A 500-bp Hpal fragment containing the type la DHFR 
gene was isolated from pFE506 (Fling & Elwell, 
1980) and used as the type I probe. The type II 
DHFR probe used originated from pFE364 and 
consisted of an 800-bp fragment cloned into the 
EcoRI site of pUC4 (a gift from M.E. Fling).
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2.2.4 Preparation and purification of gene probes
Plasmid DNA was extracted by the method of Clewell 
and Helinski (1969) with the following 
modifications. Bacterial cultures were grown 
overnight in Luria Broth (10% tryptone, 5% yeast 
extract, 5% NaCl) and 100 ml volumes were used for 
the preparation of plasmid. The pelleted bacteria 
were resuspended in 2 ml 20% sucrose and 0.25 ml 
of 10 mg/1 lysozyme (Sigma) was added. Following 
this 2.5 ml of both the 0.5 M EDTA solution 
(pH 8.5) and the lysing solution (10% Triton X-100, 
0.0625 M EDTA pH 8.5, 0.05 M Tris pH 8.5) were
added. The lysates were cleared by centrifugation 
in a Beckman J2-21 centrifuge (Beckman Instruments 
Inc., Palo Alto, California, USA) at 29 000 g for 
45 m. The plasmids were purified by cesium 
chloride density centrifugation as described by 
Maniatis et al. (1982). The plasmids were then 
restricted with the appropriate enzymes according 
to the manufacturer's specifications (Boehringer 
Mannheim GmbH, Penzberg, West Germany) and the 
fragments separated by a minisub gel 
electrophoresis apparatus (Biorad Laboratories, 
Munich, West Germany) with 2% NuSieve agarose (FMC
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Corporation, Rockland, M.E. 04841, USA) for the
pFE506 digestion and 1% SeaPlaque agarose (FMC
Corporation) for the pUC4-12 digestion. The
appropriate fragments were cut out of the gels and
placed in 1.5 ml reaction tubes (Eppendorf
Geratebau Netheler + Hinz GmbH, Hamburg, West
Germany) with 0.2 ml Tris-EDTA (TE) buffer (10 mM
Tris, 1 mM EDTA, pH 8) . The tubes were placed in a
o
waterbath at 60 C until the gel was liquified
(approximately 10 m) . The DNA was extracted
from the gel using 2x the volume phenol saturated 
with TE buffer. The tubes were vortexed briefly and 
centrifuged in a benchtop microfuge (Eppendorf) 
at 14 000 rpm for 7 m. The supernatants were 
removed, reserved and a further 0.1 ml TE buffer 
added to the phenol/gel mix. The extraction 
procedure was repeated. The supernatants were
combined and extracted twice with ether. The DNA 
was precipitated with 2x volume of absolute 
ethanol/300 mM sodium acetate, centrifuged, washed 
with 70% ethanol and dried. The pellets were
resuspended in TE buffer to an approximate 
concentration of 1 pg/5 pi.
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2.2.5 Nick translation and hybridization
32
Nick translation was performed with P-dCTP and a 
nick translation kit (Amersham International PLC, 
Bucks., UK) following the manufacturer's 
instructions (Appendix A) . Plasmid and chromosomal 
DNA were extracted from each of the 36 isolates and 
the appropriate controls by the method of Kado & 
Liu (1981), electrophoresed on a horizontal 0.7% 
agarose gel and transferred onto Biodyne nylon 
membrane (Pall Ultrafine Filtration Corporation, 
Glen Cove, N.Y., USA). This procedure and 
subsequent hybridization of the labelled probes 
were performed according to the manufacturer's 
instructions (Appendix B) . The washed blots were 
autoradiographed, stripped of the first probe and 
re-hybridized with the second probe.
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2.3 RESULTS
2.3.1 Trimethoprim resistance in all hospital strains
The results of the survey are summarized in Table 
2.1. The total number of isolates collected was 
2 914 and of these 1 141 (39.2%) were Escherichia 
coli, 540 (18.5%) Klebsiella s o p.. 438 (15%)
Pseudomonas s p p.. 346 (11.9%) Proteus s o p.. 289
(9.9%) Enterobacter spp. and 160 (5.5%) various
other gram-negative bacilli. The number of bacteria 
resistant to trimethoprim (MIC >8 mg/1) was 1 637 
(representing 56.2%) and 700 (24%) had high-level 
resistance (MIC >1 024 mg/1). Therefore, 42.8% of 
the resistant strains were resistant to >1 024 mg/1 
trimethoprim.
The overall resistance rate in
Enterobacteriaceae (MIC >8 mg/1) was 48.5%
(1 196/2 464) and amongst these the highest 
percentage resistance occurred in Klebsiella spp. 
(75.4%). The Klebsiella s p p. isolated in the 
Hillbrow Hospital were particularly resistant to 
trimethoprim as a total of 90.1% (136/151) were 
resistant to 16 mg/1 or more of trimethoprim. 
However, the majority of these resistant strains
Table 2.1. Trimethoprim resistance in gram-negative bacteria
ISOLATE BARAGWANATH JOHANNESBURG HILLBROW TOTAL
Total HLR LLR Total HLR LLR Total HLR LLR Total HLR LLR
ENTERQBACTERIACEAE
E.CPll 429 159 11 475 119 15 237 71 15 1 141 349 41
Klebsiella s p p . 275 104 101 114 27 39 151 18 118 540 149 258
P roteus b p p . 23 2 17 125 20 40 198 44 109 346 66 166
Enterobacter s o d . 97 17 23 95 12 37 97 6 24 289 35 84
Other entero- 
bacteria____________
46 7 1 62 6 13 38 7 14 148 20 28
A: TOTAL 872 269 153 871 184 144 721 146 280 2 464 619 577
O T H E R  S T R A I N S
Pseudomonas spp. 129 31 98 129 12 115 180 37 143 438 80 356
1 0 0 - - - 3 0 1 4 0 1
aJ.Kallg.eDes spp.. - 4 1 1 4 0 2 8 1 3
B: TOTAL 130 31 98 133 13 116 187 37 146 450 81 360
A+B: TOTAL 1 002 320 251 1 004 197 260 906 183 426 2 914 700 937
HLR « High-level resistance (MIC >1 024 mg/1)
LLR ■ Low-level resistance (MIC 16 to 1 024 mg/1)
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(118/136, 86.8%) fell into the low-level resistance 
category. Of the E.coli isolates only 34.2% (390/1 
141) were resistant to trimethoprim (MIC >8 mg/1) . 
However, 89.5% (349/390) of the resistant strains 
were highly resistant (MIC >1 024 mg/1). This was 
a surprisingly high proportion especially when this 
figure is compared with those of other genera; 
36.6% of resistant Klebsiella s o p ., 28.4% of 
resistant Proteus spp. and 29.4% of resistant 
Enterobacter spp. had MICs of >1 024 mg/1.
The proportion of high-level resistant isolates in 
each genus varied considerably. In Enterobacter 
spp. only 12.1% (35/289) of all isolates were 
highly resistant, in Proteus sop. 19.1% (66/346), 
in Klebsiella spp. 27.6% (149/540) and in E.coli 
30.6% (349/1 141). Since E.coli represents 46.3% of 
the enterobacteria isolated, this affects the final 
percentage of high-level resistance in the whole 
enterobacterial population. In spite of this, 
however, the final percentage of 25.1% (619/2 464) 
is not remarkably high.
Significant resistance to trimethoprim was observed 
in Pseudomonas s o p , as only two out of 438 strains 
were sensitive to trimethoprim. Amongst the 436 
resistant pseudomonads, however, only 18.3% were
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resistant to >1 024 mg/1 of trimethoprim.
2.3.2 Trimethoprim resistance in urinary isolates
Since trimethoprim is used frequently and is 
particularly indicated in the treatment of urinary 
tract infections, an analysis of bacteria isolated 
from urine specimens was performed. These results 
are presented in Table 2.2.
There were 2 914 strains isolated in the original 
survey and 1 218 (41.8%) of these were obtained 
from urine specimens. Amongst the urinary strains 
771 (63.3%) were E.coli. 168 (13.8%) Klebsiella
spp., 115 (9.4%) Proteus s p p ., 68 (5.6%)'
Enterobacter spp. and 96 (7.9%) various
gram-negative bacilli. Overall resistance to 
trimethoprim (MIC >8 mg/1) was 49.1% (598/1 218).
However, this proportion included the Pseudomonas 
s p p . . When the Pseudomonas spp. were excluded 46% 
(529/1 149) were resistant to trimethoprim.
When all the resistant strains were examined for 
high-level resistance (MIC >1 024 mg/1) 66.6%
(398/598) fell into this category. When the
pseudomonads were excluded an even higher
percentage of 71.8% (380/529) of the resistant
Table 2.2. Trimethoprim resistance in urinary isolates
I S O L A T E  B A R A G W A N A T H  J O H A N N E S B U R G  H I L L B R O W  T O T A L
Total HLR LLR Total HLR LLR Total HLR LLR Total HLR LLR
ENTEROBACTERIACEAE
E.coll 275 114 9 384 102 12 112 44 9 771 260 30
Klebsiella b p p . 82 34 28 64 18 20 22 5 13 168 57 61
Proteus spp. 4 1 1 65 7 23 46 23 14 115 31 38
Enterobacter s d d . 28 11 6 33 9 8 7 1 1 68 21 15
Other entero- 3 3 0 17 3 4 7 5 1 27 11 5
bacteria
TOTAL 392 163 44 563 139 67 194 78 38 1 149 380 149
QXtiER .STR&IES
6 4 2 43 6 37 20 8 12 69 18 51
TOTAL 398 167 46 606 145 104 214 86 50 1 218 398 200
HLR = High-level resistance (MIC >1 024 mg/1)
LLR = Low-level resistance (MIC 16 to 1 024 mg/1)
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isolates grew in the presence of trimethoprim at 
1 024 mg/1.
The highest percentage of high-level resistance was 
in those isolates from Baragwanath Hospital where 
78.4% (167/213) of the resistant isolates had 
trimethoprim MICs >1 024 mg/1. Thus, 42% of all 
urine isolates from this hospital were highly 
resistant to trimethoprim.
The Klebsiella spo. were again the most resistant 
organisms amongst the Enterobacteriaceae. The 
overall rate of trimethoprim resistance in this 
genus was 70.2% (118/168). However, only 48.3% 
(57/118) of these were highly resistant to 
trimethoprim.
E .coli isolates represented 63.3% (771/1 218) 
of all the urinary strains examined and of these 
37.6% (290/771) were resistant to >8 mg/1 
trimethoprim. Moreover, 89.7% (260/290) of these 
resistant bacteria had MICs >1 024 mg/1. The 
resistant E.coli strains isolated at Baragwanath 
Hospital had the highest percentage at 92.7% 
(114/123) of high-level resistance. Other genera in 
the three hospitals had lower proportions of 
high-level resistance in Tp-resistant bacteria; 
Klebsiella spp. 48.3% (57/118) , Proteus spp.
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45% (31/69), Enterobacter s p p. 58% (21/36) and
Pseudomonas spp. 26% (18/69).
2.3.3 Comparison of the incidence of trimethoprim
resistance in urinary and non-urinarv isolates
A comparison of the prevalence rates of resistance
in urinary and non-urinary isolates is presented in
Table 2.3. Overall there were more resistant
isolates in the non-urinary group (61.3%,
1 039/1 696) than in the urinary group (49.1%,
598/1 218) . Analysis of these figures shows,
however, that 70.9% (737/1 039) of the resistance
in non-urinary isolates was low-level (MIC 16 to
1 024 mg/1) compared to 33.4% (200/598) in urinary
isolates. This difference is statistically 
2
significant (X = 216.41, p < 0.0001).
Analysis of resistance in the four main genera 
shows that amongst both E.coli and Enterobacter 
spp. isolated from urine specimens a greater 
proportion were resistant to trimethoprim than 
their non-urinary counterparts. High-level 
resistance accounted for 89.7% and 58.3% in urinary 
isolates of E.coli and Enterobacter s p p. 
respectively. Klebsiella spp. and Proteus s p p .
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Table 2.3. Comparison of the percentage of trimethoprim
resistance in urinary and non-urinary isolates.
URINARY NON-URINARY
Total Tp Resistance (%) 49.1 61.3
% HLR in resistant isolates 66.6 29.1
% HLR in all isolates 32.7 17.8
Resistance in: T o t a l (%) H L R (%) T o t a l (%) H L R (%)
E.^£ali 37.6 89.7 27.0 89.0
Klebsiella b e d . 70.2 48.3 77.7 31.8
Proteus b p d . 60.0 44.9 70.6 21.5
Enterobactex-Bgit. 52.9 58.3 37.6 16.9
HLR » High-level resistance (MIC >1 024 mg/1)
isolated from 
from other 
proportion of
urine were less resistant than those 
specimens. However, the greater 
the resistant urinary strains had
trimethoprim MICs >1 024 mg/1. Overall, therefore,
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a much greater proportion of urinary isolates were 
highly resistant to trimethoprim than non-urinary 
isolates (66.6% vs 29.1%).
2.3.4 Comparison of trimethoprim resistance in different 
hospitals
The frequency of trimethoprim resistance (MIC
>8 mg/1) in the three hospitals varied
considerably. When only the enterobacterial strains
were examined 59% (426/721) of the Hillbrow
Hospital isolates were resistant compared with
50.6% (442/872) for Baragwanath Hospital and 37.6%
(328/871) for the Johannesburg Hospital. These
differences are statistically significant
2
(X = 26.36, p < 0.001) .
2.3.5 DNA hybridization
In the preliminary study a small number of E.coli. 
Klebsiella s o p , and Proteus spp. isolates were 
investigated by DNA hybridization for the presence 
of the type I and type II genes. The only criterion 
used for their selection was an MIC >1 024 mg/1. 
Twenty-seven isolates from the 1986/7 survey were
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investigated together with nine others isolated in 
1983. There were twelve each of E.coli. Klebsiella 
spp. and Proteus sop.. None of the isolates from 
the 1983 group and none of the Proteus spp. from 
the 1986/7 group hybridized with either probe. Of 
the E.coli isolates only two hybridized positively 
with the type I probe but none with the type II 
probe. Similarly, only six of the Klebsiella s p p. 
hybridized positively with the type I probe but 
none with the type II probe. Thus, a total of eight 
of the 36 isolates hybridized positively with the 
type I probe but none with the type II probe. 
Figures 2.1. and 2.2. illustrate some of these
results.
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Figure 2.1. A: Gel electrophoresis of plasmid and 
chromosomal DNA extracted from E.coli isolates. 
Lane 1, Tps E.coli; 2, pFE506 (type I DHFR) ; 3,
pUC4-12 (type II DHFR); 4 - 12, E.coli isolates
(MIC >1 024 mg/1). B: autoradiogram of the gel in A 
hybridized with a type I DHFR gene probe. C: 
autoradiogram of the gel in A hybridized with a 
type II DHFR gene probe. Tp = trimethoprim.
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Figure 2.2. A: Gel electrophoresis of plasmid and 
chromosomal DNA extracted from various Proteus 
species. Lane 1, Tps Proteus: 2, pFE506 (type I
DHFR); 3, pUC4-12 (type II DHFR); 4-12, Proteus
isolates (MIC >1 024 mg/1) . ( Lane 6 =
P.mirabilis (J120)). B: autoradiogram of the gel in 
A hybridized with a type I DHFR gene probe. C: 
autoradiogram of the gel in A hybridized with a 
type II gene probe. Tp = trimethoprim
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2.4 DISCUSSION
Table 2.4. compares trimethoprim resistance reported from 
several European centres with that from developing 
countries. In these studies resistance to trimethoprim 
alone was determined and the bacteria were isolated from 
hospitalized patients.
The incidence of resistance in urinary isolates from 
London, Edinburgh and Turku was similar, falling within 
the range 8.6% to 12.3% (Huovinen, Mantyjarvi & Toivanen, 
1982; Brumfitt, Hamilton-Miller & Wood, 1983; Amyes, 
1986). Of these resistant strains the percentage which 
were highly resistant varied somewhat: 29.5% to 78%. 
However, of all the urinary isolates tested in these 
surveys high-level resistance only occurred in 2.7% to 
9.5%.
In comparing the values obtained in the Indian study with 
those of Western Europe a marked difference is evident. A 
total of 64.1% of the Indian strains (as compared to 8% 
to 12% of European strains) was resistant to 
trimethoprim, 89.6% of these being highly resistant. 
Therefore, a massive 57.3% of all strains isolated were 
highly resistant to trimethoprim (Amyes, Doherty & Young, 
1986) . The values obtained for the three South African 
hospitals fall between those of Western Europe and India,
Comparison of trimethoprim resistance in various centres.
DATE PLACE TOTAL Tp %HLR/RES % HLR/TOTAL TOTAL No.OF REFERENCE
RESISTANCE (%) ISOLATES No . ISOLATES ISOLATES
1980/1 Turku (Finland)
Turku University 12.2 (29.5) 3.6 436 Huovinen et al. (1982)
Kuopio University 8.6 (31.4) 2.7 430 Huovinen et al. (1982)
1981 London (UK) 12.2 78 ( 9.5) 1 444 Brumfitt et al. (1983)
1984 Edinburgh (UK) 12.3 (65.0) 8 323 Amyes (1986)
URINARY 1984 Vellore (India) 64.1 89.6 57.3 284 Young et al. (1986)
ISOLATES 1985 Dar es Salaam
(Tanzania) - - 27 - Amyes (1986)
1986/7 Johannesburg
(South Africa)
Baragwanath 53.5 78.4 42.0 398 This study
Johannesburg 41.1 58.2 23.9 606 This study
Hillbrow 63.6 63.2 40.2 214 This study________________
1984 Paris (France) 24.3 95.4 (23.2) 5 494 Goldstein et al. (1986)
1985 Dar es Salaam
(Tanzania) 36.0 - 22.0 - Amyes (1986)
ENTERO- 1986/7 Johannesburg
BACTERIA (South Africa)
Baragwanath 50.7 65.4 33.1 872 This study
Johannesburg 37.7 56.1 21.1 871 This study
Hillbrow_______________-JtlA__________ 34.3____ 20.2______ 721 This studv
Notei The figures in parenthesis were not quoted in the referenced paper
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although they resemble the Indian values more closely. 
Resistance to trimethoprim ranged from 41.1% to 63.6% 
while high-level resistance occurred in 66.3 to 79.3% of 
all resistant isolates. Therefore, between 27.2% and 43% 
of all urinary isolates were resistant to >1 024 mg/1 
trimethoprim. In this, therefore, South Africa can be 
classed with other developing countries.
The reason (or reasons) for the high frequency of 
resistance is a matter for speculation. Antibiotics are 
not available over the counter as in other developing 
countries and thus this form of abuse cannot contribute 
to the high incidence of resistance. However, the amount 
of trimethoprim dispensed per annum to both in-patients 
and out-patients at these hospitals is large. Baragwanath 
Hospital uses 47.5 kg per annum as cotrimoxazole, 
Hillbrow Hospital 16 kg as cotrimoxazole and 2.3 kg as 
trimethoprim and Johannesburg Hospital 1.2 kg as 
cotrimoxazole and 20 kg as trimethoprim. These amounts 
are of the same order as those used in the Muhimbili 
Hospital, Dar es Salaam, and in the Christian Medical 
College Hospital, Vellore, but significantly more than 
that used in the Royal Infirmary, Edinburgh, (Amyes & 
Young, 1987) . Because the greater proportion of 
trimethoprim dispensed at Baragwanath Hospital is 
prescribed to out-patients (43 kg per annum), patient
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non-compliance in completing the course of antibiotics 
may be an important factor in the prevalence of 
resistance. With such large amounts of trimethoprim 
consistently present in the community the selective 
pressure created may also promote the spread of 
R-plasmids carrying trimethoprim-resistant DHFR genes. 
Comparative figures for the Hillbrow and Johannesburg 
Hospitals were not available.
In enterobacteria as a whole isolates from Western 
countries were generally less resistant than those from 
developing countries. Taking the values reported from 
Paris (Goldstein, Papadopoulou & Acar, 1986) as an 
example, resistance in enterobacteria was 24.3% as 
compared to 36% in Dar es Salaam and 37.7% to 59.1% in 
Johannesburg.
Comparison of high-level resistance from the same centres 
shows great consistency, however, with only Baragwanath 
Hospital having a higher proportion of enterobacteria 
resistant to >1 024 mg/1 trimethoprim. Intrinsic 
mechanisms of resistance and/or plasmid-mediated 
intermediate resistance must, therefore, account for the 
higher resistance percentage in Tanzania and South 
Africa.
Comparison of resistance in urinary and non-urinary 
isolates shows that although there are more resistant
90
non-urinary isolates, high-level resistance is much more 
prevalent in urinary isolates. Since trimethoprim is one 
of the drugs of choice in the treatment of urinary tract 
infections its use (which results in high urinary 
concentrations) appears to be creating selective pressure 
for high-level resistance determinants in these bacteria. 
In the preliminary hybridization study only eight out of 
36 isolates (22%) hybridized with the type I probe and 
none with the type II probe. These results were 
unexpected as high-level resistance mediated by the 
type I DHFR has been shown to be common in many 
countries. Resistance in the remaining isolates may, 
therefore, be due to one or more unidentified DHFRs.
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CHAPTER 3 IDENTIFICATION OF A NOVEL PLASMID-ENCODED 
DIHYDROFOLATE REDUCTASE MEDIATING HIGH-LEVEL 
RESISTANCE TO TRIMETHOPRIM
52
3.1 INTRODUCTION
Enzymes are proteins specialized to catalyze biological 
reactions. They are remarkably specific and have great 
catalytic power, some depending on co-factors and/or 
co-enzymes for activity. Enzymes are classified according 
to the type of reaction they effect e.g. oxido-reductases 
are involved in oxidation-reduction reactions, 
transferases effect the transfer of functional groups and 
ligases are required in reactions where bonds are 
created.
Enzymes have many different properties which are used in 
their characterization. The most fundamental of these are 
the kinetics of the reaction they catalyze. The general 
theory of enzyme action and kinetics, developed in 1913 
by L. Michaelis and M.L. Menton and extended in 1925 by 
G.E. Briggs and J.B.S. Haldane, gave rise to the 
well-known Michaelis-Menton equation
Vmax[S]
V° ~ Km + [S]
where v0 is the initial rate of the reaction and [S] is 
the substrate concentration. The Michaelis constant (Km)
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reflects the rate at which the enzyme-substrate complex 
is formed while the maximum velocity of the reaction 
(Vmax) reflects the rate at which the enzyme-product 
complex dissociates. The values of Km and Vmax are 
determined experimentally and are characteristic for each 
enzyme. In order to obtain accurate values for Km and 
Vmax single or double reciprocal plots of the Michaelis 
equation can be used. The equation for the 
Lineweaver-Burk plot is derived by taking the reciprocal 
of both sides of the Michaelis-Menton equation and 
rearranging to yield
Km 1 1
Vmax [ S] Vmax
When l/vQ is plotted against 1/[S], a straight line is 
obtained with a slope of Km/Vmax, an intercept of 1/Vmax 
on the l/vD axis and an intercept of -1/Km on the 1/[S] 
axis.
A second useful transformation of the Michaelis-Menton 
equation is obtained by multiplying the above equation by 
Vmax and rearranging to yield
vovQ - -Km -—  + Vmax [S]
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A plot of v0 vs vQ /[S] (Eadie-Hofstee plot) yields a 
straight line from which values for Km and Vmax can be 
obtained.
The study of enzyme inhibitors has provided important 
information on the mechanism and pathway of enzyme 
catalysis. There are three types of reversible enzyme
inhibition viz. competitive, uncompetitive and 
noncompetitive. These can be experimentally distinguished 
by the effects of the inhibitor on the reaction kinetics 
of the enzyme and these may be analyzed in terms of the 
basic Michaelis-Menton rate equation.
i) A competitive inhibitor reacts with the enzyme in
such a way that it competes with the normal
substrate for binding at the active site. The 
inhibitor is not changed in any way during this 
reaction. The inhibitor constant (Ki) is the 
dissociation constant of the enzyme-inhibitor
complex.
ii) In uncompetitive inhibition the inhibitor binds to
the enzyme-substrate complex to give an
enzyme-substrate-inhibitor complex which cannot 
undergo any further reaction. Uncompetitive 
inhibition is rare in single substrate reactions but 
is more common where two substrates are involved.
iii) Noncompetitive inhibitors bind to either the enzyme
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or the enzyme-substrate complex at a site other than 
the active site. This causes the formation of 
abnormal enzyme-substrate complexes which cannot 
undergo further reaction.
The three types of inhibitors can be distinguished by 
plotting l/vQ vs 1/[S] for different, fixed 
concentrations of inhibitor. The plots obtained are 
characteristic for each type of inhibition.
Other distinguishing features used to characterize 
enzymes include determinations of molecular weight, 
sub-unit structure, isoelectric point (pi), substrate and 
inhibitor profiles, thermolability or stability and amino 
acid and DNA sequences. Sophisticated techniques such as 
X-ray crystallography have also provided valuable 
information on the three-dimensional structure of enzymes 
alone and in combination with their substrate and/or 
co-enzyme. Substrate, inhibitor and co-enzyme binding 
sites have been identified in this way.
Dihydrofolate reductases (DHFRs) catalyze the conversion 
of dihydrofolate to tetrahydrofolate in a reaction which 
requires the co-enzyme nicotinamide adenine dinucleotide 
phosphate (NADPH). Although all DHFRs catalyze the same 
reaction they are not identical molecules and have been 
assigned to different groups using the approaches to 
characterization listed above.
96
Prior to 1987 the molecular basis of high-level 
trimethoprim resistance in South African isolates had not 
been investigated. The pilot hybridization study, 
described in Chapter 2, suggested that the type I and 
type II DHFR genes were not as common in local isolates 
as expected. It was possible, therefore, that another 
resistant DHFR was mediating high-level resistance in 
these organisms. Several isolates whose DNA did not 
hybridize with either of the probes were investigated for 
DHFR activity. One organism, Proteus mirabilis (J120),
was selected for further investigation.
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3.2 MATERIALS AND METHODS
3.2.1 Bacteria
P.mirabilis (J120) which was resistant
to ampicillin, tetracycline and trimethoprim was 
isolated from wound irrigation fluid. Escherichia 
coli K12 strain J62-2 (pro his trp rif) (Bachmann, 
1972) was used as the recipient in conjugation 
experiments.
3.2.2 Minimum inhibitory concentration (MIC) 
determination
The MICs of trimethoprim for P.mirabilis (J120) 
and the E.coli transconjugants were determined as 
previously described in Chapter 2. Davis Mingioli 
minimal medium supplemented with 2.8% glucose was 
used.
3.2.3 Plasmid demonstration and sizing
DNA was extracted from the bacteria by the method 
of Kado & Liu (1981) . Samples from each culture 
were electrophoresed in a flatbed, 0.7% agarose gel
98
at 3.75 V/cm for 5 h. The gel was stained 
with ethidium bromide (1 mg/1 final concentration) 
for 2 to 3 h. Plasmid sizes were determined 
from the distance they had migrated in comparison 
with standard plasmids as previously described 
(Amyes & Gould, 1984) .
3.2.4 Conjugation studies
Bacterial conjugation studies were performed by the
method of Amyes & Gould (1984). The donor
(P.mirabilis (J120)) and recipient (E.coli J62-2)
strains were inoculated into nutrient broth and
o
grown for approximately 5 h at 37 C in an
environmental shaker (Gallenkamp) . Fresh 
o
nutrient broth (4.5 ml) was warmed to 37 C and
inoculated with 0.1 ml of the donor and
1.0 ml of the recipient. The mixture was
o
incubated overnight at 37 C. After vortexing the
broth 0.1 ml aliquots were plated onto DM minimal
medium plates supplemented with 2.8% glucose
and containing histidine (50 mg/1), tryptophan
(50 mg/1), proline (50 mg/1), trimethoprim
lactate (10 mg/1) and rifampicin (25 mg/1). The
o
plates were incubated at 37 C for 16 h.
99
3.2.5 DHFR assay
DHFR activity was assayed by the method of Osborn &
Heunnekens (1958). Reactions were performed in a
o
Pye Unicam spectrophotometer (Phillips) at 37 C. 
The reaction mixture consisted of 40 mM sodium 
phosphate buffer pH 6.0, 0.1 mM NADPH,
10 mM /3-mercaptoethanol, enzyme, trimethoprim or 
methotrexate where appropriate and distilled 
water to 0.95 ml. This was allowed to equilibrate 
for one minute before the reaction was started by 
the addition of dihydrofolate to 0.05 mM. The 
reaction was followed by noting the decrease in 
absorbance at 340 nm over a period of 3 minutes. 
The activity of the enzyme was defined as:
AOD/min x 82.5 x dilution factor (nmol DHF 
reduced /min/ml).
3.2.6 DHFR preparation and purification
Three litres of bacterial culture were grown
overnight in nutrient broth (Oxoid) on a shaking
platform. The bacteria were harvested by
o(3 800 g) at 4 C for 10 min.centrifugation
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All further manipulations were performed at 4 C. 
The bacterial pellet was washed with 50 ml DM 
minimal medium, pelleted again and finally 
resuspended in 20 ml ice-cold buffer A
(50 mM sodium phosphate buffer pH 7.4 containing 
10 mM 0 -mercaptoethanol and 1 mM EDTA). The 
suspension was sonicated for 3 x 45 sec using a MSE 
Soniprep 150 then clarified by centrifugation at 
40 000 g for 1 h. The resultant supernatant was the 
crude enzyme preparation. Nucleic acids were 
removed by precipitation with 1% streptomycin 
sulphate and the enzyme was precipitated with 
ammonium sulphate as detailed in the results 
section. The final ammonium sulphate precipitate 
was pelleted and resuspended in 2 ml Buffer A. 
The enzyme activity and protein concentration 
(Waddell, 1956) were determined at each stage.
3.2.7 Molecular weight determination
The molecular weight of the enzyme was determined
by Sephadex exclusion chromatography as previously
described (Amyes & Smith, 1974). Partially purified
DHFR preparation (2 ml) was applied to a Sephadex
2
G-75 column (2 cm cross sectional area x 90 cm)
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which had been previously calibrated using
ovalbumin (Mr = 45 000) , chymotrypsinogen (Mr =
25 500) and cytochrome c (Mr = 12 384). The enzyme
was eluted from the column with Buffer A containing
1 mg/1 bovine serum albumin at a flow rate of
10 ml/h. Fractions (2 ml) were collected using a
Model 2214 fraction collector (LKB) and analyzed
for DHFR activity. Finer determination was
2
obtained with a Sephadex G-50 column (2 cm 
x 90 cm) when chymotrypsinogen, cytochrome c and 
the (3 subunit of insulin (Mr = 3 878) were
employed as molecular weight standards.
3.2.8 Heat sensitivity
Aliquots of enzyme preparation were maintained at 
' o
45 C in a preheated waterbath from 15 seconds to 
two minutes. A sample was removed every 15 seconds, 
rapidly cooled on ice and the enzyme activity 
assayed.
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3.3 RESULTS
3.3.1 MIC, conjugation and DHFR purification
The clinical strain P.mirabilis (J120) was highly 
resistant to trimethoprim (MIC >1 024 mg/1). 
The trimethoprim resistance determinant was 
transferred into E .coli J62-2. A single, large 
plasmid of approximately 79 kb, designated 
pUK672, was demonstrated in both the wild type and 
its transconjugant. This plasmid was presumed to 
carry the trimethoprim resistance determinant. 
Cell-free extracts from both the original clinical 
strain (J120) and its E.coli J62-2 transconjugant 
(strain J62-2(pUK672)) were assayed for DHFR 
activity. Both strains had similar levels of 
activity (Table 3.1.) which were 20- to 40-fold 
higher than those in plasmid-free cells. The 
presence of trimethoprim in the growth medium did 
not significantly elevate the enzyme levels, 
suggesting that expression was not inducible.
DHFR activity was purified from both J120 and 
J62-2(pUK672) . After removal of the nucleic acids 
with streptomycin sulphate the protein was 
selectively precipitated with ammonium sulphate.
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Table 3.1. The specific activities of dihydrofolate 
reductase in P.mirabilis (J120) and its transconjugant.
Bacterial Strain Designation Plasmid
SA of DHFR 
(nmol DHF reduced 
/min/ma orotein)
P.mirabilis J120 (pUK672) 42.2
E.coli J62-2 (pUK672) 20.8
E.coli J62-2 R 1.1
Previous plasmid-encoded DHFR enzymes have all 
precipitated when the ammonium sulphate 
concentration was raised from 50 to 80% saturation. 
However, in this case 69.2% of the DHFR activity 
had precipitated at 50% saturation (Table 3.2.). 
When precipitate arising from this step was applied 
to a Sephadex G-75 column a single peak of 
dihydrofolate reductase activity was found at 
fraction 58. This trimethoprim-sensitive DHFR peak 
had a molecular weight of 23 600 and was assumed to 
be the chromosomal enzyme. However, when gel 
filtration was repeated with bovine serum albumin
Table 3.2. Purification of dihydrofolate reducatase from P.mirabilis (J120).
Stage Volume
(ml)
Protein cone, 
(mg/ml)
'DHFR Activity 
(nmol/min/ml)
SA
(nmol/min/mg
protein)
Purification
(-fold)
Recovery
(%)
Bulk 17 28.17 1 188 42.17 1 100
50% (NH ) SO 4 2 4 supernatant 17.5 5.08 49.5 9.74 0.23 4.3
50% (NH ) 4pellet
SO2 4 2 84.5 6 987.75 82.7 1.96 69.2
80% (NH ) 4pellet
SO2 4 2 67.73 759 11.21 0.27 7.5
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(10 mg/1) added to the elution Buffer A, a larger 
DHFR peak emerged at fraction 75. The enzyme in 
this peak was resistant to trimethoprim.
3.3.2 Molecular weight of the plasmid DHFR
The elution behavior of the trimethoprim-resistant
DHFR activity on Sephadex G-75 suggested an enzyme
with a low molecular weight. Therefore, the
precipitate arising from increasing ammonium
sulphate saturation from 35% to 60% was applied to
2
a Sephadex G-50 column (2 cm x 90 cm) , which had 
been calibrated with proteins of known molecular 
weight. After elution with Buffer A containing 
bovine serum albumin (10 mg/1) extracts from both 
J120 and J62-2 (pUK672) gave a single peak 
corresponding to a molecular weight of 10 000
(Figure 3.1.) .
106
Figure 3.1. Sephadex G-50 gel filtration of the
type VI dihydrofolate reductase. •--- - ,
Dihydrofolate reductase activity;e---» , elution of
standard marker protein (OD2so)* A '
chymotrypsinogen (Mr = 25 500); B, cytochrome c 
(Mr = 12 384); C, chain of insulin (Mr = 3 878).
3.3.3 Sensitivity of the plasmid DHFR to antifolate 
compounds
The enzymes eluted from the Sephadex G-50 peaks 
were assayed in the presence of increasing 
concentrations of trimethoprim. Both the DHFR from 
the original strain and its E.coli transconjugant 
lost 50% of activity in the presence of around
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200 /xM trimethoprim (Figure 3.2.). The 
concentration of methotrexate required for 50% 
inhibition was 7.25 /xm. In both cases the enzyme 
activity was inversely proportional to the 
logarithm of the inhibitor concentration over the 
concentration range tested.
Figure 3.2. Determination of the ID50 for 
trimethoprim of the type VI DHFR from P.mirabilis 
(J120) .
3.3.4 DHFR activity under limiting substrate 
concentrations
The activities of the enzymes were examined under 
partial saturation with dihydrofolate and full 
saturation with NADPH (50 /XM) . Control studies
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showed that increasing the concentration of NAD PH 
above 20 /xM did not affect the rate of the 
reaction. The results analyzed by Lineweaver-Burk 
plots (Figure 3.3.) showed that the Km of 
dihydrofolate for the enzyme was 66 /xM. The assays 
were repeated in the presence of 100 /xM 
trimethoprim and it was found that the 
maximum velocity of the reaction was unchanged 
(Figure 3.3.) , indicating that although this enzyme 
was relatively resistant to trimethoprim it was 
eventually competitively inhibited by the drug. The 
Ki of trimethoprim for the novel plasmid DHFR was 
about 50 /xM.
Figure 3.3. Lineweaver-Burk plots of partially 
purified type VI plasmid dihydrofolate reductase 
from the transconjugant strain J62-2 (pUK672).
•--- • fNo trimethoprim; o-- o , 100 /xM trimethoprim.
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3.3.5 Heat sensitivity of the DHFR
The novel enzyme was extremely heat labile, losing
59% of its activity in 24 seconds when heated to 
o
45 C.
These results are summarized in Table 3.3.
Table 3.3. Properties of the type VI DHFR encoded by plasmid pUK672.
Host strain Mr 150 Tp 150 Mtx TD50 Km DHF Ki Tp
(pM) (pM) (min) (pM) (pM)
P . m l i a b l l i s  (J120) 10 000 200 7.25 0.4 31.25 75
ILuCfili J62-2 10 000 150 10 0.35 66 50
Tpi trimethoprim; H t x : methotrexate; SA: specific activity
•
150: inhibitor concentration required to reduce enzyme activity by 50%. o
TD50: time required for 50% inactivation of the enzyme when heated to 45 C.
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3.4 DISCUSSION
Plasmid pUK672 encoded a DHFR enzyme that was insensitive 
to inhibition by trimethoprim and conferred a high-level 
of resistance to trimethoprim on its host strain. The 
properties of this enzyme were different to those of all 
other types of plasmid-encoded DHFR enzymes occurring in 
gram-negative rods and staphylococci (Amyes & Towner, 
1990). This new enzyme was designated DHFR type VI. The 
type VI DHFR differed from the others in most of its
biochemical properties. It seemed to be an unstable
enzyme. This was demonstrated in the rapid loss of
activity found on separation of the enzyme by gel
filtration. The enzyme activity was preserved, however,
if the background protein concentration was kept high. No
other plasmid dihydrofolate reductase loses so much
activity on the removal of extraneous protein. A further
indicator .of the enzyme's instability was its rapid
o
denaturation at 45 C. Only the type I plasmid DHFR from 
gram-negative bacteria denatures so rapidly. However, the 
type VI enzyme shares few other properties with the type 
I dihydrofolate reductases.
The most striking feature of the type VI enzyme was its 
low molecular weight. The size of the type VI enzyme was 
very similar to the sub-unit size of the type II plasmid
Ill
dihydrofolate reductases (Smith et al., 1979). However, 
the type II enzyme sub-units are not functional in a 
disaggregated form. Interestingly, the levels of 
resistance to trimethoprim and methotrexate conferred by 
the type VI enzyme were higher than those for any of the 
other plasmid-encoded DHFRs except for the type II. It is 
possible that the type VI enzyme is related to the type 
II, though a lack of direct hybridization of the type VI 
gene with the type II gene probe (Wylie & Koornhof, 1989) 
suggests that any such relationship is not close.
This is the first new plasmid-encoded dihydrofolate 
reductase to be found in Africa and, indeed, is the only 
one identified on this continent apart from the type la 
(Young & Amyes, 1986b).
CHAPTER 4 NUCLEOTIDE SEQUENCE OF THE DIHYDROFOLATE
REDUCTASE TYPE VI GENE
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4.1 INTRODUCTION
The development of techniques for rapid sequencing of DNA 
has led to many advances in molecular biology. The better 
known techniques are those of Maxam & Gilbert (1980) and 
Sanger et al. (1977). Maxam & Gilbert developed a 
sequencing technique which employed base-specific, 
chemical cleavage of end-labelled DNA. This method 
involves modification of a base, removal of the modified 
base from its sugar and DNA strand scission at that 
sugar. While this method produces adequate results the 
procedure developed by Sanger is more commonly used as it 
offers significant advantages in terms of rapidity and 
simplicity of protocol. It is based on the use of 
deoxynucleotide analogues which are randomly incorporated 
into a growing strand of DNA to give specific chain 
termination. One enzyme commonly used for this purpose is 
the Klenow fragment of E.coli DNA polymerase I. It has 
several properties which make it suitable for DNA 
sequencing:
i) it can only extend the DNA strand in the 5' to 3' 
direction from the primer as it does not possess 
the 5' to 3' exonuclease activity of the intact 
enzyme
ii) it faithfully synthesizes a complementary strand
iii)
114
from a single-stranded template
it is able to incorporate dideoxynucleotides in 
place of deoxynucleotides 
iv) it has an absolute requirement for a primer with a 
3'-hydroxyl group.
Dideoxynucleoside triphosphates (ddNTPs) lack a 
3'-hydroxyl group and, therefore, when incorporated into 
a growing strand of DNA cause chain termination. By 
controlling the ratio of ddNTP to the appropriate dNTP, 
incorporation of the dideoxynucleotide, and hence chain 
termination, occurs randomly.
Another enzyme frequently used in DNA sequencing is a DNA 
polymerase described by Tabor & Richardson (1987) . It is 
a modified DNA polymerase from bacteriophage T7 with 
additional properties which make it eminently suitable 
for use in "dideoxy" sequencing. Its processivity i.e. 
the average number of nucleotides polymerized on a 
particular primer-template prior to dissociating is high, 
being in the region of 2 000. In addition to its 
high rate of polymerization it has a wide tolerance for 
and utilization of nucleotide analogues.
Sequencing is performed using four separate reactions. 
Each reaction contains all four dNTPs (one or more of 
which is radioactively labelled) , single-stranded DNA 
template (which has been primed), enzyme and one of the
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four ddNTPs. Four sets of fragments are generated, each 
set specifically terminating with either ddA, ddC, ddG or 
ddT. The fragments are separated using thin
polyacrylamide gels and the sequence is read from the 
position of the bands across the four tracks. Between 200 
and 400 bases can be determined from an average gel but 
the use of gradient gels, wedge gels and metre-long gels 
can increase the number of readable bases significantly. 
The quality of DNA used in sequencing has an important 
effect on the readibility of the autoradiograms. 
Contamination with either extraneous DNA or RNA results 
in random priming which, in turn, causes multiple banding 
and/or high background "noise". This makes interpretation 
of the sequence difficult. The development of the M13 
bacteriophage cloning vectors (Messing et al., 1977) has 
largely overcome these limitations. M13 is a 
single-stranded, filamentous phage, the life cycle of 
which is suitable for cloning of "foreign" DNA and the 
preparation of single-stranded template. The 
bacteriophage enters the host cell (E.coli F') where it 
is stripped of its protein coat. The single-stranded 
viral DNA is then converted to a double-stranded 
replicative form (RF). This is followed by replication to 
give 100+ progeny RF molecules from which new
single-stranded viral DNA is synthesized. RF DNA which is
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required for cloning purposes can be purified from the 
cells at this point using standard methods for plasmid 
purification. The viral genome is then packaged into 
viral coat protein and extruded from the host without 
lysis. Some 200 phage progeny are produced per cell per 
generation and can be harvested free of contaminating 
material from the host cells by polyethylene glycol (PEG) 
precipitation. The single-stranded DNA can then be 
purified and used for DNA sequencing. Cloning of 
"foreign" DNA into the replicative form of M13 has been 
facilitated by the insertion of a multiple cloning site 
(MCS) at a point in the genome where essential viral 
functions are not disrupted. The MCS contains several 
unique restriction enzyme sites which can be utilized for 
insertion of "foreign" DNA.
The DNA sequences of dihydrofolate reductase genes have 
been analyzed in terms of the structure of the genes, the 
predicted amino acid sequences and the regions 
controlling their expression.
Comparison of the nucleotide sequences of the types I, II 
and V DHFRs (Fling and Richards, 1983; Swift, McCarthy & 
Heffron, 1981; Sundstrom et al., 1988) has revealed 
considerable homology between enzymes of the same group 
e.g. >78% between types Ila, b and c (Brisson and Hohn, 
1984; Flensburg and Steen, 1986) . There is no sequence
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homology between the type I and type II and between the 
type II and type V genes (Fling and Richards, 1983; 
Sundstrom et al., 1988). The type I and type V DHFR genes 
do have a number of similar features. Both genes code for 
a polypeptide of 157 amino acids and there is an overall 
amino acid homology of 75% (Sundstrom et al., 1988). 
However, these genes do not hybridize with each other 
(Thomson and Amyes, 198 8) . The type I and type V DHFR 
genes have regions which are homologous to the 
chromosomal DHFR gene of E,coli K12 (Sundstrom et al.,
1988).
nucleotide
TheAsequence of the type VI DHFR was determined in order 
to establish its relationship with other DHFRs mediating 
high-level resistance to trimethoprim.
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4.2 MATERIALS AND METHODS
4.2.1 Bacteria
The gene encoding the type VI DHFR was isolated 
from Proteus mirabilis J120 (pUK672).
The cloning vectors used were pUC18 and
bacteriophages Ml3mpl8 and mpl9 which were
propagated in Et.CQ.ll K12 JM10 3 and JM101
respectively (Yanisch-Perron, Vieira & Messing, 
1985) .
4.2.2 DNA isolation and purification
Plasmid DNA was purified using a Circleprep Kit 
(Bio 101 Inc., La Jolla, CA, USA) according to the 
manufacturer's instructions (Appendix C).
DNA fragments were purified by separation in and 
extraction from low melting point agarose as 
previously described in Chapter 2.
4.2.3 Cloning procedure
All cloning procedures using the vectors pUC18 and 
bacteriophages Ml3mpl8 and mpl9 were performed
119
according to the methods recommended by the 
supplier (Boehringer Mannheim). These are detailed 
in Appendices D and E.
Purified plasmid DNA (pUK672) was partially or 
fully digested with EcoRI and ligated with suitably 
restricted pUC18 using T4 DNA ligase. The hybrid 
plasmids were transformed into competent E.coli K12 
JM103 and clones containing the DHFR gene were 
selected on a medium containing trimethoprim 
lactate (100 mg/1, Wellcome) in addition to 
ampicillin (100 mg/1) , isopropyl- (3 -D-galactoside 
(IPTG) and X-gal
(5-bromo-5-chloro-3-indolyl-/3-D-galactopyranoside) . 
Plasmid DNA from each clone was screened by the 
method of Maniatis et al. (1982). Similarly DNA 
fragments from pUK672 were ligated with suitably 
digested replicative form bacteriophage DNA and 
transformed into E.coli K12 JM101.
4.2.4 Sequence determination
Sequencing was performed by the chain termination 
method of Sanger, Nicklen & Coulson (1977) using an 
M13 sequencing kit (Boehringer) according to the 
manufacturer's instructions (Appendix F). The
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sequence was determined from both strands with the 
exception of £. 200 base pairs at the 5' end, the 
sequence of which was determined from one strand 
only. The sequence around the Hindlll restriction 
site was confirmed using a 20-bp oligonucleotide 
primer which was complementary to the negative 
strand of the insert from position 266 to 285.
The sequence was analyzed using the Mount sequence 
analysis package (Genetics Software Centre, 
Department of Molecular and Cellular Biology, 
Biosciences West, University of Arizona, Tuscon, 
AZ85721, USA).
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4.3 RESULTS AND DISCUSSION
4.3.1 Isolation of the type VI DHFR gene
After partial digestion with EcoRI of the plasmid 
pUK672 the fragments were ligated with suitably 
restricted pUC18 and transformed into E.coli K12 
JM103. A clone expressing trimethoprim resistance 
was found to contain a vector plasmid with an 
insert of q . 9.0 Kb. The insert DNA was excised 
from the vector, purified and digested a second 
time with EcoRI. The fragments were recloned into 
pUC18. Clones expressing trimethoprim resistance 
were screened and the vector with the smallest 
insert - c. 1.5 Kb - was identified. Attempts to 
remove the £. 1.5 Kb fragment from the plasmid 
revealed that the internal EcoRI site and the 
adjacent Xbal site of the vector had been damaged. 
However, the PstI site was functional and was used 
together with the second EcoRI site to remove the 
insert.
Digestion of the q . 1.5 Kb insert with a
number of restriction enzymes showed that single 
sites for both Xbal and Hindlll were present and 
that the fragments generated by each enzyme were
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large enough to contain the DHFR gene. These 
fragments were cloned into pUC18 but only the 
Pstl/Xbal insert expressed trimethoprim resistance. 
This insert, which was £. 1.0 Kb in size, also 
contained the Hindlll site.
The biochemical properties of the enzyme expressed 
by this gene were identical to those expressed 
by the gene in P.mirabilis (J120).
For sequencing three fragments were cloned into
Ml3mpl8 and mpl9 . These were the £ .  1.0 Kb
Pstl/Xbal fragment, the q .  600-■bp Pstl/Hindlll
fragment and the £ . 400-bp Hindlll/Xbal fragment
(Figure 4.1.) .
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Figure 4.1. Restriction map of the 1 026 base pair 
insert containing the type VI DHFR gene 
(cross-hatched area). Arrows indicate the direction 
and extent of sequencing.
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4.3.2 Nucleotide sequence of the type VI DHFR gene
Since the type VI enzyme had been previously 
assigned a molecular weight of 10 Kda a gene of 
about 240 to 300 base pairs was expected. Analysis 
of the sequence of the 1 026-bp insert yielded only 
one open reading frame (ORF) larger than 240 bases. 
This was 471-bp long and encoded an amino acid of 
157 residues with a calculated molecular weight 
of 17 424 daltons. The nucleotide and predicted 
amino acid sequences are shown in Figure 4.2.
The proposed type VI structural gene was found to 
be bounded by an initiation codon (ATG) at position 
336 and a termination codon (TAA) at position 807. 
At position 646 there was a Eindlll restriction 
site. Other restriction sites are shown in Figure 
4.1.
4.3.3 Analysis of the 51 and 3' nucleotide sequence
Analysis of the DNA sequence upstream of the ORF 
showed a set of possible -35 and -10 promotor 
sequences. The most highly conserved base pairs of 
the -35 consensus sequence in E.coli promotors are 
-TTGACA- (Rosenburg and Court, 1979) . The hexamer
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-TAGACA- found at position 260 of this sequence was 
identical in five of the six base pairs and could, 
therefore, have fulfilled this function. Harley and 
Reynolds (1987), in an analysis of 253 E .coli 
promotors, found that the optimum distance between 
the -35 and -10 regions was 17+1 base pairs. Taking 
this into consideration the hexamer -AGAAAT-, which 
was 18 base pairs downstream from the proposed -35 
sequence, could have formed the -10 region. 
However, this sequence differed in three of the six 
base pairs found most commonly in E.coli -10 
sequences viz. -TATAAT-. If these regions did 
function as the RNA polymerase binding site, they 
were further upstream than expected. However, 
longer leader sequences have been noted previously 
although their function is not known (Andrews 
et al., 1985; Swift, McCarthy & Heffron, 1981). 
There was a ribosomal binding site (-AGGA-) at an 
appropriate distance from the proposed initiation 
codon (Shine and Dalgarno, 1975) .
A possible transcription termination site was 
present downstream of the coding region. An 
inverted repeat sequence centred at position 845/6 
might be involved in the formation of a stem and 
loop structure in which the stem contains eight
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Figure 4.2. Nucleotide sequence of the 1 026-bp insert. The DHFR 
coding region extends from base 336 to base 806 . The deduced 
amino acid sequence is written below the DNA sequence. The -35 
and -10 regions and the ribosomal binding site are underlined. 
The inverted repeat sequence is overlined.
PstI . . . . . .
CCTGCAGTTGCCATGTTTTACGGCAGTGAAGAGATAGCGAGCGCTGATGTCCGGCGGTGC 6 0
TTTTGCCGTTACGCACCACCCCGTCAGTAGATGAACAGGAGGGACAGCTGATAGAAACAG 120
AAGCCACTGGAGCACCTCAAAAACACCATCATACACTAAATCAGTAAGTTGGCAGCATCA 180
CCCTATTTAACTTAATTCAAATATTTTAGAAAACTTAGTGATAGTAATACCTTAGGATAT 240
TTGTTAAAACTATATAGAGTAGACAAATGAGCGTTTAGTCGGCAGAAATATGCGCGATGA 300 
-35 -10
GCGCACTATTAAATTGTTAGCCCTCAGGAGGAAAA ATG AAA ATA TCT CTT ATG 3 53
SD Met Lys lie Ser Leu Met
GCA GCT GTT TCC GAG AAT GGA GTA ATT GGC TCT GGA TTG GAT ATA 398
Ala Ala Val Ser Glu Asn Gly Val lie Gly Se r Gly Leu Asp lie
CCT TGG CAT GTA CAA GGC GAG CAG CTC CTA TTC AAA GCC ATG ACT 443
Pro Trp Ris Val Gin Gly Glu Gin Leu Leu Phe Lys Ala Met Thr
TAC AAT CAA TGG CTT CTA GTT GGT CGT AAA ACC TTC GAC TCA ATG 488
Ty r Asn Gin Trp Leu Leu Val Gly Arg Lys Thr Phe Asp Ser Met
GGT AAA CTT CCG AAT AGA AAA TAT GCA GTG GTT ACT CGT TCT AAA 533
Gly Lys Leu Pro Asn Arg Lys Tyr Ala Val Val Thr Arg Ser Lys
ATT ATC TCG AAT GAC CCT GAT GTT GTG TAT TTC GCA AGT GTT GAA 578
H e lie Ser Asn Asp Pro Asp Val Val Tyr Phe Ala Ser Val Glu
TCG GCA TTA GCT TAC CTA AAC AAT GCG ACA GCA CAT ATC TTT GTT 623
Ser Ala Leu Ala Tyr Leu Asn Asn Ala Thr Ala His lie Phe Val
TCT GGT GGT GGT GAA ATA TAT AAA GCT TTA ATC GAT CAA GCA GAT 668
Ser Gly Gly Gly Glu lie Tyr Lys Ala Leu lie Asp Gin Ala Asp
GTT ATC CAT CTT TCA GTG ATT CAC AAG CAT ATC TCT GGC GAT GTG 713
val lie Ris Leu Ser Val lie His Lys His lie Ser Gly Asp Val
TTT TTT CCT CCA GTT CCA CAG GGC TTC AAG CAA ACA TTT GAG CAA 758
Phe Phe Pro Pro Val Pro Gin Gly Phe Lys Gin Thr Phe Glu Gin
AGT TTC AGT TCA AAT ATT GAT TAC ACG TAC CAA ATT TGG GCA AAG 803
Ser Phe Ser Ser Asn lie Asp Tyr Thr Tyr Gin lie Trp Ala Lys
GGC TAA CAATCTGTTTAAGAGTGATTCGCAACGCGTGGAATTTTTACTATGCGTTGCG 860 
Gly TER
TTTAGTGTTTAAGGTGGTATGCGGAGGCTTCGGTATTGCGTTGCTCACACCTTAACAGGG 920
• • • • • •
CGTTATGTGTCTCTTGGATTTAGGTGAAATAAACTATGTTGAATATCATTAAATTTATTC 980
. Xbal
TTATTTCCTTAATGCTTTCAGTGATTTTTATCTATATTGCTCTAGA 1026
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base pairs and the loop 16 bases. Other features 
consistent with rho-independent termination were 
not present.
4.3.4 Comparison of the amino acid sequences of the
types I. V, VI and E.coli K12 chromosomal DHFRs
The types I, V and VI DHFR genes encode
polypeptides of 157 amino acids while the gene for 
the E.coli chromosomal DHFR encodes a polypeptide 
of 159 residues (Smith and Calvo, 1980). These
sequences are aligned in Figure 4.3. and numbered 
according to the E.coli DHFR.
Overall amino acid homology between the type I and 
type VI enzymes was 63% but within the first 50
amino acids, where both co-enzyme and inhibitor 
binding take place (Matthews et al., 1978), there 
was 80% homology. There was even greater identity - 
86.6% - in the residues 51 to 65.
Similarly comparison of the type V and type VI
sequences showed 61% homology; 78% of the first 50 
residues and 86.6% of residues 51 to 65 were 
identical.
The degree of homology between the chromosomal 
DHFR of E.coli K12 and the type VI was only 31%.
127
Figure 4.3. Comparison of the amino acid sequences of the 
types I, V, VI and E.coli K12 dihydrofolate reductases. The 
numbering is according to the E.coli DHFR. Conserved residues 
are shaded.
10
Lys Thr Phe! Asp Ser Met Gly - Lys Leu Pro Asn Arg Lys Tyr
Lys Thr Phe Glu Ser Met Gly - Ala Leu Pro Asn Arg Lys Tyr
Lys Thr Phe Glu Ser Met Gly - Ala Leu Pro Asn Arg Lys _I f
His Thr Trp Glu S e r f lie Gly Arg Pro Leu Pro) Gly Arg Lys Asn
60 70
Ala Val Val Thr Arg Ser Lys lie lie Ser Asn Asp Pro Asp Val
Ala Val Val Thr Arg Ser Ser Phe Thr Ser Asp Asn Glu Asn Val
Ala Val Val Thr Arg Ser Ala Trp Thr Ala Asp Asn Asp Asn Val
lie lie Leu - -  I Ser Ser Gin Pro Gly Thr Asp ASp| Arg Val
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Val Tyr Phe Ala Ser Val Glu Ser Ala Leu! Ala Tyr Leu Asn Asn
Leu lie Phe Pro Ser lie Lys Asp Ala Leuj Thr Asn Leu Lys Lys
lie Val Phe Pro Ser lie Glu Glu Ala|" Met Thr Gly Leu Ala Glu
Thr Trp Val Lys Ser Val Asp Glu Ala| lie Ala Ala Cys Gly Asp
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Type VI 
Type I 
Type V 
Chr K12
90 100
Ala Thr Ala j His lie Phe Val Ser Gly Gly Gly Glu lie Tyr Lys!
lie Tht Asp His Val He Val Ser Gly Gly Gly Glu He T y r  l vs
Leu Thr Asp His Val He Val Ser Gly Gly Gly Glu lie Tyr Arg
Val Pro Glu lie Met - Val | He Gly Q'y Gly Arg Val Glu
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Ala Leu lie Asp Glu Ala Aspj_ Val lie His(_ Leu J S e r Val He His
Ser Leu He Asp Glu Val Asp Thr Leu His He Ser Thr lie Aspj
Glu Thr Leu Pro Met Ala Ser | Thr Leu His He Ser Thr lie Aspl
Glu Phe Leu Pro Lys Ala Gin Lys Leu Tyr Leu Thr His lie Aspj
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Lys His He Ser Gly Asp Val Phe Phe Pro Pro Val Pro Gin
lie Gin Pro Glu Gly Asp Val Tyr Phe Pro Glu lie - Pro Ser
lie Gin Pro Glu Gly Asp Val Phe Phe Pro Asn He - Pro Asn
Ala Glu n^ r Glu Gly Asp Thr His Phe Pro Asp Tyr Gly Pro Asp
140
Gly Phe Lys Gin Thr Phe Glu Gin Ser Phe Ser Ser Asn lie
Asn Phe Arg Pro Val Phe - Thr Gin Asp Phe Ala Ser Asn He
Thr Phe Glu Val Val Phe - Glu Gin His Phe Ser Ser Asn He
Asp Trp Glu Ser Val Phe Ser Glu Pro His Asp Ala Asp Ala Gin
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Asp - - - Tyr Thr Tyr Gin lie Trp Ala Lys Gly Stop
Asn - - - Tyr Ser Tyr Gin lie Trp Gin Lys Gly Stop
Asn - - - Tyr Cys Tyr Gin He Trp Gin Lys Gly Stop
Asn Ser His Ser Tyr Cys Phe Glu lie Leu Glu Arg Arg] Stop
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The residues known to be involved in folate binding 
are 5, 6, 7, 15, 20, 22, 28, 30, 31 and 94 
(Bystroff et al., 1990). The resistant DHFRs have 
identical residues to E.coli K12 DHFR at positions 
5, 7, 22, 31 and 94. The remaining 5 amino acids 
differ from the K12 enzyme but the substituted 
residues (Met-6, Ile-20, Glu-27, Gln-28 and Leu-30) 
are identical in each of the resistant DHFRs. 
Similarly residues associated with methotrexate 
binding in E.coli are Ile-5, Ala-7, Asp-27, Leu-28, 
Phe-31, Ser-49, Ile-50, Leu-54, Arg-57, Ile-94 and 
Thr-113 (Matthews et al., 1977; Matthews et al., 
1978). Only five of the 11 residues were conserved 
in the resistant DHFRs. These substitutions may 
explain why the binding affinities of the resistant 
DHFRs and the chromosomal enzyme differ.
Although the similarity in gene length, DNA and 
amino acid homology suggests common ancestry the 
biochemical properties of these enzymes were 
distinct. The type V and type VI DHFRs do, however, 
have certain physical properties in common. By 
Sephadex column chromatography the size of the 
type V DHFR was estimated to be 5 Kda (Thomson & 
Amyes, 1988), whereas the gene sequence data showed 
the size of the polypeptide to be 17 531 daltons
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(Sundstrom et al., 1988). Similarly the molecular 
weight of the type VI DHFR was estimated to be 
10 Kda (Wylie et al., 1989) whereas the gene 
determined a polypeptide of over 17 Kda. The reason 
for this behavior is unknown but it could be due to 
the hydrophobicity of the enzyme molecules (Towner 
et al., 1990). The molecular weight of the type V 
DHFR was subsequently reported to be 35 Kda by 
native polyacrylamide gel electrophoresis (PAGE) 
(Thomson, 1990) indicating that, like the type I 
DHFRs, the type V enzyme functions as a dimer. In 
preliminary investigations using SDS-PAGE the 
molecular weight of the type VI DHFR appears to be
17.5 Kda. It has not yet been determined whether it 
functions as a dimer but the similarities between 
these three enzymes support this possibility.
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CONCLUSION
The investigations relating to trimethoprim resistance in 
South African isolates described here have merely served as 
an introduction into this field of study. Much work remains 
to be done, especially in molecular epidemiology, if 
trimethoprim resistance in South Africa is to be 
comprehensively understood and accurately assessed.
The incidence of trimethoprim resistance in gram-negative 
organisms isolated in South Africa is high. In order to 
establish trends in resistance patterns similar surveys 
should be performed at regular intervals. In addition the 
linkage of trimethoprim resistance genes with those of other 
antibiotics should be examined. This information would assist 
in formulating hospital antibiotic prescription policy and 
control of nosocomial spread of resistant organisms. In a 
country where cost-benefit considerations are of paramount 
importance the use of a drug as efficient and relatively 
inexpensive as trimethoprim should not be compromised by a 
high frequency of resistance.
The importance of the type VI DHFR in mediating resistance in 
bacterial populations in South Africa and elsewhere will be 
investigated. Local studies are being planned and a suitable 
probe will be developed from the cloned fragment and used in 
hybridization studies. Should the occurrence of this gene not
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account for a major portion of the high-level trimethoprim 
resistance, further investigations into other mechanisms of 
resistance and their frequency will be necessary. It is 
possible that, because of the geographical isolation of South 
Africa from Europe and the USA, the genes mediating 
high-level trimethoprim resistance will have evolved 
differently and that other novel DHFRs will be identified.
o o 0 o o
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APPENDIX A.
NICK TRANSLATION
T o  a v o id  c o n ta m in a tio n  b y  D N A -d e g ra d in g  n u c le a s e s  
fo u n d  o n  Ih e  s k in  w e  re c o m m e n d  lh a t p ro te c liv e  g lo ve s  
b e  w o rn  w h ils l h a n d lin g  all re a g e n ts  lo r  the  n ick  
tra n s la t io n  re a c lio n .
a ) S e le c t D N A  s p e c if ic  a c tiv ity  re q u ire d .
b ) S e le c t the  re a c lio n  c o n d it io n s  a p p ro p ria te  to  Ihe D N A  
s p e c if ic  a c tiv ity  re q u ire d  by re fe rr in g  to  tab le  1.
c )  D is s o lv e  th e  D N A  fo r la b e llin g  in e ith e r d is tille d  w a te r 
o r 10 m W  T r is /H C I p H 8 -0 , 1 m M  E D TA . to  a 
c o n c e n tra t io n  o f 2 0 0 p g /m l.  C a re  s h o u ld  be  ta ke n  to 
e n s u re  th a t all im p u r it ie s  (s u c h  as a g a ro se ) w h ic h  m ig h t 
in te r fe re  in th e  la b e llin g  re a c tio n  have  b e e n  re m o v e d  
fro m  th e  D N A .
d )  T o  a c o n ic a l p o ly p ro p y le n e  re a c tio n  tu b e  (c a p a c ity  up  
to  1 -5 m l)  p la c e d  in  an ice  ba th , ad d  th e  a p p ro p ria te  
v o lu m e  o f e a c h  re a g e n t (se e  tab le  1) in  th e  fo llo w in g  
o rd e r :
D N A  s o lu t io n
N u c le o t id e /b u f fe r  s o lu t io n ’
R a d io a c liv e ly  la b e lle d  dN T P  
W a te r
E n z y m e  s o lu t io n  (s o lu t io n  2)
'  W h e n  u s in g  kit N .5 5 0 0  y o u  w ill ne e d  to  p re p a re  th is  
s o lu t io n  y o u rs e ll  as d e s c r ib e d  o n  pa ge  10
e) C a p  th e  lu b e  an d  m ix  g e n tly  b y  in v e r tin g  seve ra l 
l im e s .  T h e  tu b e  m a y  th e n  be  sp u n  fo r a le w  se c o n d s  in a 
m ic ro c e n lr i lu g e  to  c o lle c t the  c o n te n ls  at the  b o tto m  o l 
th e  tu b e ). A v o id  v ig o ro u s  ag ita tio n  o f Ihe  re ac tion  
m ix tu re  as th is  m a y  ca u se  s e v e re  lo ss  o f e n z y m e  
a c tiv ity .
f )  P la ce  Ih e  tu b e  in a c o n s ta n t te m p e ra tu re  ba th  at 15°C 
C a re fu l c o n tro l o f te m p e ra tu re  is n e c e s s a ry  (se e  paqe 
12) .
g) M o n ito r  (he  p ro g re s s  o f the  re a c tio n , if re q u ire d , as 
d e ta ile d  o n  p a g e  13.
h )  W h e n  th e  d e s ire d  D N A  s p e c if ic  a c tiv ity  has be e n  
a c h ie v e d , te rm in a te  th e  re a c tio n  u s in g  an ap p ro p ria te  
m e th o d , s u c h  as:
—  g e l f ilt ra t io n
—  a d d it io n  o f E D T A
Table 1. Volum es of components required for labelling DNA with phosphorus-32 using 
|a -32P]dCTP, code PB.10165, In the standard protocol.
Procedure to be used: 
A B C D
notes
(overleaf)
D N A  s p e c if ic  a c tiv ity  re q u ire d !  (d p m /p g ) 5 x 10 ' 1 x 10* 2 x 1 0 * 4 x 10*
Q u a n t ity  o l D N A  to  be  la b e lle d  (p g ) 2 1 to  2 1 to  2 1 (a)
V o lu m e  o f n u c le o t id e /b u f fe r  s o lu t io n  (s o lu tio n  1 
k it N .5 0 0 0 )  (p i)
20 20 20 20 (b)
V o lu m e  o l [ a - 3JP ]d C T P  s o lu t io n , c o d e  P B .1 0 1 6 5  (p i) 10 10 to  20 2 5  to  50 50 (c) (d)
P ic o m o le s  o f [ a - ” P ]d C T P  a d d e d 25 0 2 5 0 -5 0 0 6 2 5 1 O 1 2 5 0 12 50
V o lu m e  o f e n z y m e  s o lu t io n  (s o lu tio n  2) (p i) 10 10 10 10 (e)
V o lu m e  o f w a te r S u ffic ie n t to  b r in g  to ta l in cu b a tio n  vo lu m e  
to  10OpI
(0
|  at th e  a c tiv ity  re fe re n c e  da te  o f th e  la b e lle d  n u c le o tid e
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Figure 1. T im e  c o u rs e  o f n ic k  tra n s la tio n  re a c tio n  u s in g  
[ a - ” P ]d C T P  a n d  p ro c e d u re  B.
Monitoring the progress of the reaction
II re q u ire d  Ih e  p ro g re s s  o l the  la b e llin g  m a y  be 
m o n ito re d  as fo llo w s . P la s tic  o r s il ic o n iz e d  g la ss  lu b e s  
m u s t b e  u s e d  to  a v o id  a d s o rp t io n  o l D N A .
1) For DNA labelled with ” P, 35S or '“ I:
a) T ra n s fe r  a 1 o r  2 p l a liq u o t o l th e  re a c tio n  m ix tu re  to  a 
tu b e  c o n ta in in g  2 0 0 p l w a te r o r 0 -2 M  E D TA . M ix  w e ll.
b ) T ra n s le r  2 0 p l o l th is  's lo p p e d ' s o lu t io n  to  a tu b e  
c o n ta in in g  5 0 p l c a rr ie r  D N A  s o lu t io n  (s o lu t io n  3). M ix  
w e ll.  U s e  th is  m ix tu re  in  s te p  4 .
4) T o  Ih e  d ilu te d  s a m p le  fro m  s te p  1 (b ) o r s te p  2, add 
2 m l ic e -c o ld  1 0 %  tr ic h lo ro a c e tic  a c id  (T C A ) s o lu t io n , 
m ix  w e ll,  a n d  a llo w  to  s ta n d  in an ic e -b a th  fo r 1 0 -1 5  
m in u te s . T h e  la b e lle d  a n d  c a rr ie r  D N A  w ill co - 
p re c ip ita te  (N o le  tha t T C A  is  c o r ro s iv e  an d  ca re  sh o u ld  
b e  ta k e n  in its  h a n d lin g ).
5 ) C o lle c t th e  p re c ip ita te d  D N A  by  v a c u u m  filtra tio n  o n  a 
g la s s  f ib re  o r n it ro c e llu lo s e  f i l le r  d isc .
6 ) W a s h  th e  f i l le r  d is c  w ith  a fu r th e r 2 m l 1 0 %  TC A  
s o lu t io n  a n d  d ry  th e  f ilte r  d is c  th o ro u g h ly , fo r  exa m p le  
u s in g  an  in fra - re d  lam p .-
7 ) C o u n t th e  d r ie d  f i lte r  d is c  b y  liq u id  s c in tilla tio n  (a ll 
n u c lid e s ) ,  C e re n k o v  ( ” P) o r g a m m a  ( ' ” l) c o u n tin g , 
ta k in g  c a re  tha t th e  c o u n t ra te  is no t so  h ig h  as to  sa tu ra te  
th e  c o u n te r .
Termination of the reaction
T h e  n ic k  tra n s la t io n  re a c tio n  m a y  be  s to p p e d  in va rio us  
w a y s . T h e  m e th o d  c h o s e n  m u s t, o f c o u rs e , be 
c o m p a t ib le  w ith  th e  p ro p o s e d  use  o f the  la b e lle d  D N A  
p ro d u c t .  F o r e x a m p le .
a) T h e  re a c tio n  m ix tu re  m a y  be  lo a d e d  d ire c tly  o n  to  a
10 c m  c o lu m n  o f S e p h a d e x  G - 10 o r G -5 0  s u s p e n d e d  in 
b u t le r  c o n ta in in g  1 5 0 m M  N aC I, 10 m M  E D TA , 0 -1 %  
s o d iu m  d o d e c y l su lp h a te  (S D S ) an d  5 0 m M  T r is /H C I, 
p H 7 -5 . 1 0 -d ro p  o r 1 m l fra c tio n s  are  c o lle c te d  and 
m o n ito re d  fo r ra d io a c tiv ity . T h e  la b e lle d  D N A  is e lu te d  
f irs t a n d  m a y  b e  re c o v e re d  fro m  th e  p o o le d  fra c tio n  by 
a lc o h o l p re c ip ita t io n . T h e  D N A  is o la te d  b y  th is  te ch n iq u e  
is  s u ita b le  fo r  u se  as a p ro b e  in h y b rid iz a tio n  
e x p e r im e n ts .
b) T h e  re a c tio n  m ix tu re  m a y  be  e x tra c te d  w ith  p h e n o l lo 
s e p a ra te  th e  D N A  Iro m  p ro te in .
c )  A  g e n e ra l p ro te o ly t ic  e n z y m e  ( lo r  e xa m p le , tryp s in ) 
m a y  b e  a d d e d  w h ic h  w ill d ig e s t Ihe  D N ase  I and D N A  
p o ly m e ra s e  I.
d )  0 -2 M  E D T A  m a y  be  u s e d  to  c h e la te  the  m e ta l ions  
e s s e n t ia l lo r  e n z y m e  ac tiv ity .
APPENDIX B.
DNA TRANSFER AND HYBRIDIZATION 
Membrane Handling
Membranes do not have to be prewetted and can be removed 
from gel or agar surfaces without risk of tearing. Biodyne 
A membranes may be handled in any convenient manner. Gloves 
or forceps should be used to prevent membrane contamination. 
Forceps will not damage the membranes. Either scissors or a 
sharp scalpel must be used to cut the membranes. A vacuum 
oven is not required for baking of nucleic acids onto 
Biodyne A membranes; a conventional air circulating oven is 
adequate.
Stock Solutions
3.1 Denaturing solution: 1.5M NaCl, 0.5M NaOH.
3.2 Neutralizing solution: 3M NaAcetate, pH 5.5.
3.3 2OX SSC: 3M NaCl, 0.3M NaCitrate, pH 7.
3.4 Nonhomologous DNA: 2 mg/ml Herring Sperm DNA. Dissolve 
in water overnight, then sonicate for 1 hour. Store at 
4 0 C.
3.5 100X Denhardt's (1966): 2% (w/v) Ficoll (400,000.
m.wt.), 2% (w/v) Polyvinylpyrrolidone (360,000 m.wt.), 
2% (w/v) Bovine Serum Albumin. Store at 4°C.
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3.6 20X SSPE: 3.6M NaClr 0.2M NaPhosphate, pH 8.3, 0.02M 
EDTA.
3.7 10% (w/v) Sodium dodecyl sulphate (SDS).
3.8 Wash Buffer: 5mM NaPhosphate pH 7.0, ImM EDTA, 0.2% 
sodium dodecyl sulphate.
3.9 1M NaPhosphate, pH 6.5
3.10 Formamide: Deionised using a mixed-bed ion exchange
resin such as Bio-Rad AG501-X8.
4. DNA Transfer Procedures
These protocols have been optimised for use with Biodyne A 
nylon membranes. They may differ significantly from 
published procedures.
4.2 Southern Transfer
Southern Transfers are performed by a modification of 
the procedure described by Southern (1979) .
4.2.1 Place two reservoirs containing 20X SSC (3.3)
side by side, and span with a glass plate.
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4.2.2 Place a sheet of dry filter paper from one 
reservoir, over the glass plate, to the 
adjacent reservoir. Saturate the filter 
paper with 20X SSC (3.3).
4.2.3 After electrophoresis, remove gel from 
apparatus, and place in 150ml of denaturing 
solution (3.1) for 30 minutes with gentle 
agitation.
4.2.4 Replace buffer with neutralising solution 
(3.2). Agitate gently for 30 minutes.
4.2.5 Drain excess buffer from the gel.
4.2.6 Place gel on the paper/glass support and 
surround with strips of a waterproof material 
such as plastic film to ensure that the 
blotting buffer goes through the gel, not 
around it.
4.2.7 Carefully place a piece of dry or prewetted 
Biodyne A membrane on top of and completely 
covering the gel surface. Roll a clean 
pipette over the membrane to remove trapped
air bubbles.
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4.2.8 Place two sheets of filter paper over the 
membrane.
4.2.9 Cover with a 3" stack of paper towels, a 
glass plate and a 1kg weight.
4.2.10 Carefully inspect to ensure that the paper 
towels do not contact the gel.
4.2.11 Allow transfer of DNA from the gel to the 
membrane to proceed for at least 12 hours.
4.2.12 Remove membrane from gel surface. Do not 
rinse as this may result in loss of nucleic 
acid from the membrane.
4.2.13 Bake at 80°C for 1 hour.
7 ..1. 1 Prehybridization
7 . 1 . 1 . 1 Denature nonhomologous DNA (3.4) by 
the addition of 1/10 volume IN NaOH and 
heating at 65°C for 10 minutes.
7. 1 . 1 . 2 Neutralise the DNA solution by the 
addition of 1/10 volume IN HC1.
7.1. 1.3 Hybridization solution contains 
(final concentration): 5X Denhardt's buffer 
(3.5) , 5X SSPE (3.6) , 0.2% (w/v) Sodium 
Dodecyl Sulphate (3.7), 500 pg/ml denatured 
nonhomologous DNA.
7.1.1.4 Seal the membrane in a plastic bag
with 4ml of hybridization solution per 100
cm2 of membrane.
7.1.1.5 Seal the bag inside the second bag 
with a damp paper towel.
7.1.1.6 Immerse the bag in a 65°C bath for
1 hour.
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7.1.2 Hybridization
7.1.2.1 Open the bags containing the membrane
and remove excess hybridization solution. 
Roll a pipette over the inner bag to 
remove as much of the solution as 
possible.
7.1.2.2 Add the labeled probe to the 
nonhomologous DNA and denature and 
neutralise as described in 7. 1.1.1 and 
7. 1.1.2. Final probe concentrations in 
excess of 10 6 cpm per ml-can result in 
some background.
7.1.2.3 To the membrane add 2ml of fresh 
hybridization solution per 100cm2 of 
membrane.
7. 1.2.4 Reseal the double bags and
immerse at 65°C for duration of
hybridization.
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7.1.3. Washing
7.1.3.1 After hybridization, dip the membrane in 
wash buffer (3.8).
7.1.3.2 Place the membrane in a plastic bag.
7.1.3.3 Add 250ml of wash buffer per 100cm2 of 
membrane.
7.1.3.4 Agitate the bags vigorously (200 rpm) 
for 30 minutes at room temperature, then 
discard the buffer.
7.1.3.5 Repeat steps 7.1.3.3 and 7.1.3.4 two 
times.
7.1.3.6 The membrane is now ready for 
autoradiography (or detection of 
biotinylated probe with an avidin 
conjugate). Do not allow membrane to 
dry if the probe is to be removed for 
subsequent rehybridization experiments 
(section 8).
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3. Rehybridization
Biodyne A will sustain multiple cycles of hybridization and 
probe removal. Do not allow membrane to dry following the 
wash procedure. Removal of probe is carried out as follows:
8.1 Place the membrane in a plastic bag with 100ml of lOmM
NaPhosphate, pH 6.5 (3.9), 50% (v/v) formamide (3/10)
per 100cm2 of membrane.
8.2 Incubate at 65°C for 1 hour.
8.3 Wash the membrane once in 250ml of 2X SSC (3.3), 0.1%
(w/v) SDS (3.7) per 100cm2 of membrane for 15 minutes 
at room temperature with vigorous agitation (100 rpm).
8.4 The membrane can now be prehybridized and hybridized 
with the desired probe.
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PLASMID PURIFICATION
THE CIRCLEPREP"' KIT CONTAINS:
CIRCLEGROW capsules, container 0 2 lo 3 Capsules will make 50 ml ol a 
special high-density growth medium lor maintaining high copy numbers of 
plasmid in host cells wilhout amplification
PRE-LYSIS BUFFER. Tris/EDTA/glucose solulion, 120 ml Bollle H
ALKALINE LYSIS REAGENT. 0.2 N NaOH and 1% SOS. 120 ml Bollle 0. 
Store al room temperature lo avoid precipitation ol SOS
NEUTRALIZING SOLUTION. 3 M potassium acetate. 120 ml Bollle 0
LITHIUM CHLORIDE SOLUTION, near saluraled solulion in 7ml vial 0  
Slore al room temperature lo avoid precipitation ol LiCI.
CIRCLEPREP GLASSMILK. 1 vial containing 1.5 ml, 0.
BINDING BUFFER. KBr/NalFTris mixture in 60 ml Bollle 0
Promotes binding of DNA, but not RNA or protein lo CIRCLEPREP GLASSMILK
WASH SOLUTION, 30 ml ol salt solulion in GO ml Bottle H  .
NOTE: Add 30 ml of 100% ethanol before use
Sieve material.
BIOFLOAT for floating microcentrituge tubes in water bath during elution 
incubation.
Instructions.
Isopropanol is used during the CIRCLEPREP procedure lo precipitate plasmid 
DNA but is not supplied in the kit. Also, as indicated above. 30 ml of 100% 
ethanol must be added to Bottle P 8. WASH SOLUTION, before use.
A .  P l a s m i d  G r o w t h ,  A l k a l i n e  L y s i s  o f  C e l l s  a n d  P r e c i p i t a ­
t i o n  o f  C e l l u l a r  D N A :
g  Grow cells in CIRCLEGROW medium overnight.
Add 4 ml ol PRE-LYSIS BUFFER and resuspend cell pellet
g  Add 4 ml ol ALKALINE LYSIS REAGENT In lyse cells.g Add 4 ml ol NEUTRALIZING SOLUTION
Pellel precipilale in cenlriluge and Iranslcr supemalanl Ihrough sieve lo 
new lube.Add 1 volume ol isopropyl alcohol, cenlriluge precipilale and 
drain pellel.
B .  E l i m i n a t i o n  o t  c e l l u l a r  D N A  a n d  R N A .
Second alkaline denaluralion and precipilalion ol linear DNA
Add 0 5 ml ol water and dissolve pellel Transler lo a 2 ml microcenlri- 
luge lube.
g  Add 250 ul ol ALKALINE LYSIS REAGENT
g  Add 250 ul ol NEUTRALIZING SOLUTION.
Spin lor 2 minutes in microcenlriluge lo pellel precipilale 
Transler supernalanl lo new 2 ml microcenlriluge lube.
Add 0 6 lo 1 volume ol isopropanol; cenlriluge precipilale 
Dissolve pellel in 500 ul ol waler.
(Recommended Option: Repeal sleps B 2 and 3 one or more limes )
L i C I  p r e c i p i t a t i o n  o f  R N A  a n d  s s D N A
£23 Add 300 ul of LiCI solulion; 5 minutes at room temperature; spin for 2 
minutes and transfer supernatant to new lube
C .  P u r i f i c a t i o n  o f  P l a s m i d  D N A  o n  s i l i c a :
[p | Add 75 ul of CIRCLEPREP GLASSMILK Let sit al room temperature 
for 5 minutes. Spin lor 5 seconds and discard supernatant
Q j Wash pellel 2 limes with 1 ml BINDING BLIFTER 
Remove all liquid from pellet.
Q  Wash pellet 2 limes with 1 ml WASH SOLUTION
E l u t e  p l a s m i d  D N A  in  1 0 0  t o  3 0 0  u l  o f  w a t e r .
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APPENDIX D.
pUC CLONING
P r in c ip le
p U C l 8 a n d  p U C l9  h a v e  b e e n  c h o s e n  f ro m  Ih e  p U C  p la s m id
v e c to r  s e r ie s  fo r  u s e  h e re  b e c a u s e  th e y  d e m o n s t r a te  th e  fo l ­
lo w in g  a d v a n ta g e s :
-  T h e y  h a v e  a  la rg e  n u m b e r  o f u n iq u e  c le a v a g e  s i te s  in  o n e  
p o ly l in k e r  re g io n  in to  w h ic h  r e s t r ic t io n  f r a g m e n ts  c a n  b e  
in s e r te d  w ith  Ih e  h e lp  o f  T 4  D N A  l ig a s e .
-  V e c to r s  w ith  in s e r te d  D N A  a re  e a s ily  d e te c te d  a f te r  t r a n s ­
fo r m a t io n  o f E . c o l i  h o s t  s t ra in s .  W h e n  p la te d  o n  s o l id  
m e d ia  c o n ta in in g  5 - b ro m o -4 -c h lo r o -3 - in d o ly l- [5 -D - g a la c to -  
s id e  (X -g a l) ,  E . c o l i  c e l ls  c o n ta in in g  r e c o m b in a n t  v e c to rs  
fo rm  c o lo r le s s  c o lo n ie s .  C e l ls  c o n ta in in g  n o n - r e c o m b in a n t  
p U C  v e c to r s  fo rm  b lu e  c o lo n ie s  o n  X -g a l p la te s  (s e e  fig . 13 
o n  p . 19 ).
-  T h e  s m a ll  p U C  p la s m id s  c a n  e a s ily  b e  in t r o d u c e d  in to  
E .c o l i  c e l ls  b y  I r a n s lo r m a l io n  e v e n  w h e n  th e y  c o n ta in  
la rg e  D N A  in s e r ts .  T h e y  a re  re p l ic a te d  to  a  h ig h  c o p y  n u m ­
b e r .
-  C o m p a r e d  to  e a r l ie r  r e p r e s e n ta t iv e s  o f  th e  p U C  v e c to r  s e ­
r ie s ,  p U C l 8 a n d  p ( J C l9  a re  c h a r a c te r iz e d  b y  a n  in c r e a s e d  
n u m b e r  o f c le a v a g e  s i te s  in  th e  p o ly l in k e r  re g io n  w h ic h  
a l lo w s  in s e r t io n  o f  a  la rg e  v a r ie ty  o f  d i f fe r e n t  r e s t r ic t io n  
f r a g m e n ts  (s e e  ta b le  3  a n d  f ig .  7 1 )  a s  w e l l  a s  b y  its  e n t i r e ly  
r e d e te r m in e d  b a s e  s e q u e n c e  ( 1).
A p p l i c a t i o n
C h a r a c te r iz a t io n  o f  in s e r te d  f r a g m e n ts  is  f a c i l i ta le d  b y  th e s e
c h a r a c te r is t ic s  o f  th e  p U C  p la s m id s :
-  R e s t r ic t io n  m a p p in g  is  f a c i l i ta le d  b y  Ih e  s m a ll  s iz e  o f  Ih e  
v e c to r .
-  P la s m id  p r e p a r a t io n  y ie ld s  a re  h ig h  a n d  a l lo w  e a s y  is o la ­
t io n  o f th e  in s e r te d  f r a g m e n ts .  O n e  c a n  re a d i ly  o b ta in  s u f f i ­
c ie n t  in s e r t  D N A  fo r  e g  h y b r id iz a t io n  e x p e r im e n ts  o r  
s e q u e n c in g  (2 ).
-  T h e  n u c le o t id e  s e q u e n c e  o f  in s e r te d  f r a g m e n ts  c a n  q u ic k ­
ly  a n d  e a s ily  b e  d e te r m in e d  b y  th e  d o u b le - s t r a n d  s e q u e n c ­
in g  m e th o d  (3 ) w ith  th e  h e lp  o f  th e  M 1 3 /p U C  s e q u e n c in g  
p r im e r  (s e e  p . 1 3 7 ).
-  F u r th e r m o r e ,  it is  p o s s ib le  to  e x p re s s  g e n e s  in  p U C  p la s ­
m id s  u n d e r  c o n t r o l  o f  Ih e  la c  p r o m o te r  (4 ).
B antl Asp718 H«ndll
E coHI S a d  Kpnf Xma* Bam HI Xbal Sa/1 Psft Sph  I H fod lll
5' CACACAGGAAACAGClATGACCATGAnACGAAnCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCnGGCACTGGCCGTCGITTTACAACGTCGTGACTGGGAAAACCCT 31
5‘CAGGAAACAGCTA IGAC 3* 17-mer "reverse sequencing primer" 3* TGACCGGCAGCAAAATG 5' 17-mer "se<|ucncing primer"
ON A-synthesis -------- > *----------  DNA-synlhcsis
U n iq u e  c le a v a g e  s ite s In s e r ta b le  f r a g m e n ts
A c c  1 G T /C G A C C /a  I A T /C G A T
N a r  I G G /C G C C
A s u  II T T /C G A A
A h a  II g (g ) / c g (c ) c
4 M a e  II A /C G T
H in  P11 G /C G C
H pa  IIIM s p  I C /C G G
Taq  I T /C G A
A s p  7 1 8 G /G T A C C A s p  7 1 8 G /G T A C C
B a m  H I G /G A T C C B a m  H I G /G A T C C
B g l II A /G A T C T
B e l I T /G A T C A
X ho  II ( £ ) /G a t c (J )
S au  3 A /G A T C
E co  R l G /A A T T C E c o  R l G /A A T T C
E c o  R l* /A A T T
H in d  II G T C /G A C e v e ry  e n z y m e  w h ic h
p r o d u c e s  b lu n t  e n d s
H in d  III A /A G C T T H in d  III A /A G C T T
K p n  I G G T A C /C K pn  I G G T A C /C
P s t  I C T G C A /G P st I C T G C A /G
N s i I A T G C A /T
S a c  I, B a n  I G A G C T /C S ac  I G A G C T /C
S a l I G /T C G A C S a l I G /T C G A C
X ho  1 C /T C G A G
S m a  I C C C /G G G e v e r y  e n z y m e  w h ic h
p r o d u c e s  b lu n t  e n d s
S ph  I G C A T G /C S ph  1 G C A T G /C
N s p  H I (g ) c a T < 3 /(q )
N la  III C A T G  /
X ba  I T /C T A G A X ba  1 T /C T A G A
S pe  1 A /C T A G T
A v r  II C /C T A G G
N he  1 G /C T A G C
X m a  I, A v a  I C /C C G G G X m a  1 C /C C G G G
B s p  M i l T /C C G G A
Clr 101 (g ) / g g g g @
Table 3: Unique cleavage sites in the pUC 18/19 polylinker and insertable 
fragments produced by restriction endonucleases
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T h e  k i t  c o n t a in s
1. E . c o l i  J M 8 3
O n e  a m p u le  1 w ith  ly o p h i l iz e d  c e l ls  o t  th e  h o s t  s t ra in  E . c o t i 
K 1 2  J M 8 3  (ara , rpsL , A (ta c -p ro A B ),  <8 8 0 , /a c Z z IM 1 5 ) .
2  E . c o l i  J M 1 0 9
O n e  a m p u le  2  w i th  ly o p h i l iz e d  c e l ls  o t  th e  h o s t s t r a in  E . c o li  
K 1 2  J M 1 0 9  (re cA  1, e n c M 1 , g y rA 9 6 , Ih i, h s d R  17 , su p E 4 4 , 
r e lA t ,  A ( la c -p ro A B ),  [ F ’ , f ra D 3 6 ,  p r o A 'B ',  la c P Z A M  15 ])
3 . p U C 1 8 D N A
O n e  v ia l  3  w ith  1 0 0  p i p U C l 8 D N A , 0 .1  p g /p l ;  in  T r is -H C I ,  
10  m m o l/ l ;  E D T A , 1 m m o l/ l ,  p H  8 .0  (2 5  ° C ) .
4 . p U C 1 9 D N A
O n e  v ia l  4 w ith  1 0 0  t i l  p U C 1 9  D N A , 0 .1  p g /p l ,  in  T r is -H C I,  
10  m m o l/ l ;  E D T A , 1 m m o l/ l ;  p H  8 .0  (2 5  ° C ) .
5 . p U C 1 8  D N A ,  E c o  R t - c le a v e d
O n e  v ia l  5  w ith  4 0  p i p U C 1 8  D N A , c le a v e d  w ith  E co  R l,  
2 5  n g / | i l ;  in  T r is -H C I ,  10  m m o l/ l ;  E D T A , 1 m m o l/ l ;  p H  8 .0  
(2 5  ° C ) .
6 T 4  D N A  l ig a s e
O n e  v ia l 6 w i th  2 5  p i  T 4  D N A  l ig a s e ,  1 u n it /p l .
7 . 10 x  L ig a t io n  b u f f e r
O n e  v ia l 7  w ith  2 5 0  p i 1 0 - l im e s - c o n c e n tra te d  l ig a t io n  b u f fe r
8 . X -g a l s o lu t io n
O n e  v ia l 8 w ith  1 m l 5 -b ro m o -4 -c h lo ro -3 - in d o ly l- [ ) -D -g a la c to -  
s id e ,  2 %  (w /v ) ,  in  d im e th y l lo r m a m id e .
9 . IP T G  s o lu t io n
T h re e  v ia ls  9  w i th  8 5 0  p i is o p r o p y l- [ ) - D - th io g a la c !o s id e ,  
100 m m o l/ l ,  e a c h ;  s te r i le  f i l te r e d .
S t a b i l i t y
T h e  k it  c a n  b e  s to r e d  a t -  2 0  ° C  u n t i l  th e  d a te  in d ic a te d .  R e ­
p e a te d  th a w in g  a n d  f r e e z in g  s h o u ld  b e  a v o id e d .  A f te r  in i t ia l  
th a w in g ,  v ia ls  3  a n d  4 c o n ta in in g  p U C  D N A , s h o u ld  n o t b e  
f ro z e n  a g a in  b u t  s to r e d  a t + 4 ° C .
Im m e d ia te ly  b e fo r e  u s e ,  m ix  g e n l ly  a n d  c o l le c t  th e  s o lu t io n s  
a t th e  b o t to m  o f  th e  v ia ls  b y  a  s h o r t  c e n t r i fu g e  s p in .
A d d i t i o n a l l y  r e q u i r e d  s o lu t io n s  a n d  m e d ia
a. A p p r o p r ia te  r e s t r ic t io n  e n z y m e s  a n d  r e s t r ic t io n  b u f fe r s .
b . P h e n o l,  e q u i l ib r a t e d ,  p H  7 .0  (a c c . to  M a n ia t is ,  5 ).
c . P h e n o l / c h lo r o f o r m / is o a m y l  a lc o h o l;  2 5 /2 4 /1 ,  e q u i l ib r a t ­
e d , p H  7 .0  (a c c . to  M a n ia t is ,  5).
d . C h lo r o fo r m / is o a m y l  a lc o h o l:  2 4 /1  (a c c . to  M a n ia t is ,  5 )
e . L iC I s o lu t io n ,  4 m o l/ t ;  s te r i le  f i l te r e d .
I. E th a n o l A . R ., 9 5 %  a n d  7 0 %  (v /v ) .
g . T E  b u f fe r :  T r is -H C I ,  1 0  m m o l/ l ;  E D T A , 1 m m o l/ l ;  p H  8 .0 .
h . C a C l j  s o lu t io n ,  5 0  m m o l/ l ;  s te r i le .
i. T r is -H C I ,  5 0  m m o l/ l ,  p H  7 .2 ;  s te r i le .
k . A m p ic i l l in  s o lu t io n ,  2 0  m g /m l;  s te r i le  f i l te r e d .
l. L B  l i q u id  m e d iu m
D is s o lv e  1 0  g  B a c to  I r y p to n e  (D i lc o ) ,  5  g  B a c to  y e a s t  e x ­
tra c t  (D i lc o )  a n d  5  g  N a C I w ith  d e io n iz e d  w a te r  a n d  f i l l  u p  
to  1 I.
m . L B  p la t e s
A d d  15 g  B a c to  a g a r  (D i lc o )  to  1 1 L B  l iq u id  m e d iu m  (I), 
a u to c la v e  a n d  p o u r  2 5  m l e a c h  in to  s te r i le  p e lr i  d is h e s  a n d  
a l lo w  to  s o l id i fy .
n . L B /A m p / X - g a l / IP T G  p la t e s
A u to c la v e  5 0 0  m l L B  a g a r  (m ). c o o l d o w n  to  a p p ro x .  5 0  ° C .  
a d d  u n d e r  s te r i le  c o n d it io n s :
2  5 m l a m p ic i l l in  s o lu t io n  (k ) a  1 0 0  p g /m l.
1 m l X -g a l s o lu t io n  ( s o lu t io n  8 ) =  0 .0 0 4 % . W e a r  g lo v e s 1
2 .5  m l IP T G  s o lu t io n  (s o lu t io n  9) — 0 .5  m m o l/ l .
P o u r  2 5  m l e a c h  in to  s te r i le  p e lr i  d is h e s  a n d  a l lo w  to  
s o l id i ty .
o . M 9  m in im a l - m e d iu m  p la t e s  (w ith  v ita m in  8 1  a n d  g lu c o s e )  
10 x  M 9  s a lt  s o lu t io n :
D is s o lv e  6 0  g  N a 2H P O d, 3 0  g  K H jP O , ,  10  g  N I- I.C ! a n d  
5  g  N a C I w ith  d e io n iz e d  w a te r ,  f i l l  u p  to  1 I a n d  a u to c la v e .  
F o r  0 .5  I m e d iu m  s te r i l iz e  th e  fo l lo w in g  c o m p o n e n ts  s e p a ­
ra te ly ,  c o o i d o w n  to  a p p ro x .  5 0  ° C  a n d  m ix  u n d e r  s te r i le  
c o n d it io n s :
4 5 0  m l d e io n iz e d  w a te r  w ith  a d d it io n  o f 7 5  g  B a c to  a g a r  
( D ilc o ) ,  a u to c la v e d ,
5 0  m l 1 0  x  M 9  s a lt  s o lu t io n ,  a u to c la v e d ,
0 .5  m l M g S 0 4 s o lu t io n ,  1 m o i/ l,  a u to c la v e d ,
0 .0 5  m l C a C l j  s o lu t io n ,  1 m o l/ l,  a u to c la v e d ,
2 .5  m l v i ta m in  B1 s o lu t io n ,  1 m g /m l,  s te r i le  f i l te r e d ,
5  m l g lu c o s e  s o lu t io n ,  2 0 %  (w /v ) , a u to c la v e d
P o u r  2 5  m l e a c h  in to  s te r i le  p e lr i  d is h e s  a n d  a l lo w  to  
s o l id i fy .
C lo n in g  e x p e r im e n t
I. P re p a ra tio n  o f c le a v e d  p U C  v e c to r  D N A
1. A d d  th e  fo l lo w in g  to  a s te r i le  m ic r o fu g e  tu b e  (2 0  p i f in a l 
v o lu m e ) :
10  p i — 1 p g  p U C 1 8  o r  p U C 1 9  D N A  (s o lu t io n s  3  o r 4),
2 p i 10 x  r e s t r ic t io n  b u f le r  (a ),
7  p i s te r i le  re d is t .  w a te r ,
1 - 2  p i — 2 - 5  u n its  r e s t r ic t io n  e n z y m e  (a ).
2 . In c u b a te  lo r  1 h a l 3 7 ° C .
3 . A d d  2 0 5  p i T E  b u f le r  (g ) a n d  e x t r a c t  o n c e  w ith  2 0 0  p i 
p h e n o l /c h lo r o fo r m / is o a m y l  a lc o h o l (c ) , a n d  o n c e  w ith  
200  p i c h lo r o lo r m / is o a m y l  a lc o h o l (d ).
4  A d d  2 5  m I s te r i le  L iC I s o lu t io n  (e ) a n d  7 5 0  p i e th a n o l,  
9 5 %  (f).
5 . C h i l l  fo r  15  m in  a t - 7 0 ° C  ( e lh a n o l /d r y  ic e  m ix tu re ) .
6 . C e n t r i fu g e  fo r  1 0  m in ,  r e m o v e  s u p e r n a ta n t  c a r e fu l ly  a n d  
d is c a r d .
7. A d d  1 m l e th a n o l,  7 0 %  ((), to  th e  p r e c ip i ta te  
8 C e n t r i fu g e  fo r  5  m in .
9 . R e m o v e  s u p e r n a ta n t .  D ry  p r e c ip i ta te d  D N A  b r ie f ly  u n d e r  
v a c u u m .
10 . D is s o lv e  in  10  p i s te r i le  T E  b u f fe r  (g ) ( — 0 .1  p g  D N A /p l) .
I I .  C h e c k  1 p i — 0 .1  p g  o n  a n  0 .8 %  a g a ro s e  g e l.
1 p i — 0 .1  p g  u n c le a v e d  p U C  D N A  (s o lu t io n  3  o r  4 ) a n d  
4 p i — 0 .1  p g  p U C l 8 E co  R l f r a g m e n ts  ( s o lu t io n  5) c a n  b e  
u s e d  lo r  c o m p a r is o n .
T h e  D N A  s h o u ld  b e  c o m p le te ly  l in e a r iz e d  a n d  re c o v e re d  
w ith o u t  a n y  lo s s .
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II. P re p a ra tio n  o l fra g m e n ts  lo r  in s e rtio n
1. A d d  th e  fo l lo w in g  to  a  s te r i le  m ic r o lu g e  tu b e  (2 0  m I ( in a ! 
v o lu m e ) :
2  p g  D N A  to  b e  c lo n e d ,
2 | i l  1 0 x  r e s t r ic t io n  b u l le r  (a ),
( ill u p  to  19  | i l  w ith  s te r i le  r e d is l . w a te r ,
a d d  1 - 2  | i l  — 2 - 1 0  u n its  r e s t r ic t io n  e n z y m e  (a ).
2 . In c u b a te  lo r  1 h  a t 3 7  ° C .
3 - 9 .  a s  d e s c r ib e d  in  s e c t io n  I.
10 . D is s o lv e  in  10  p i s te r i le  T E  b u l le r  (g ) ( — 0 .2  | ig  D N A / | i l ) .
III. L ig a tio n
1. Im m e d ia te ly  b e fo re  s e t t in g  u p  a  s t ic k y -e n d  l ig a t io n  r e a c ­
t io n ,  m a k e  d i lu t io n s  o l  T 4  D N A  l ig a s e  a n d  1 0  x  l ig a t io n  b u l ­
le r  in  fo l lo w in g  m a n n e r :
-  M ix  1 v o lu m e  10  x  l ig a t io n  b u f fe r  ( s o lu t io n  7 ) w i th  9  v o l­
u m e s  s te r i le  re d is t .  w a te r  to  m a k e  1 x  l ig a t io n  b u l le r .
-  A d d  1 ( i l T 4  D N A  l ig a s e  ( s o lu t io n  6 ) to  4 | i l  1 x  l ig a t io n  
b u l f e r  to  g iv e  f in a l e n z y m e  c o n c e n t r a t io n  o f  0.2  u n it s /n l .  
T h e  d i lu te d  e n z y m e  s o lu t io n  is  s ta b le  lo r  o n ly  a  le w  
h o u r s  a t +  4  ° C .
2  A d d  th e  fo l lo w in g  to  a s te r i le  m ic r o lu g e  tu b e  o n  ic e :
1 id  — 0 .1  p g  c le a v e d  p U C  D N A , 
v a r ia b le  p i — 0 . 1 - 0 . 2  p m o l c le a v e d  in s e r t  D N A  
(e  g . 0 . 1 5 - 0 . 3  | ig  2 k b  f r a g m e n ts ) ,
1 p i 10  x  l ig a t io n  b u f fe r  ( s o lu t io n  7)
1 j i l  =  0 .2  u n its  T 4  D N A  l ig a s e  d i lu te d  a s  a b o v e  lo r  s t ic k y -  
e n d  l ig a t io n s ,  o r  1 | i l  =  1 u n it  T 4  D N A  l ig a s e  u n d i lu te d  
s o lu t io n  6 fo r  b lu n l- e n d  l ig a t io n s .
3 . In c u b a le  o v e r n ig h t  (6 h m in im u m )  a t 1 5 ° C  fo r  s t ic k y -e n d  
l ig a t io n s  o r  a t  2 2  ° C  fo r  b lu n t - e n d  l ig a t io n s .
IV. P re p a ra tio n  o f c o m p e te n t E. c o li c e lls  (see  a lso  VII)
1. R e m o v e  a s in g le  c o lo n y  o l  E . c o l i  J M 8 3  f ro m  th e  L B  p la te ,  
o r  J M 1 0 9  f ro m  th e  M 9  m in im a l- m e d iu m  p la te  r e s p e c t iv e ly ,  
a n d  in o c u la te  in to  5  m l L B  l iq u id  m e d iu m  (I).
In c u b a te  th e  c u l tu r e  o v e r n ig h t  a t 3 7  ° C  w ith  s h a k in g .
2. In o c u la te  4 0  m l L B  l iq u id  m e d iu m  (I) w ith  0  4 m l f re s h  o v e r ­
n ig h t  c u l tu r e ,  a n d  in c u b a te  w ith  s h a k in g  fo r  a p p ro x .  2 .5  h  a t 
3 7  ° C  to  A 550 =  0 .5  w ith  J M 8 3 ,  o r  to  A 550 =  0 .2  w ith  J M 1 0 9  
re s p e c t iv e ly .
3 . C e n t r i fu g e  c e l ls  fo r  1 0  m in  a t 3 0 0 0  g  in  a  p r e - c o o le d  ro to r  
(e  g . S o rv a ll  S S -3 4  r o to r  a t 5 0 0 0  rp m ) .
4 . R e s u s p e n d  p e lle t  in  2 0  m l ic e -c o ld  s te r i le  C a C I2 s o lu t io n  
(h ) A l lo w  to  s ta n d  o n  ic e  lo r  3 0  m in .
5 . C e n t r i fu g e  c e l ls  a s  d e s c r ib e d  a b o v e  (s te p  3).
6 R e s u s p e n d  p e lle t  in  4 m l ic e - c o ld  s te r i le  C a C I2 s o lu t io n  (h ). 
T h e s e  c o m p e te n t  c e l ls  c a n  b e  s to r e d  o n  ic e  u p  to  24  h o u rs .  
T h e  c e l l  p e lle t  m a y  a ls o  b e  r e s u s p e n d e d  in  ic e -c o ld  s te r i le  
g ly c e r o l /C a C I2 s o lu t io n  ( g ly c e r o l ,  1 5 %  (v /v ) ;  C a C I2, 
5 0  m m o l/ l )  a n d  s to r e d  in  3 0 0  p i  a l iq u o ls  a t - 7 0 ° C .  T r a n s ­
fo r m a t io n  e f f ic ie n c y  m a y  d r o p  in  th e  p r o c e s s .
V. T ra n s fo rm a tio n
1. M ix  th e  l ig a te d  D N A  (s e c t io n  II!)  o r  c o n t r o l  D N A  (s e c t io n  VI) 
w ith  s te r i le  T r is -H C I  s o lu t io n  (i) to  g iv e  a  l in a l  v o lu m e  o f 
5 0  p i (e  g . 5 p i l ig a t io n  m ix tu r e  + 4 5  p i T r is -H C I s o lu t io n )
2 . M ix  D N A  in  a s te r i le  th in - w a l le d  le s t  tu b e  o n  ic e  w ith  3 0 0  p i 
c o m p e te n t  E , c o li  c e l ls  a n d  in c u b a te  o n  ic e  fo r  4 0  m in .
3  W a rm  le s t  tu b e s  in  a  w a te r  b a th  to  4 2  ° C  (3  m in )  a n d  le t 
th e m  s ta n d  a t r o o m  te m p e r a tu r e  lo r  10 m in .
4 . A d d  1 m l L B  l iq u id  m e d iu m  (I) a n d  ro ll o r  s h a k e  fo r 3 0 - 6 0  
m in  a t 3 7  ° C  (p o s s ib ly  t r a n s fe r  in to  s te r i le  1 0  m l c u ltu re  
tu b e s ) .
5 . D is t r ib u te  0 .2  m l e a c h  o n  L B /A m p /X - g a l/ IP T G  p la te s  (n )
6 . I n c u b a le  p la te s  u p s id e  d o w n  a t 3 7  ° C .
VI. R e c o m m e n d e d  c o n tro ls
1. C e l l  c o m p e te n c e  c h e c k :
D i lu te  1 p i p U C l8 D N A  (s o lu t io n  3) in  1 0 0 0  p i s te r i le  T r is -  
H C I s o lu t io n  (i).
U s e  5 0  p i ( =  5 n g  p U C l 8 D N A )  o l th is  s o lu t io n  lo r  t r a n s fo r ­
m a t io n  ( s e c t io n  VO.
A f te r  in c u b a t io n ,  m o re  th a n  1 0 5 b lu e  c o lo n ie s /p g  p U C l8 
D N A  ( ty p ic a l ly  1 -  2 x  1 0 6 b l j e  c o lo n ie s /p g  p U C l8 D N A ) 
s h o u ld  b e  o b ta in e d .
L o w e r  c o lo n y  c o u n t  in d ic a te s  th a t th e  q u a l i t y  o f  th e  c o m p e ­
te n t  c e l ls  is  in a d e q u a te .
2 . C h e c k s  lo r  l ig a t io n  w i th  e n c lo s e d  c o n t ro l  D N A :
A d d  th e  fo l lo w in g  to  a s te r i le  m ic r o fu g e  lu b e  (1 0 0  p i f in a l 
v o lu m e ) :
4  p i  — 1 0 0 n g  c o n t r o l  D N A  p U C l8 , E co  R l- c le a v e d  ( s o lu ­
t io n  5 ),
8 5  p i s te r i le  re d is t  w a te r ,
1 0  p i 1 0  x  l ig a t io n  b u f fe r  ( s o lu t io n  7),
1 p i — 0 .2  u n its  T 4  D N A  l ig a s e  (d ilu te  s o lu t io n  6 w ith  
1 x  l ig a t io n  b u f fe r  1 + 4 ;  s e e  s e c t io n  III).
I n c u b a le  o v e r n ig h t  (6 h  m in im u m )  a t 15 ° C .  U s e  5  p i o f  th e  
m ix tu re  ( — 5 n g  p U C l8 D N A ) fo r  t ra n s fo r m a t io n  (s e c t io n  V). 
T h e  n u m b e r  o f  b lu e  c o lo n ie s  p e r  p g  v e c to r  D N A  s h o u ld  b e  
a t le a s t  5 0 %  o f th e  n u m b e r  o b ta in e d  in  c o n t r o l  VI, 1 ( t y p ic a l­
ly  >  7 0 % ) .
A l te r n a t iv e ly ,  th e  in c re a s e  in  th e  m o le c u la r  w e ig h t  o l th e  
c o n t r o l  D N A  a f te r  s e p a ra t io n  b y  e le c t r o p h o r e s is  o n  a n
0 .8 %  a g a ro s e  g e l c a n  b e  m o n ito re d .
3 . C o n t ro l  fo r  v e c to r  D N A  c le a v a g e :
U s e  1 p i  a  1 0 0  n g  c le a v e d  v e c to r  D N A  ( f r o m  s e c t io n  /) o r  
a s  c o m p a r is o n  4 p i — 1 0 0  n g  c o n t r o l  D N A  (s o lu t io n  5) fo r  
t r a n s fo r m a t io n  ( s e c t io n  V).
T h e  c o lo n y  y ie ld  s h o u ld  b e  n o  m o re  th a n  1 %  o f th a t fo u n d  
in  s e c t io n  VI, 1. O th e r w is e  th e  v e c to r  D N A  w a s  n o t e n t ir e ly  
c le a v e d  a n d  th e  p r e p a r a t io n  a c c o r d in g  to  s e c t io n  /  m u s t  b e  
re p e a te d
4 . C h e c k  fo r  s te r i l i ty :
U s e  5 0  p i s te r i le  T r is -H C I s o lu t io n  (i) w ith o u t  D N A  a d d it io n  
fo r  t r a n s fo r m a t io n  ( s e c t io n  VO T h is  s e r v e s  to  c h e c k  w h e th e r  
c o m p e te n t  c e l ls ,  b u f fe r s  a n d  m e d ia  w e re  p r o d u c e d  w ith o u t  
b a c te r ia l  c o n ta m in a t io n .  N o  c o lo n ie s  s h o u ld  b e  o b s e rv e d .
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VII. N o te  on  the  use  o f  the  E. c o li s tra in s
1. R e v i ta l iz a t io n  o ( th e  E . c o l i  s t r a in s  f r o m  th e  a m p u le s  c o n ­
ta in in g  ly o p h i l iz e d  b a c te r ia :
-  S c r a tc h  a m p u le  a p p ro x .  1 c m  f ro m  th e  e n d  w ith  a n  a m ­
p u le  l i le  (w e a r  s a fe ly  g o g g le s ! )
-  Im m e rs e  in  e th a n o l fo r  2  m in  to  s te r i l iz e  a m p u le .
-  R o ll in to  s te r i le  c o t to n  w o o l a n d  b r e a k  o p e n .
-  T i l t  g la s s  ro d  in  th e  a m p u le  in to  a te s t lu b e  w ith  5  m l L B  
l ig u id  m e d iu m  (I) u n d e r  s te r i le  c o n d i t io n s  a n d  m ix  b r ie f ly  
(V o r te x ) .
-  S t re a k  b a c te r ia  o n to  a n  L B  p la te  (m ) u s in g  a  s te r i le  lo o p . 
In c u b a te  o v e r n ig h t  a t 3 7  ° C .  (W e  r e c o m m e n d  a ls o  in c u ­
b a t in g  a te s t tu b e  w ith  l iq u id  m e d iu m  s o  th a t  th e  b a c te r ia  
m a y  b e  r e s t r e a k e d  if n e c e s s a ry . )
2 . S to ra g e :
F o r  s h o r t - te r m  s to r a g e  o f  th e  E . c o l i  s t r a in s  (a p p ro x .  1 - 2  
m o n th s ) ,  a  s t r e a k  o n  L B  p la te s  (m ) s h o u ld  b e  m a d e  w ith  
J M 8 3 ,  fo r  J M 1 0 9  o n  M 9  m in im a l- m e d iu m  p la te s  (o ), a n d  
s to r e d  a t +  4 ° C .
E . c o l i  J M 1 0 9  c a r r ie s  th e  la c Z A  M 1 5  m u ta t io n ,  w h ic h  is  n e ­
c e s s a r y  fo r  b lu e /c o lo r le s s  d is c r im in a t io n  w ith  X -g a l,  o n  a n  
F - e p is o m e .  G ro w th  o n  M 9  m in im a l- m e d iu m  in d ic a te s  p r e ­
s e n c e  o f  th e  F -e p is o m e .  F o r  c lo n in g  e x p e r im e n ts ,  th e r e ­
fo re ,  a  s in g le  c o lo n y  o f  J M 1 0 9  s h o u ld  a lw a y s  b e  p ic k e d  
f r o m  a n  M 9  m in im a l- m e d iu m  p la te .
F o r  lo n g e r  s to r a g e  p e r io d s  o l  th e  s t r a in s  th e  u s u a l p r o c e ­
d u r e s  m a y  b e  a p p l ie d  (e  g . g ly c e r o l  c u l tu re ) .
3 . S e le c t io n  o f  th e  a p p r o p r ia te  E . c o l i  s t ra in :
E . c o li  J M 8 3  is  c h a r a c te r iz e d  b y  g o o d  t r a n s fo r m a b il i t y  a n d  
h ig h  y ie ld s  o f p la s m id  D N A  P la s m id  D N A  w h ic h  is  is o la te d  
f r o m  th is  s t r a in  u s in g  r a p id  p r e p a r a t io n  m e th o d s ,  is  s u i t ­
a b le  to r  s e q u e n c in g  o f d o u b le - s t r a n d e d  D N A  (3 ). 
H o w e v e r ,  th is  s t r a in  is  b o th  r e s t r ic t io n -  a n d  m o d if ic a t io n -  
p o s it iv e *  ( rk, m k*) (1 ), i . e .  w h e n  c lo n in g  D N A  fra g m e n ts  
w h ic h  a re  p r e p a r e d  fro m  a  m o d if ic a t io n - n e g a t iv e  E .c o l i  
s t r a in  o r  f r o m  o r g a n is m s  o th e r  th a n  E .c o l i  K . t r a n s fo r m a ­
t io n  e f f ic ie n c y  is  m a r k e d ly  r e d u c e d  T h is  p r o b le m  c a n  b e  
a v o id e d  b y  u s in g  th e  r e s t r ic l io n - n e g a l iv e  E . c o li  s t ra in  
J M 1 0 9  (1 ). N o  l im i ta t io n s  a re  o b s e rv e d  w h e n  c lo n in g  n o n -  
m o d i f ie d  D N A  in  th is  s t ra in .  H o w e v e r ,  E c o li  J M 1 0 9  h a s  a 
s o m e w h a t  lo w e r  t r a n s fo r m a t io n  e f f ic ie n c y  th a n  J M 8 3 .
Q u a l i t y  c o n t r o l
L ig a t io n  o f  th e  c o n t r o l  D N A  ( p U C l8 , E co  R l- c le a v e d ) ,  as  d e ­
s c r ib e d  in  c o n t r o l  VI, 2 , a n d  s u b s e q u e n t  t r a n s fo r m a t io n  y ie ld s  
a t le a s t  5 0 %  o f  th e  n u m b e r  o f c o lo n ie s  p e r  n g  v e c to r  o b ta in e d  
w ith  u n c le a v e d  p U C l 8 D N A  ( ty p ic a l ly  >  7 0 % )
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APPENDIX E.
M13 CLONING
P r in c ip le
F ro m  th e  f i la m e n to u s  M 1 3  p h a g e ,  J . M e s s in g  e l a l. c o n s t ru c te d  
a  n u m b e r  o t  c lo n in g  v e h ic le s ,  e .g .  M 1 3 m p l8  a n d  M 1 3 m p 1 9  
(1 ). T h e  d o u b le - s t r a n d e d  D N A  o l th e s e  p h a g e s  c a n  b e  c le a v ­
e d  w ith  a n u m b e r  o l  r e s t r ic t io n  e n d o n u c le a s e s  a l u n iq u e  
c le a v a g e  s i te s  in  a p o ly l in k e r  (s e e  ta b le  2 a n d  f ig .  6 4 )
V e c to r s  w ith  in s e r te d  D N A  a re  e a s ily  d e te c te d  a l te r  t r a n s fe c ­
t io n  o l  a p p r o p r ia te  E . c o l i  h o s t  s t ra in s .  W h e n  p la te d  o n  s o l id  
m e d ia  c o n ta in in g  5 -b ro m o -4 -c h lo r o -3 - in d o ly l- /? -D - g a la c to s id e  
(X -g a l) ,  r e c o m b in a n t  p h a g e  v e c to r s  g iv e  r is e  to  c o lo r le s s  
p la q u e s .  N o n - r e c o m b in a n t  p h a g e  v e c to r s  g iv e  r is e  lo  b lu e  
p la q u e s  o n  X -g a l p la te s  (s e e  f ig . 13).
M 1 3  p h a g e s  m u lt ip ly  in  in fe c te d  E . c o l i  c e l ls  f ir s t  b y  fo r m in g  
d o u b le - s t r a n d e d  c i r c u la r  D N A  ( " r e p l ic a t iv e  f o r m ”  =  R F  D N A ) . 
W h e n  th e  R F  D N A  c o n c e n t r a t io n  r e a c h e s  a p p ro x .  2 0 0  c o p ie s  
p e r  c e ll ,  s in g le - s t r a n d e d  (s s ) D N A , c o m p r is in g  o n ly  o l  th e  
(+ )  s t ra n d  c o n t in u e s  to  b e  s y n th e s iz e d  f ro m  th e  R F  D N A . T h e  
n e w ly  s y n th e s iz e d  D N A  is  p a c k a g e d  in to  p h a g e  p a r t ic le s ,  
w h ic h  a re  th e n  s e c r e te d  f r o m  Ih e  c e l l  in lo  th e  m e d iu m  (2 ).
T h is  m e a n s  th a t b y  u s in g  s ta n d a r d  p la s m id  p r e p a r a t io n  te c h ­
n iq u e s ,  d o u b le - s t r a n d e d  R F  D N A  c a n  b e  is o la te d  f r o m  in fe c t ­
e d  c e l ls  a n d  u s e d  lo r  r e s t r ic t io n  a n a ly s e s  o r  lo r  lu r lh e r  c lo n in g  
e x p e r im e n ts .
O n  th e  o th e r  h a n d ,  a f te r  th e  E . c o l i  c e l ls  h a v e  b e e n  re m o v e d  
b y  c e n lr i lu g a t io n ,  p h a g e  p a r t ic le s  c a n  b e  is o la te d  I ro m  Ih e  
m e d iu m  a n d  s s  (+ )  D N A  p r e p a r e d  I ro m  th e  p h a g e .  s s D N A  c a n  
b e  u s e d  fo r  s e q u e n c in g  ( d id e o x y  m e th o d  (3 ,4 ) ) ,  fo r  in  v itro  
m u ta g e n e s is  e x p e r im e n ts  w ith  s y n th e t ic  o l ig o n u c le o t id e s  (5 ) 
o r  fo r  p r e p a r in g  r a d io a c l iv e ly - la b e le d  s l r a n d - s p e c i l ic  D N A  
p r o b e s  (6 ,7 ) .
U n iq u e  c le a v a g e  s ite s In s e r ta b le  f ra g m e n ts
A c c  1 G T /C G A C C /a  I A T fC G A T
A far I G G /C G C C
A s u  II T T /C G A A
A h a  II g (g ) / c g (q ) c
M a e  II A /C G T
H in  P 1 I G /C G C
H pa  I I IM s p  I C /C G G
Taq I T /C G A
A s p  718 G /G T A C C A s p  718 G /G T A C C
B a m  H I G /G A T C C B a m  H I G /G A T C C
S g f  II A /G A T C T
B e l I T /G A T C A
X ho  II (g ) / g a t c Q
S au  3 A /G A T C
E co  R l G /A A T T C E co  R l G /A A T T C
E co  R l* /A A T T
H in d  II G T C /G A C e v e ry  e n z y m e  w h ic h
p r o d u c e s  b lu n t  e n d s
H in d  III A /A G C T T H in d  III A /A G C T T
K pn  I G G T A C /C K pn  I G G T A C /C
P st I C T G C A /G Pst I C T G C A /G
N s i I A T G C A /T
S a c  I G A G C T /C S a c  I G A G C T /C
S a l I G /T C G A C S a l I G /T C G A C
X ho  I C /T C G A G
S m a  I C C C /G G G e v e ry  e n z y m e  w h ic h
p ro d u c e s  b lu n t  e n d s
S p h  I G C A T G /C S ph  I G C A T G /C
N sp  H I (g ) c a t g / @
N la  III C A TG  /
X ba  I T /C T A G A X ba  I T /C T A G A
S pe  I A /C T A G T
A vr  II C /C T A G G
N he  I G /C T A G C
X m a  I C /C C G G G X m a  I C /C C G G G
B s p  M i l T /C C G G A
C lr  101 ( q ) /C C G G ( q )
Table 2: Unique cleavage sites in the M13 mp18/19 polylinker and insert- 
able fragments produced by restriction endonucleases
S»d Kprrt Xrnul BemMI
Acct 
H tn d II 
Safi Tsfl SpM Hind til
5* CACACAGGAAACAGCTATGACCATGATTACGAAnCGAGCTCGGlACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCrTGGCACIGGCCGTCGMTTACAACGTCGTGACTGGGAAAACCCT 3'
3’ TGACCGGCAGCAAAATG 5' 17-mer "sequencing pnmer" 
—  DMA synthesis
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M 1 3 -S y s te m
M ultiple cloning site
C lo n in g
DNA to be cloned/sequenced
Cut with
restriction endonuclease 
(see table of com patible 
restriction sites)
Transfection o l E coli JM I03 
(E. coli JM109 w ith non- 
EcoK-m odified DNA) 
Plate on petri disk
Pick colorless plaques 
grow phage, prepare ss-DNA
prepare RF-DNA 
from cell sediment
prepare ss-DNA 
Irom phage particles
R estriction analysis, etc
Annealing of sequencing 
primer
recom binant 
M13 ss
S e q u e n c in g
Add radioactive dNTP. 
KJenow enzyme 
and dNTP/ddNTP-mixes 
lor chain elongation
r
G
l
v
A
4 I
C
4
Load samples 
on sequencing gel. 
autoradiograph
Read
sequence
p U C -S y s le m
Multiple cloning site
ICut withrestriction endonuclease
Transformation o f E coli JM 83 
(E coli JM109 w ith non-EcoK- 
m odified DNA)
R a le  on petri disk
Pick colorless colonies
grow cells, prepare plasmid DNA
Restriction analysis, etc.
Alkaline denaturation. 
then annealing of sequencing 
primer or reverse sequencing 
primer
Add radioactive dNTP.
T KJenow enzyme
C and dNTP/ddNTP-mixes
4 for chain elongation
Load samples 
on sequencing gel. 
autoradiograph
Read
sequence
n . . , n i  i n  o/ r t i  i r  a i .
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T h e  k i l  c o n t a in s
1 E . c o l i  J M 1 0 3
O n e  a m p u le  1 w i lh  ly o p h i l iz e d  c e lls  o ( th e  h o s t  s t ra in  E . c o li  
K 1 2  J M 1 0 3  (Ih i, rpsL , en d A , s b c B t5 ,  supE , A (ta c -p ro A B ), 
[ F tra D 3 6 , p ro A ‘ B ‘ , tacP Z c1M 15 ]).
2  E . c o l i  J M 1 0 9
O n e  a m p u le  2  w i lh  ly o p h i l iz e d  c e l ls  o f  th e  h o s t  s t ra in  E . c o li  
K 1 2  J M 1 0 9  (re cA 1 , e n d A 1 , g y rA 9 6 , Ih i, h s d R  1 7 , s u p E 4 4, 
re lA  1, A (la c -p ro A B ),  [ F ' ,  tra D 3 6 , p ro A ‘ B ‘ , la c P Z A M  15)).
3 . M 1 3  m p 1 8 R F  D N A
O n e  v ia l  3  w ith  1 0 0  i l l  M 1 3 m p 1 8  R F  D N A , 0 .1  | ig / | t l ;  in  T r is -  
H C I, 10  m m o l/ l ;  E D T A , 1 m m o l/ l ;  p H  8 .0  (2 5  ° C ) .
4 . M 1 3 m p 1 9  R F  D N A
O n e  v ia l 4 w ith  1 0 0  | i l  M 1 3 m p 1 9  R F  D N A , 0 .1  ( ig / j i l ;  in  T r is -  
H C I,  1 0  m m o l/ l ;  E D T A , 1 m m o l/ l ;  p H  8 .0  (2 5  ° C ) .
5 . M 1 3 m p 1 8  R F  D N A ,  E co  R l- c le a v e d
O n e  v ia l  5  w i lh  4 0  p i N /I1 3 m p 1 8  R F  D N A , c le a v e d  w i lh  
E co  R l,  2 5  n g /p l ;  in  T r is -H C I ,  10  m m o l/ l ,  E D T A , 1 m m o l/ l ;  
p H  8 .0  (2 5  ° C ) .
6 . T 4  D N A  l ig a s e
O n e  v ia l  6 w i lh  2 5  p i T 4  D N A  l ig a s e ,  1 u n it /p l .
7 . 1 0  x  L ig a t io n  b u t l e r
O n e  v ia l 7  w i lh  2 5 0  p i 1 0 - t im e s - c o n c e n lra te d  l ig a t io n  b u f fe r .  
8 X -g a l s o lu t io n
O n e  v ia l 8 w i lh  1 m l 5 -b ro m o -4 -c h lo ro -3 - in d o ly l- (5 -D -g a la c lo -  
s id e ,  2 °/o (w /v ) ,  in  d im e lh y l fo r m a m id e .
9. IP T G  s o lu t io n
O n e  v ia !  9  w i lh  1 m l is o p r o p y l- [F D - th io g a la c lo s id e ,  1 0 0  
m m o l/ l ;  s le r i le  f i l te r e d .
S t a b i l i t y
T h e  k it  c a n  b e  s to r e d  a t -  2 0  ° C  u n t i l  th e  d a le  in d ic a te d .  R e ­
p e a le d  th a w in g  a n d  f r e e z in g  s h o u ld  b e  a v o id e d .  A l te r  in i t ia l  
th a w in g ,  v ia ls  3  a n d  4  c o n ta in in g  th e  M 1 3  R F  D N A , s h o u ld  n o t 
b e  f r o z e n  a g a in  b u t  s to r e d  a t +  4 ° C .
Im m e d ia te ly  b e fo re  u s e ,  m ix  g e n t ly  a n d  c o l le c t  th e  s o lu t io n s  
a t th e  b o t to m  o l  th e  v ia ls  b y  a  s h o r t  c e n t r i fu g e  s p in .
A d d i t i o n a l l y  r e q u i r e d  s o lu t io n s  a n d  m e d ia
a . A p p r o p r ia te  r e s t r ic t io n  e n z y m e s  a n d  re s t r ic t io n  b u f fe r s .
b . P h e n o l,  e q u i l ib r a t e d ,  p H  7 .0  (a c c . to  M a n ia t is ,  8 ).
c .  P h e n o l /c h lo r o fo r m / is o a m y l  a lc o h o l:  2 5 /2 4 /1 ,  e q u i l ib r a t e d ,  
p H  7 .0  (a c c . to  M a n ia t is ,  8 ).
d  C h lo r o fo r m / is o a m y l  a lc o h o l:  2 4 /1  (a c c . to  M a n ia t is ,  8 ). 
e  L iC I s o lu t io n ,  4 m o l/ l ;  s te r i le  f i l te r e d ,  
f. E th a n o l A . R .,  9 5 %  a n d  7 0 %  (v /v ) . 
g  T E  b u f fe r :  T r is -H C I ,  1 0  m m o l/ l ;  E D T A , 1 m m o l/ l ;  p H  8 .0 .
h . C a C I2 s o lu t io n ,  5 0  m m o l/ l ;  s te r i le .
i. T r is -H C I ,  5 0  m m o l/ l ,  p H  7 .2 ; s te r i le .
k . M 9  m in im a l - m e d iu m  p la t e s  (w ith  v i ta m in  B1 a n d  g lu c o s e )  
1 0  x  M 9  s a lt  s o lu t io n :
D is s o lv e  6 0  g  N a 2H P 0 4, 3 0  g  K H 2P 0 4, 10  g  N H 4C I a n d  
5  g  N a C I w i lh  d e io n iz e d  w a te r ,  f i l l  u p  to  1 I a n d  a u to c la v e .
F o r  0 .5  I m e d iu m  s te r i l iz e  th e  fo l lo w in g  c o m p o n e n ts  
s e p a r a te ly ,  c o o l d o w n  to  a p p ro x  5 0 ° C  a n d  m ix  u n d e r  
s te r i ie  c o n d it io n s :
4 5 0  m l d e io n iz e d  w a te r  w ith  a d d i t io n  o f  7  5 g  B a c to  a g a r  
(D i lc o ) ,  a u to c la v e d ,
5 0  m l 10  x  M 9  s a lt  s o lu t io n ,  a u to c la v e d .
0 .5  m l M g S O „  s o lu t io n ,  1 m o l/ l,  a u to c la v e d ,
0  0 5  m l C a C l j  s o lu t io n ,  1 m o l/ l,  a u to c la v e d .
2 .5  m l v i ta m in  B1 s o lu t io n ,  1 m g /m l,  s te r i le  f i l te r e d ,
5  m l g lu c o s e  s o lu t io n ,  2 0 %  (w /v ) ,  a u to c la v e d  
P o u r  2 5  m l e a c h  in to  s le r i le  p e t r i  d is h e s  a n d  a llo w  to  s o l id ­
ify .
l. 2  x  T Y  l i q u id  m e d iu m
D is s o lv e  16  g  B a c to  t r y p to n e  (D ilc o ) ,  10 g  B a c to  y e a s t  e x ­
tra c t  (D ifc o )  a n d  5 g  N a C I w i lh  d e io n iz e d  w a te r  a n d  f i l l  u p  
to  1 I a n d  a u to c la v e .
m . 2  x  T Y  p la t e s
A d d  15  g  B a c to  a g a r  (D ifc o )  to  1 I 2  x  T Y  l iq u id  m e d iu m  (I), 
a u to c la v e  a n d  p o u r  2 5  m l e a c h  in to  s te r i le  p e tr i  d is h e s  a n d  
a l lo w  to  s o l id i fy .
n . H m e d iu m  p la t e s  a n d  H t o p  a g a r
D is s o lv e  10  g  B a c to  t r y p to n e  (D i lc o )  a n d  8 g  N a C I w i lh  
d e io n iz e d  w a te r ,  f i l l  u p  to  1 I a n d  a u to c la v e  
F o r  p o u r in g  p la te s  a d d  12  g  B a c to  a g a r  ( fo r  lo p  a g a r :  8 g  
B a c to  a g a r )  a n d  a u to c la v e .
P o u r  2 5  m l e a c h  in to  s te r i le  p e t r i  d is h e s  a n d  a l lo w  to  
s o l id i fy .
C lo n in g  e x p e r im e n t
I. P re p a ra tio n  o l c le a v e d  M 1 3  v e c to r  D N A
1. A d d  th e  fo l lo w in g  to  a  s te r i le  m ic r o fu g e  tu b e  (2 0  i t !  f in a l 
v o lu m e ) :
10  t i l  — 1 t ig  M 1 3  m p 1 8  o r  M 1 3  m p 1 9  D N A  (s o lu t io n  3  o r  4 ), 
2 t i l  10 x  r e s t r ic t io n  b u f fe r  (a ),
7  p i s le r i le  re d is t .  w a te r ,
1 -  2  p i a  2  -  5  u n its  r e s t r ic t io n  e n z y m e  (a )
2 . In c u b a te  fo r  1 h  a t 3 7  ° C .
3 . A d d  2 0 5  | t l  T E  b u f fe r  (g ) a n d  e x t r a c t  o n c e  w ith  2 0 0  | i l  
p h e n o l /c h lo r o lo r m / is o a m y l  a lc o h o l (c ) , a n d  o n c e  w i lh  
200  | i l  c h lo r o fo r m / is o a m y l  a lc o h o l (d ).
4 . A d d  2 5  | i l  s le r i le  L iC I s o lu t io n  (e ) a n d  7 5 0  | i l  e th a n o l,  
9 5 %  (f).
5 . C h i l l  fo r  15 m in  a t -  7 0  ° C  ( e lh a n o l /d r y  ic e  m ix tu re ) .
6 . C e n t r i fu g e  fo r  1 0  m in ,  r e m o v e  s u p e r n a ta n t  c a r e fu l ly  a n d  
d is c a r d .
7. A d d  1 m l e th a n o l,  7 0 %  (f) , to  th e  p r e c ip i ta te .
8 . C e n t r i fu g e  fo r  5  m in .
9 . R e m o v e  s u p e r n a ta n t .  D ry  p r e c ip i ta te d  D N A  b r ie f ly  u n d e r  
v a c u u m .
10. D is s o lv e  in  1 0  p i s te r i le  T E  b u f fe r  (g ) ( i  0  1 | ig  D N A / | i l ) .
I I .  C h e c k  1 p i a  o .1  n g  c le a v e d  M 1 3  D N A  o n  a 0  8 %  a g a r o ­
s e  g e l e le c t r o p h o r e s is  1 | i !  a  o,1 | ig  u n c le a v e d  M 1 3  R F  
D N A  (s o lu t io n  3  o r  4 ) a n d  4 | i !  a  o .1  | ig  M 1 3  m p 1 8  E co  R l-  
f r a g m e n ls  ( s o lu t io n  5 ) c a n  b e  u s e d  fo r  c o m p a r is o n
T h e  D N A  s h o u ld  b e  c o m p le te ly  l in e a r iz e d  a n d  r e c o v e re d  
w ith o u t  a n y  lo s s .
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II. P re p a ra tio n  o f  fra g m e n ts  lo r  in s e rtio n
1. A d d  Ih e  fo l lo w in g  to  a  s te r i le  m ic r o fu g e  lu b e  (2 0  p i  l in a l  
v o lu m e ) :
2 r ig  D N A  lo  b e  c lo n e d ,
2 | i l  10 x  r e s t r ic t io n  b u t le r  (a ),
t i l l  u p  to  19  p i w ith  s te r i le  re d is t .  w a te r ,
a d d  1 - 2  p i =  2 - 1 0  u n its  re s t r ic t io n  e n z y m e  (a ).
2  In c u b a te  (o r 1 h  a l 3 7  ° C .
3 - 9 .  a s  d e s c r ib e d  in  s e c t io n  I.
10. D is s o lv e  in  10  | i l  s te r i le  T E  b u l le r  (g ) ( =  0 .2  p g  D N A /p l) .
III. L ig a tio n
1. Im m e d ia te ly  b e fo re  s e t t in g  u p  a  s t ic k y - e n d  l ig a t io n  r e a c ­
t io n ,  m a k e  d i lu t io n s  o f T 4  D N A  l ig a s e  a n d  10  x  l ig a t io n  b u f ­
fe r  in  fo l lo w in g  m a n n e r :
-  M ix  1 v o lu m e  1 0  x  l ig a t io n  b u f fe r  ( s o lu t io n  7 ) w ith  9 v o l­
u m e s  s te r i le  re d is t .  w a te r  to  m a k e  1 x  l ig a t io n  b u f fe r .
-  A d d  1 | i l  T 4  D N A  l ig a s e  ( s o lu t io n  6 ) to  4  | i l  1 x  l ig a t io n  
b u f fe r  lo  g iv e  f in a l e n z y m e  c o n c e n t r a t io n  o f  0.2  u n i ls / | i l .  
T h e  d i lu te d  e n z y m e  s o lu t io n  is  s ta b le  fo r  o n ly  a fe w  
h o u rs  a l +  4 ° C .
2 . A d d  th e  fo l lo w in g  to  a s te r i le  m ic r o fu g e  tu b e  o n  ic e :
1 p i — o .1 | ig  c le a v e d  M 1 3  D N A ,
v a r ia b le  | i l  — 0 . 1 - 0 . 2  p m o l c le a v e d  in s e r t  D N A  (e  g.
0 . 1 5 - 0 . 3  | ig  2 k b  f ra g m e n ts ) ,
1 | i l  1 0  x  l ig a t io n  b u f fe r  ( s o lu t io n  7)
1 ( i l  =  0 .2  u n its  T 4  D N A  l ig a s e  d i lu te d  a s  a b o v e  fo r  s t ic k y -  
e n d  l ig a t io n s ,  o r  1 | i l  =  1 u n it  T 4  D N A  l ig a s e  u n d i lu te d  
s o lu t io n  6 fo r  b lu n t-e n d .  l ig a t io n s .
3 . In c u b a te  o v e r n ig h t  (6 h  m in im u m )  a t 1 5 ° C  fo r  s t ic k y -e n d  
l ig a t io n s  o r  a t 22  ° C  fo r  b lu n t - e n d  l ig a t io n s .
IV. P re p a ra tio n  o l  c o m p e te n t E. c o li c e lls  (see  a ls o  VII)
1 R e m o v e  a  s in g le  c o lo n y  o f  E . c o l i  J M 1 0 3  o r  J M 1 0 9  f ro m  M 9  
m in im a l- m e d iu m  p la te  a n d  in o c u la te  in  5  m l 2 x  T V  l iq u id  
m e d iu m  (I). In c u b a te  Ih e  c u l tu r e  o v e r n ig h t  a t 3 7  ° C  w ith  
s h a k in g .
2 . In o c u la te  4 0  m l 2  x  T Y  l iq u id  m e d iu m  (I) w ith  0 .4  m l f r e s h  
o v e r n ig h t  c u l tu r e ,  a n d  in c u b a te  to r  a p p ro x .  2  h  a t 3 7  ° C  lo  
A 550 =  0 .2  w ith  s h a k in g
3 . C e n t r i fu g e  c e l ls  fo r  1 0  m in  a l 3 0 0 0  g  in  a p r e -c o o le d  ro to r  
(e  g . S o rv a ll  S S -3 4  ro to r  a t 5 0 0 0  rp m ).
4 R e s u s p e n d  p e lle t  in  2 0  m l ic e -c o ld  s te r i le  C a C I2 s o lu t io n  
(h ) A l lo w  to  s ta n d  o n  ic e  fo r  3 0  m in .
5. C e n t r i fu g e  c e l ls  a s  d e s c r ib e d  a b o v e  ( s te p  3).
6 . R e s u s p e n d  p e lle t  in  4 m l ic e -c o ld  s te r i le  C a C I2 s o lu t io n  (h ). 
T h e s e  c o m p e te n t  c e l ls  c a n  b e  s to r e d  o n  ic e  u p  to  2 4  h o u rs .  
T h e  c e ll  s e d im e n t  m a y  a ls o  b e  r e s u s p e n d e d  in  ic e - c o ld  s te ­
r i le  g ly c e r o l /C a C I2 s o lu t io n  ( g ly c e r o l ,  1 5 %  (v /v ) ;  C a C I2, 
5 0  m m o l/ l )  a n d  s to r e d  in  3 0 0  | i l  a l iq u o ts  a t - 7 0 ° C .  T r a n s ­
fe c t io n  e f f ic ie n c y  m a y  d r o p  in  th e  p r o c e s s .
V. T ra n s fe c tio n
1. In o c u la te  2 0  m l 2  x  T Y  l iq u id  m e d iu m  (I) w i th  1 d r o p  E . c o li  
J M 1 0 3  o r  J M 1 0 9  f ro m  a  I re s h  o v e r n ig h t  c u l tu r e  a n d  s h a k e  
a t 3 7  ° C .
2 . M ix  Ih e  l ig a te d  D N A  (s e c t io n  III) or  c o n tro l  D N A  (s e c t io n  VI) 
with  s te r i le  T r is - H C I  so lu t io n  (i) to g iv e  a linal v o lu m e  of 
5 0  p i (e . g. 5  jil l ig a t io n  m ix tu re  +  4 5  |il T r is - H C I  so lu t ion) .
3 . M ix  D N A  in  a  s te r i le  th in - w a l le d  te s t tu b e  o n  ic e  w ith  3 0 0  | i l  
c o m p e te n t  E . c o l i  c e l ls  a n d  in c u b a te  o n  ic e  fo r  4 0  m in
4 . W a r m  te s t tu b e s  in  a  w a te r  b a th  to  4 2  ° C  (3  m in ) ,  a n d  p u t o n  
ic e .
5. M e lt  H to p  a g a r  (n ), c o o l d o w n  to  4 2  ° C .  F o r  e a c h  t r a n s fe c ­
t io n  e x p e r im e n t  m ix :
2 0 0  | i l  E .c o l i ,  e x p o n e n t ia l ly  g r o w in g  c e l ls  ( c u ltu re  fro m  
s e c t io n  V, 1 ., A 550 a p p ro x .  0 .3 ) ,
4 0  ( i l  IP T G  s o lu t io n  ( s o lu t io n  9 ),
4 0  p i X -g a l s o lu t io n  ( s o lu t io n  8 ) W e a r  g lo v e s !
6 . T o  e a c h  te s t tu b e  c o n ta in in g  c o m p e te n t  c e l ls ,  a d d  u n d e r  
s te r i le  c o n d it io n s :
2 7 0  | i l  J M 1 0 3 / IP T G /X - g a l m ix tu re ,
3  m l H to p  a g a r  (n ).
M ix  c a r e fu l ly  ( ro ll)  a n d  p o u r  im m e d ia te ly  o n to  a w a rm e d  
H m e d iu m  p la te  (n ).
7 . A f te r  s o l id i f ic a t io n  o f  to p  a g a r ,  in c u b a te  p la te s  u p s id e  d o w n  
a l 3 7  ° C .
VI. R e c o m m e n d e d  c o n tro ls  
1 . C e ll c o m p e te n c e  c h e c k :
D i lu te  1 ( i l M 1 3 m p 1 8  R F  D N A  (s o lu t io n  3 ) in  1 0 0 0  | i l  s te r i le  
T r is -H C I  s o lu t io n  (i). U s e  5 0  p i ( =  5  n g  M l3 m p 1 8  R F  D N A ) 
o f  th is  s o lu t io n  fo r  t r a n s fe c t io n  ( s e c t io n  V).
A f te r  in c u b a t io n ,  m o re  th a n  2 5 0  b lu e  p la q u e s  ( =  5 x  10* 
p la q u e s / | ig  M 1 3 m p 1 8  D N A ) , t y p ic a lly  5 0 0  to  1 0 0 0  b lu e  
p la q u e s  ( =  1 - 2  x  1 0 5 p la q u e s / | ig  M 1 3 m p 1 8  D N A ) s h o u ld  
b e  o b ta in e d .  L o w e r  p la q u e  c o u n t  in d ic a te s  th a t th e  q u a l i ty  
o f  th e  c o m p e te n t  c e l ls  is  in a d e q u a te .
2  C h e c k s  lo r  l ig a t io n  w ith  th e  e n c lo s e d  c o n t r o l  D N A :
A d d  th e  fo l lo w in g  to  a s te r i le  m ic r o fu g e  tu b e  (1 0 0  p i f in a l 
v o lu m e ) :
4 p i — 1 0 0  n g  c o n t r o l  D N A , M 1 3 m p 1 8 , E co  R l-c le a v e d ,  
( s o lu t io n  5 ),
8 5  p i s te r i le  re d is t  w a te r ,
1 0  p i  1 0  x  l ig a t io n  b u f fe r  ( s o lu t io n  7),
1 p i — 0 .2  u n its  T 4  D N A  lig a s e  (s o lu t io n  6 d i lu te d  1 + 4  
w ith  1 x  l ig a t io n  b u f fe r ,  s e e  s e c t io n  III, 1).
In c u b a te  o v e r n ig h t  (6 h m in im u m )  a t 1 5 ° C .  U s e  5  | i l  o f  Ih e  
m ix tu r e  ( — 5 p g  M 1 3 m p l8  D N A ) fo r  t r a n s fe c t io n  (s e c t io n  
V).
T h e  n u m b e r  o f b lu e  p la q u e s  p e r  n g  v e c to r  D N A  s h o u ld  b e  
a l le a s t  5 0 %  o f th e  n u m b e r  o b ta in e d  in  c o n t r o l  VI, 1. ( t y p i ­
c a l ly  >  7 0 % ) .
A lte r n a t iv e ly ,  th e  in c re a s e  in  th e  m o le c u la r  w e ig h t  o f  th e  
c o n t r o l  D N A  a f te r  s e p a ra t io n  b y  e le c t r o p h o r e s is  o n  a n  
0 .8 %  a g a ro s e  g e l c a n  b e  m o n ito r e d .
3 . C o n t ro l  fo r  v e c to r  D N A  c le a v a g e :
U s e  1 | i l  a  1 0 0  n g  c le a v e d  v e c to r  D N A  ( f r o m  s e c t io n  /) o r 
a s  c o m p a r is o n  4 p i — 1 0 0  n g  c o n t r o l  D N A  (s o lu t io n  5) fo r  
t r a n s fe c t io n  ( s e c t io n  V).
T h e  p la q u e  y ie ld  s h o u ld  b e  n o  m o re  th a n  1%  o l  th a t fo u n d  
in  s e c t io n  VI, 1. O th e r w is e  th e  v e c to r  D N A  w a s  n o t e n t ir e ly  
c le a v e d  a n d  th e  p r e p a r a t io n  a c c o r d in g  to  s e c t io n  / s h o u ld  
b e  re p e a te d .
4 . C h e c k  fo r  s te r i l i t y :
U s e  5 0  p i s te r i le  T r is -H C I s o lu l io n  (i) w ith o u t  D N A  a d d it io n  
lo r  t r a n s fe c t io n  ( s e c t io n  V). T h is  s e rv e s  to  c h e c k  w h e th e r  
c o m p e te n t  c e l ls ,  b u f fe r s  a n d  m e d ia  w e re  p r o d u c e d  w ith o u t  
p h a g e  c o n ta m in a t io n .  N o  p la q u e s  s h o u ld  b e  o b s e rv e d
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VII. N o te s  o n  the  use  o f  the  E. c o li s tra in s
1. R e v ita l iz a t io n  o f  th e  E .c o l i  s t r a in s  f ro m  th e  a m p u le s  c o n ­
ta in in g  ly o p h it iz e d  b a c te r ia :
-  S c r a tc h  a m p u le  a p p ro x .  1 c m  fro m  th e  e n d  w ith  a n  
a m p u le  f i le  (w e a r  s a fe ty  g o g g le s ! ) .
-  Im m e rs e  in  e th a n o l lo r  2  m in  to  s te r i l iz e  a m p u le .
-  R o ll in to  s te r i le  c o t to n  w o o l a n d  b r e a k  o p e n .
-  T i l l  th e  g la s s  ro d  in  th e  a m p u le  in to  a  te s t tu b e  w ith  5  m l 
2 x  T Y  l iq u id  m e d iu m  (t) u n d e r  s te r i le  c o n d i t io n s  a n d  m ix  
b r ie f ly  (V o r te x ) .
-  S t re a k  b a c te r ia  o n to  a 2 x T Y  p la te  (m ) u s in g  a s te r i le  
lo o p .  In c u b a te  o v e r n ig h t  a t 3 7  ° C .  (W e  re c o m m e n d  a ls o  
in c u b a t in g  a  te s t  tu b e  w ith  l iq u id  m e d iu m  s o  th a t  th e  
b a c te r ia  m a y  b e  r e s t r e a k e d  if  n e c e s s a ry . )
2 . S to ra g e :
F o r  s h o r t - te r m  s to r a g e  o l  th e  s t r a in s  (a p p ro x .  1 - 2  m o n th s )  
b a c te r ia  s h o u ld  b e  s t r e a k e d  o n  M 9  m in im a l- m e d iu m  p la te s  
(k ) . T h is  is  n e c e s s a r y  fo r  th e  m a in te n a n c e  o f  th e  F - e p is o m e  
o l Ih e  s t r a in s  w h ic h  is  e s s e n t ia l  b o th  fo r  th e  in fe c l iv i t y  fo r  
M 1 3  p h a g e s  a s  w e l l  a s  fo r  b lu e /c o lo r le s s  d is c r im in a t io n  
w i th  X -g a l.
F o r  c lo n in g  e x p e r im e n ts  w e  th e r e fo r e  re c o m m e n d  s ta r l in g  
w ith  a s in g le  c o lo n y  p ic k e d  f ro m  a n  M 9  m in im a l- m e d iu m  
p la te .
F o r  lo n g e r  s to r a g e  o f Ih e  s t r a in s  th e  u s u a l p r o c e d u r e s  m a y  
b e  a p p l ie d  (e  g . g ly c e r o l  c u l tu re ) .
3 . S e le c t io n  o l  th e  a p p r o p r ia te  E . c o l i  s t r a in :
T h e  k it  c o n ta in s  tw o  E . c o l i  s t r a in s .  E . c o l i  J M 1 0 3  is  a n  M 1 3  
h o s l s t r a in  w h ic h  is  c h a r a c te r iz e d  b y  g o o d  I r a n s fe c t ib i l i t y  
a n d  h ig h  y ie ld s  w h e n  p r e p a r in g  s s D N A  a n d  R F  D N A . 
H o w e v e r ,  th is  s t r a in  is  b o th  r e s t r ic t io n -  a n d  m o d i f ic a t io n -  
p o s it iv e  ( rk*, m k*) (1 ), i . e .  w h e n  c lo n in g  D N A  f ra g m e n ts  
p r e p a r e d  f r o m  a  m o d i l ic a t io n - n e g a l iv e  E . c o l i  s t r a in  o r  f ro m  
o r g a n is m s  o th e r  th a n  E . c o l i  K , t r a n s fe c t io n  e f f ic ie n c y  is  
m a r k e d ly  r e d u c e d .
T h is  p r o b le m  c a n  b e  a v o id e d  b y  u s in g  th e  r e s t r ic t io n -  
n e g a t iv e  E . c o l i  s t r a in  J M 1 0 9 .  N o  l im i ta t io n s  a re  o b s e r v e d  
w h e n  c lo n in g  n o n - m o d i l ie d  D N A  in  th is  s t ra in .  H o w e v e r ,  E . 
c o l i  J M 1 0 9  h a s  a  s o m e w h a t  lo w e r  t r a n s fe c t io n  e f f ic ie n c y  
th a n  J M 1 0 3 .
VIII. P re p a ra tio n  o l re c o m b in a n t M 1 3  ssD N A
1. M a k e  a  1 : 1 0 0  d i lu t io n  o f a n  E . c o l i  J M 1 0 3  o v e r n ig h t  c u l­
tu r e  w ith  2 x  T Y  l iq u id  m e d iu m  (I) a n d  d is t r ib u te  1 .5  m l 
e a c h  in to  la rg e  s te r i le  te s t tu b e s ,  o n e  fo r  e a c h  p la q u e  to  
b e  p ic k e d .
2 . C o l le c t  in d iv id u a l  c o lo r le s s  p la q u e s  w ith  s te r i le  P a s te u r  
p ip e t te s  o r  s te r i le  to o th p ic k s  a n d  in o c u la te  in to  th e  te s t 
tu b e s .
3 . R o ll o r  s h a k e  fo r  5  h a t 3 7  ° C .
4 . T r a n s fe r  in to  1 .5  m l m ic r o fu g e  tu b e s  a n d  c e n t r i fu g e  fo r  
5  m in  a t 12 0 0 0  g . C a r e fu l ly  r e m o v e  s u p e r n a ta n t  w ith o u t  
d is tu r b in g  s e d im e n te d  c e l ls .  (S u p e r n a ta n ts  m a y  b e  
s to r e d  a t +  4 ° C  fo r  s e v e ra l d a y s  b u t  h a v e  to  b e  c e n t r i f u ­
g e d  a g a in  a f te r w a r d s .  D o  n o t a d d  c h lo r o fo r m ! )
5 . C e n t r i fu g e  s u p e r n a ta n t  a g a in  fo r  5  m in  in  o r d e r  to  re m o v e  
a ll c e l l  d e b r is .
6 . A d d  2 0 0  p i o l  a  s o lu t io n  c o n ta in in g  N a C I,  2  5  m o l/ l ;  p o ly ­
e th y le n e  g ly c o l 6 0 0 0 ,  2 0 %  (w /v ) ;  a l lo w  to  s ta n d  fo r  15  m in  
a t r o o m  te m p e r a tu r e .
7 . C e n t r i fu g e  fo r  5  m in  a t 1 2 0 0 0 g  R e m o v e  s u p e rn a ta n t  
a n d  d is c a r d .  C e n t r i fu g e  a g a in  fo r  2  m in  a n d  c a r e fu l ly  r e ­
m o v e  a ll l iq u id  r e m a in s  o f th e  p h a g e  p e lle t  u s in g  a p u lle d -  
o u t  P a s te u r  p ip e t te .
8 . R e s u s p e n d  p h a g e  p e lle t  in  1 0 0  p i T E  b u f fe r  (g ) b y  r e p e a t ­
e d  s u c t io n  in  a n  a u to m a t ic  p ip e t te ,  a d d  5 0  p i b u f fe r -  
e q u i l ib r a t e d  p h e n o l (b ) a n d  m ix  lo r  15  s (V o r te x )  A l lo w  to  
s ta n d  fo r  15  m in  a t ro o m  te m p e r a lu r e  a n d  m ix  a g a in  fo r 
15  s .
9 . C e n t r i fu g e  fo r  3  m in  a t 1 2 0 0 0  g ; t r a n s fe r  a q u e o u s  to p  
la y e r  in to  n e w  m ic r o lu g e  tu b e .
10. A d d  10  p i L iC I s o lu t io n  (e ) a n d  2 5 0  p i e th a n o l,  9 5 %  (I); 
a l lo w  to  s ta n d  o v e r n ig h t  a t - 2 0 ° C .
11 . C e n t r i fu g e  fo r  1 0  m in  a t 1 2 0 0 0  g , r e m o v e  s u p e rn a ta n t .  
A d d  1 m l e th a n o l,  7 0 %  (f) , c e n t r i fu g e  a g a in  fo r  10 m in  R e ­
m o v e  s u p e r n a ta n t  a n d  d r y  p e lle t  b r ie f ly  u n d e r  v a c u u m .
1 2 . D is s o lv e  s s D N A  in  5 0  p i T E  b u f fe r  (g ). T h e  y ie ld  s h o u ld  b e  
a p p ro x .  5 p g  ( c h e c k  b y  a g a ro s e  g e l e le c t r o p h o r e s is )
IX. P re p a ra tio n  o f  re c o m b in a n t M 1 3  R F  D N A
1. M a k e  a  1 : 1 0 0  d i lu t io n  o f  a n  E . c o l i  J M 1 0 3  o v e r n ig h t  c u l tu r e  
w ith  2  x  T Y  l iq u id  m e d iu m  (I) a n d  d is t r ib u te  1 .5  m l e a c h  in  
la rg e  s te r i le  le s t  tu b e s ,  o n e  lo r  e a c h  p la q u e  to  b e  p ic k e d .
2 . C o l le c t  in d iv id u a l  c o lo r le s s  p la q u e s  w ith  s te r i le  P a s te u r  
p ip e t te s  o r  s te r i le  to o th p ic k s  a n d  in o c u la te  in to  Ih e  te s t 
lu b e s .
3 . R o ll o r  s h a k e  fo r  4 - 5  h a l 3 7  ° C .
4 . T r a n s fe r  in to  1 .5  m l m ic r o fu g e  tu b e s  a n d  c e n t r i lu g e  fo r  
5  m in  a t 1 2 0 0 0  g . R e m o v e  s u p e rn a ta n t  a n d  s to re  a l +  4 "C .
5 . F o r  s m a ll  a m o u n ts  o f  R F  D N A :
U s in g  s ta n d a r d  p la s m id  p r e p a r a t io n  m e th o d s ,  th e  b a c te ­
r ia l  p e lle t  f ro m  N o . 4 m a y  b e  d i r e c t ly  p r o c e s s e d  to  M 1 3  R F  
D N A . T h e  b a c te r ia l  p e lle t  f ro m  th e  s s D N A  p r e p a r a t io n  m a y  
a ls o  b e  u s e d  h e re .
6 . F o r  la r g e r  a m o u n ts  o f R F  D N A :
In o c u la te  1 0 0  m l 2  x  T Y  l iq u id  m e d iu m  (I) w ith  1 m l E c o li  
J M 1 0 3  o v e r n ig h t  c u l tu r e  a n d  1 m l p h a g e  s u p e r n a ta n t  f ro m  
N o . 4.
7 . S h a k e  lo r  4 - 5  h a t 3 7 ° C .
8 . C e n t r i fu g e  c e l ls .  R F  D N A  c a n  b e  is o la te d  a c c o r d in g  to  
s ta n d a r d  p la s m id  p r e p a r a t io n  m e th o d s .
Q u a l i t y  c o n t r o l
L ig a t io n  o f th e  c o n t r o l  D N A  ( M 1 3 m p 1 8 ,  E c o R l-c le a v e d ) ,  a s
d e s c r ib e d  in  c o n t r o l  VI, 2 , a n d  s u b s e q u e n t  t r a n s fe c t io n  y ie ld s
a t le a s t  5 0 %  o f  th e  n u m b e r  o f p la q u e s  p e r  p g  v e c to r  o b ta in e d
w ith  u n c le a v e d  M 1 3 m p 1 8  D N A  ( ty p ic a l ly  >  7 0 % ) .
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Principle
T h e  n u c le o t id e  s e q u e n c e  o f  D N A  f r a g m e n ls  in s e r te d  in to  M 13 
v e c to rs  ( 1, 2 ) c a n  q u ic k ly  a n d  e a s ily  b e  d e te r m in e d  w ith  th e  
c h a in  te r m in a t io n  m e th o d  o f S a n g e r  (3 ) U s in g  th is  m e th o d  a 
s h o r t  s e q u e n c in g  p r im e r  (4 ), w h ic h  is  c o m p le m e n ta r y  to  a r e ­
g io n  n e a r  th e  3 '- t e r m in u s  o l  th e  M 13 p o ly l in k e r ,  is  a n n e a le d  lo  
a  s in g le - s t r a n d e d ( s s )  D N A  is o la te d  I ro m  M 1 3  p h a g e  p a r t ic le s
In  th e  p r e s e n c e  o f  a ll fo u r  d e o x y r ib o n u c le o s id e  t r ip h o s p h a te s  
(d N T P )  -  o n e  o f  w h ic h  is  r a d io a c t iv e ly  la b e le d  -  K le n o w  e n ­
z y m e  (D N A  p o ly m e r a s e  I, la rg e  f r a g m e n t)  c a n  b e  u s e d  lo  in i ­
t ia te  D N A  s y n th e s is  f ro m  th e  3 - t e r m m u s  o f  th is  s e q u e n c in g  
p r im e r  to w a r d  th e  p o ly l in k e r  re g io n .  T h e  r e a c t io n  is  c a r r ie d  
o u t  a s  fo u r  s e p a ra te  in c u b a t io n s ,  e a c h  o f w h ic h  is  s u p p le ­
m e n te d  w ith  a  l im i t in g  a m o u n t  o f  a  d i f f e r e n t  d id e o x y r ib o n u -  
c le o s id e  t r ip h o s p h a te  (d d N T P ) .  In  th is  w a y  s ta t is t ic  b a s e -  
s p e c if ic  c h a in  le r m in a l io n s  a re  e f fe c te d  a t s i te s  w h e r e  a 
d d N T P  is  in c o r p o r a te d .  C h a s in g  w ith  a  la rg e  e x c e s s  o f  u n ­
la b e le d  d N T P  e n s u r e s  th a t th o s e  c h a in s  w h e r e  n o  d d N T P  h a s  
b e e n  in c o r p o r a te d  a re  p o ly m e r iz e d  to  a h ig h  m o le c u la r  
w e ig h t .  T h is  p r e v e n ts  th e s e  u n ie r m in a le d  c h a in s  f r o m  d is ­
tu r b in g  s u b s e q u e n t  e v a lu a t io n  o f th e  s e q u e n c in g  e x p e r im e n t .
A f te r  d e n a tu r a t io n  b y  fo r m a m id e  a n d  h e a t  th e  la b e le d  s a m ­
p le s  a re  s e p a r a te d  b y  e le c t r o p h o r e s is  o n  p o ly a c r y la m id e  g e ls  
c o n ta in in g  u re a . A f te r  a u to r a d io g r a p h y ,  th e  ra d io a c t iv e ly  
la b e le d  f r a g m e n ls  a re  v is u a l iz e d  a s  b a n d s  o n  a n  X - ra y  f i lm . 
A s  th e  d is ta n c e  o f m ig r a t io n  o f  th e  in d iv id u a l  f r a g m e n ts  is  d i ­
r e c t ly  p r o p o r t io n a l  lo  th e ir  le n g th ,  th e  b a s e  s e q u e n c e  c a n  b e  
re a d  d i r e c t ly  I ro m  th e  o r d e r  o f  fh e  in d iv id u a l  b a n d s  o n  Ih e  
X - ra y  f i lm  (s e e  f ig . 1 3  o n  p . 19 ).
7 - D e a z a - d G T P ,  a n  a n a lo g  o f d G T P  is  a ls o  s u p p l ie d  w ith  th is  
k it .  7 - D e a z a - d G T P  is  u s e d  to  re p la c e  d G T P  in  th e  c h a in  e lo n ­
g a t io n  re a c t io n  to  o v e r c o m e  th e  p r o b le m  o f b a n d  c o m p r e s ­
s io n  ( 5 , 6 ) w h e n  s e q u e n c in g  G -C  r ic h  r e g io n s .  R e p la c e m e n t  o f  
d G T P  w ith  7 - d e a z a -d G T P  p r e v e n ts  th e  fo r m a t io n  o f u n d e ­
s ire d  s e c o n d a r y  s t r u c tu r e s  w h ic h  a l te r  th e  e le c t r o p h o r e t ic  
m o b i l i t y  o f  s in g le - s t r a n d e d  D N A  f r a g m e n ts  in  p o ly a c r y la m id e  
g e ls  a n d  le a d  to  a m b ig u o u s  o r  u n in te r p r e ta b le  s e q u e n c e  d a ta  
(s e e  f ig .  8 3  o n  p . 1 4 6 ). In  a d d i l io n ,  th e  u s e  o f  7 - d e a z a -d G T P  
re s u lts  in  in c r e a s e d  u n if o r m it y  o f  b a n d  in te n s i fy ,  e s p e c ia l ly  in  
th e  G - r e a c l io n .
[ 35S ) d A T P - u - S  h a s  c e r ta in  a d v a n ta g e s  in  c o m p a r is o n  lo  th e  
m o re  c o m m o n ly  u s e d  [ u - 32P ) d A T P  (7 ):
1 T h e  lo n g e r  h a lf - l i fe  o l  [ 35S ) (8 7 .2  d a y s )  c o m p a r e d  to  (32P) 
(1 4 .3  d a y s )  a l lo w s  lo n g e r  s to r a g e  o l  [ 35S |d A T P - a - S .  S e ­
q u e n c in g  s a m p le s  th a t  h a v e  a lr e a d y  b e e n  p r e p a r e d  c a n  b e  
s to r e d  lo r  lo n g e r  p e r io d s  b e fo re  b e in g  ru n  o n  g e ls .
2 . B a n d s  o n  a u to r a d io g r a m s  a re  s h a r p e r  w ith  [ 35S ]- la b e le d  
s a m p le s  th a n  w i th  [ 32P ]- la b e le d  s a m p le s .
APPENDIX F.
3  T h e  lo w e r  e n e r g y  o f Ih e  f l - p a r t ic le s  e m it te d  f ro m  (35S) e n ­
s u re s  s a fe r  h a n d l in g .
A n y  [a - 3:,P j d N T P  o r [ 35S jd N T P - a - S  c a n  b e  u s e d  in  th e  k it  F o r 
th e  re a s o n s  m e n t io n e d  a b o v e  w e  re c o m m e n d  th e  u s e  o l 
[ 35S ]d A T P -n -S .  M o d if ic a t io n s  n e c e s s ita te d  b y  th e  u s e  o f 
[ u - 32P ]d N T P s  a re  in d ic a te d  a t th e  c o r r e s p o n d in g  s te p s
The  kit contains
1. dATP
O n e  v ia l 1 w ith  2 5 0  p i d A T P , 0 .5  m m o l/ l ,  p H  7 .5 .
2. dCTP
O n e  v ia l 2  w ith  2 5 0  p i d C T P , 0 .5  m m o l/ l ,  p H  7 5.
3. dGTP
O n e  v ia l 3  w ith  2 5 0  p i d G T P , 0 .5  m m o l/ l ,  p H  7 .5 .
4. dTTP
O n e  v ia l 4 w ith  2 5 0  p i d T T P , 0 .5  m m o l/ l ,  p H  7 .5 .
5. ddGTP
O n e  v ia l  5  w ith  2 5  p i d d G T P ,  2  m m o l/ l ,  p H  7 .5 .
6. ddATP
O n e  v ia l 6 w ith  2 5  p i d d A T P ,  2  m m o l/ l ,  p H  7 5.
7. d dT TP
O n e  v ia l 7  w ith  1 2 0  p i d d T T P ,  2  m m o l/ l ,  p H  7 .5 .
8. ddCTP
O n e  v ia l 8 w ith  2 5  p i d d C T P ,  2  m m o l/ l ,  p H  7 .5 .
9 K lenow enzym e
O n e  v ia l 9  w ith  1 2 0  p i K le n o w  e n z y m e , 1 u n it /p l .
10. 10 x Reaction buffer
O n e  v ia l  10  w i lh  3 5 0  p i 1 0 - t im e s - c o n c e n t ra te d  b u f fe r  fo r  
h y b r id iz a t io n  a n d  c h a in  e lo n g a t io n  re a c t io n .
11. Deoxynucleot ide  mixture ( c h a s e  m ix tu re )
O n e  v ia l  11 w ith  9 0 0  p i o f  a m ix tu re  o f d A T P , d C T P , 
d G T P , d T T P ; 0 .1 2 5  m m o l/ l  e a c h ;  p H  7 .5 .
12. M 13 /p U C  sequencing primer
O n e  v ia l 12  w ith  2 2 0  p i M 1 3 /p U C  s e q u e n c in g  p r im e r  
1 7 -m e r , 0 .4  p m o l/ l ,  in  w a te r .
13 Control DNA
O n e  v ia l 13  w ith  5 0  p i s in g le - s t r a n d e d  M 1 3 m p 1 8  D N A , 
0 .1  p g /p l ,  in  T r is /E D T A  b u f fe r  (T E - b u f fe r ) ,  p H  8 .0 .
14 . Form am ide buffer ( s to p  b u f fe r )
T w o  v ia ls  14 w i lh  1 m l fo r m a m id e  b u f fe r  e a c h .
15. 7 -D eaza-dGTP
O n e  v ia l 15  w ith  2 5 0  p i 7 -d e a z a -d G T P , 0 .5  m m o l/ l ,  p H  7 .5 . 
S t a b i l i t y
T h e  k it  c a n  b e  s to r e d  a t - 2 0 ° C  a t le a s t  u n t i l  th e  d a te  in d ic a t ­
e d . R e p e a le d  th a w in g  a n d  f r e e z in g  s h o u ld  b e  a v o id e d  W e  re ­
c o m m e n d  d iv id in g  Ih e  n u c le o t id e  s o lu t io n s  (s o lu t io n s  1 - 8 )  
in to  a l iq u o ts  a l t e r  th a w in g  a n d  s to r in g  th e m  a g a in  a t - 2 0 ° C  
a f te r w a r d s .  T h e  c o n t r o l  D N A  (s o lu t io n  13 ) s h o u ld  b e  s to re d  at 
+  4  ° C  a f te r  th a w in g .
A sp7 IB
fc o R I S a d  K pn l _ X/nal fia/riM I Xbal
A c d  
H ind  II 
Sal\ Psft Sph\ H im 1111
5* CACACAGGAAACAGCTATGACCATGATTACGAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTC.GGAAAACCCT 3*
3* TGACCGGCAGCAAAATG 5' 17-mer 'sequencing primer" 
—  DNA-synlhesis
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A d d i t i o n a l l y  r e q u i r e d  r e a g e n t s
R a d io a c l iv e  la b e l:
[ 35S ]d A T P - u - S ,  8 | iC i / | i l ,  >  6 0 0  C i/m m o l,  o r  [ a - 3JP ] d A T P , 
10 p C i /p l ,  4 0 0 - 8 0 0  C i/m m o l,  a q u e o u s  s o lu t io n .
P r e p a r a t io n  o t  th e  d N T P /d d N T P  m ix t u r e s
W h e n  u s in g  ra d io a c t iv e ly  la b e le d  d A T P ,  fo l lo w  th is  p ip e t t in g  
s c h e m e :
N ucleotide
solutions
G m ixture 
lit jtm o l/l
A m ixture 
l i l  |im o l/l
T m ixture
I t  I pm ol/l
C m ixture
jil jim o l/l
dG T P  (3 ) ‘ 2 5 40 100 40 100 40 100
d T T P  (4) 40 100 40 100 2 5 40 100
d C T P  (2) 40 100 40 100 40 100 4 10
d d G T P  (5) 12 120 — — — — —
d d A T P  (6) — — 10 100 — — — —
d d T T P  (7) — — — — 50 500 — —
d d C T P  (8) — — — — — — 10 100
10x b u ffe r (10) 20 20 20 20
re d is l. w a te r 86 50 48 86
fin a l v o lu m e 200 200 200 200
• dGTP can be replaced by 7-deaza-dGTP (solution 15) in the dNTP/ddNTP 
mixtures to overcome problems in sequence evaluation caused by band 
compression.
If y o u  u s e  ra d io a c t iv e ly  la b e le d  d N T P  o th e r  th a n  d A T P ,  le a v e  
Ih e  c o r r e s p o n d in g  u n la b e le d  d N T P  o u t  o l  a ll Ih e  m ix tu r e s .  F o r  
s u c h  r e a c t io n s  a d d  4  | i l  d A T P  ( s o lu t io n  1) lo  th e  A  m ix tu r e  a n d  
4 0  i l l  d A T P  to  e a c h  o f th e  G , T  a n d  C  m ix tu r e s .  A d d  re d is t i l le d  
w a te r  to  a f in a l v o lu m e  o f 200  p i.
N o le :  T h e s e  d N T P /d d N T P  m ix tu r e s  h a v e  b e e n  o p t im iz e d  lo r  
s e q u e n c in g  D N A  w ith  a  b a s e  c o m p o s it io n  (m o l °/o G + C )  o l  a p ­
p r o x .  5 0 % .  W h e n  D N A  w i th  a  v e r y  d i l le r e n t  b a s e  c o m p o s it io n  
is  s e q u e n c e d ,  it m a y  b e  n e c e s s a r y  lo  m o d i ly  th e  m ix tu r e s  a c ­
c o r d in g ly .  T h e  to l lo w in g  ru le  s h o u ld  b e  a p p l ie d  in  th is  c a s e : II 
o n e  o f th e  b a s e - s p e c i l ic  s e q u e n c e  r e a c t io n  m ix tu r e s  g iv e s  
b a n d s  o n  th e  a u to r a d io g r a m  w h ic h  in c re a s e  in  in te n s i ty  to ­
w a r d  th e  h ig h  m o le c u la r  w e ig h t  r e g io n  (5 0 0  b a s e s ) ,  i e . c lo s e r  
lo  th e  s lo t  o l  th e  s e q u e n c in g  g e l,  Ih e  a m o u n t  o f  d d N T P  s h o u ld  
b e  in c r e a s e d  in  th a t  s e q u e n c in g  m ix tu re .  If Ih e  b a n d s  b e c o m e  
d is t in c t ly  w e a k e r  b e fo r e  a f r a g m e n t  s iz e  o f  a p p ro x .  4 0 0 - 5 0 0  
b a s e s  h a s  b e e n  re a c h e d ,  th e  a m o u n t  o f  d d N T P  s h o u ld  b e  re ­
d u c e d .
T h e  f in a l d N T P /d d N T P  m ix tu r e s  c a n  b e  s to r e d  a s  a l iq u o ts  a t 
- 2 0 ° C  fo r  s e v e ra l m o n th s .  It is  n o t  r e c o m m e n d e d  lo  f re e z e  
a g a in .
S t a n d a r d  a s s a y
I. A n n e a lin g  o l  the  s e q u e n c in g  p r im e r
A d d  to  a s te r i le  1 .5  m l m ic r o lu g e  tu b e :
5  p i c o n t r o l  D N A  ( s o lu t io n  13 ) o r 0 .5  p g  s e lf - p r e p a r e d  
M 1 3 ( s s ) D N A ,
2  p i =  0 .8  p m o l M 1 3 /p U C  s e q u e n c in g  p r im e r  ( s o lu t io n  12), 
1 .5  p i  10  x  r e a c t io n  b u f fe r  ( s o lu t io n  10 ),
1 p i s te r i le  re d is t .  w a te r .
In c u b a te  m ix tu r e  fo r  10  m in  a t 5 5  ° C  a n d  a l lo w  lo  c o o l s lo w ly  
to  ro o m  te m p e r a tu r e  a l le r w a r d s .
II. C h a in  e lo n g a tio n
A d d  to  h y b r id iz a t io n  m ix tu re :
2  p i ^  16  p C i [ 35S )d A T P -« -S  o r  1 p i a  10  p C i [a - 32P )d A T P ,
1 p i a  1 u n it  K le n o w  e n z y m e  ( s o lu t io n  9).
M ix  b y  re p e a le d  s u c t io n  w ith  th e  p ip e t te  t ip  a n d  a d d  2  5 p i o l 
Ih e  r e a c t io n  m ix tu r e  in to  e a c h  o l  fo u r  la b e le d  m ic r o lu g e  lu b e s  
(G , A , T , C ).
S ta r t  r e a c t io n  b y  a d d in g  2 p i e a c h  o f  th e  a p p r o p r ia te  d N T P /  
d d N T P  m ix tu re .
In c u b a te  fo r  2 0  m in  a t r o o m  te m p e r a tu r e  (o r 15 m in  if 
( a -3?P j d A T P  is  u s e d ) .
C h a s e  th e  r e a c t io n  b y  a d d in g  2 p i d e o x y n u c le o l id e  m ix tu re  
( s o lu t io n  11) lo  e a c h  m ic r o lu g e  tu b e  a n d  in c u b a le  lo r  15 m in  
a t r o o m  te m p e r a tu r e .
T e r m in a te  th e  r e a c t io n  b y  a d d in g  4 p i fo r m a m id e  b u f fe r  
( s o lu t io n  14).
T h e  a s s a y  m a y  a ls o  b e  f ro z e n  a n d  d r ie d  in  a  v a c u u m  c e n lr i lu -  
g e  b e fo re  a d d it io n  o f  th e  lo r m a m id e  b u f fe r  F o r  lo a d in g  o n lo  
th e  p o ly a c r y la m id e  g e l,  s m a lle r  v o lu m e s  a re  a d v a n ta g e o u s  
In  a d d i t io n ,  it is  p o s s ib le  lo  s to re  th e  d r ie d  s a m p le s  a l - 2 0 ° C  
fo r  s e v e r a l d a y s .
Hi. D e n a tu ra lio n  a n d  g e l e le c tro p h o re s is
Im m e d ia te ly  b e fo re  lo a d in g  th e  s a m p le s  o n  Ih e  s e q u e n c in g  
g e l,  d e n a tu r e  th e  s a m p le s  b y  in c u b a t io n  fo r  3  m in  a t 9 5  ° C  in  
a  w a te r -b a th ,  th e n  q u ic k ly  c o o l o n  ic e  a n d  c e n t r i fu g e  b r ie f ly .  
Im m e d ia te ly  lo a d  1 - 2  p i o l  e a c h  s a m p le  in to  Ih e  a p p ro p r ia te  
s lo t  o l  a  p r e - e le c t r o p h o r iz e d  a n d  p r e -h e a te d  (6 5  ° C )  s e q u e n c ­
in g  g e l.  W e  re c o m m e n d  u s in g  5 %  p o ly a c r y la m id e  g e ls  w ith  
a  0 . 1 - 0 . 4  m m  th ic k n e s s  g r a d ie n t  u s in g  Ih e  M a c ro p h o r" "  
S e q u e n c in g  S y s te m  (L K B ).
IV. A u to ra d io g ra p h y  a n d  e va lu a tio n
A l te r  e le c t r o p h o r e s is ,  a g ita te  th e  s e q u e n c in g  g e l in  te c h n ic a l 
a c e t ic  a c id ,  1 0 %  (v /v ) , lo r  1 0  m in  in  o r d e r  to  re m o v e  u re a .  R e ­
m o v e  th e  g e l I ro m  Ih e  b a th , r in s e  b r ie f ly  w ith  d e io n iz e d  w a te r ,  
a n d  d r y  fo r  a p p ro x .  1 h  a t 8 0  ° C .  L a y  a n  X - ra y  l i lm  o n  th e  d r ie d  
g e l,  m a rk  o r ie n ta t io n  a n d  e x p o s e  o v e r n ig h t  ( lo n g e r  o r  s h o r te r  
e x p o s u r e  m a y  b e  n e c e s s a ry ) .
Q u a l i t y  c o n t r o l
A l te r  s e q u e n c in g  Ih e  c o n t r o l  D N A  a n d  a n a ly s is  o n  a 5 %  p o ly ­
a c r y la m id e  g e l (0 .1  - 0 . 4  m m  th ic k n e s s  g r a d ie n t ) ,  a s e q u e n c e  
o f  a t le a s t  2 5 0  n u c le o t id e s  c a n  b e  d e te r m in e d  ( ty p ic a l ly  
3 0 0 - 4 0 0  n u c le o t id e s )  u n d e r  th e  c o n d i t io n s  d e s c r ib e d  h e re .
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